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Abstract  
 
Background 
The non-invasive assessment of volume status in left ventricular systolic dysfunction (LVSD) 
is challenging. The main thesis objective was to establish the feasibility and potential clinical 
utility of repeated measures assessment of non-invasive biomarkers in defining changes in 
volume status within individual volunteers.  
 
Methods 
Differential volume manipulation protocols were achieved in a three-staged plan of 
investigation, firstly, in patients with decompensated heart failure receiving intravenous 
furosemide, secondly, in normal volunteers receiving acute loads of oral water or intravenous 
saline, and thirdly, in stable LVSD patients on chronic furosemide dosing undergoing staged 
diuretic withdrawal and resumption. Repeated measures of biomarkers relevant to volume 
status including blood and urine biomarkers, echocardiographic and bioimepdance measures 
were performed to assess their sensitivity to the induced volume changes. 
 
Results Summary 
I demonstrated the smallest variance for bioimpedance measures, and the largest variance for 
urine biomarkers. In the patients with decompensated heart failure, none of the biomarkers 
studied showed potential clinical utility at tracking acute volume response to intravenous 
furosemide. In the normal volunteers, a significant change in estimated blood volume was 
observed following intravenous saline, but not with acute oral water ingestion. Only whole-
body and trunk bioimpedance measures, and to a lesser extent, mitral valve early peak 
iii 
 
velocity with and without the Valsalva manoeuvre, appeared sensitive enough to map these 
changes in volume status. In the stable LVSD patients, statistically significant increases in B-
type natriuretic peptide, urinary creatinine, urinary kidney injury molecule 1, and in 
bioimpedance-estimated body water composition were observed with diuretic withdrawal, 
with levels of these markers reducing following diuretic resumption. However, the amplitude 
of the changes observed was either lower than the respective within-subject variance or too 
small to be potentially useful as a marker of volume change. This would thus limit the clinical 
utility of these biomarkers in the routine monitoring of volume status in LVSD. 
 
Conclusion 
The repeated measures of biomarkers studied in response to different volume manipulations 
were interpreted in the context of their within-subject normal variance. None of the 
biomarkers studied appeared to have the ideal characteristics clinically for the monitoring of 
subclinical changes in volume status in stable LVSD or in response to acute diuresis in 
decompensated heart failure. The significant increases in urine biomarkers following diuretic 
withdrawal in stable LVSD suggested potentially beneficial renal effects of furosemide in 
stable LVSD.  
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1.1      Introduction 
Heart failure (HF) is a syndrome characterised by a broad spectrum of heterogeneous 
symptoms and signs, typically dyspneoa, lethargy and signs of fluid retention, in the presence 
of objective evidence of a functional or structural abnormality of the heart [Dickstein et al., 
2008]. The leading cause of the significant health burden of HF is acute decompensation, with 
80 % of acute HF presentations occurring (often recurrently) in patients with a documented 
diagnosis of HF [Cleland et al., 2003]. Defined by a coherent reduction in left ventricular 
(LV) systolic function, left ventricular systolic dysfunction (LVSD) is a readily identifiable 
type of HF which is present in approximately half of patients with a diagnosis of chronic HF, 
and in between half and two-thirds of acute HF presentations [Adams et al., 2005; Nieminen 
et al., 2006]. Despite a number of therapeutic strategies with proven benefits based on large 
scale clinical trials contributing to improved 0prognosis in LVSD, an admission with 
decompensated HF in patients with LVSD still conveys a poor prognosis [Gheorghiade et al., 
2005]. Thus, LVSD patients constitute a significant subset of the HF population in whom the 
prediction of decompensation is an important clinical goal.  
 
1.2        Clinical relevance of abnormal volume status in LVSD 
1.2.1  Abnormal volume status as a cause for decompensation 
 
Acute decompensation in HF is defined as the presence of signs and symptoms requiring 
urgent treatment or hospitalisation. Whereas factors such as sepsis, worsening renal failure, 
ischaemia, paroxysmal arrhythmia, uncontrolled hypertension and non-adherence to diet and 
medication can precipitate decompensation [Fonarow et al., 2008; 
 
Tsuyuki
 
 et al., 2001; 
Nieminen
 
 et al., 2006], the role of abnormal volume status (whether hypervolaemia, 
hypovolaemia or volume redistribution) as the final mechanism, and thus as the cause for 
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acute decompensation, has not been extensively studied. Registry data suggests that abnormal 
volume status is a significant contributor to HF hospitalisations, with approximately 66% of 
patients having auscultatory rales and peripheral oedema, and 74% of patients having 
evidence of lung congestion on admission chest radiographs [Fonarow et al., 2007].The study 
by Zile et al. [2008] is pivotal in supporting the fact that abnormal volume status (as 
evidenced by significant changes in heamodynamic measures) indeed plays a significant, if 
not the final, mechanistic role in decompensated HF. These authors used continuous invasive 
haemodynamic monitoring of stable HF patients in New York Heart Association (NYHA) 
functional class III-IV to determine changes in estimated pulmonary capillary wedge pressure 
(PCWP) in the transition from symptomatically stable HF to their end point of a HF-related 
event, defined as an acute unexpected presentation requiring intravenous therapy. 
Hypervolaemia, as adjudicated by an independent and blinded Clinical Events Review 
Committee, was present in 181 of the 197 acute HF-related events.  Hypervolaemic 
presentations were associated with significant increases in estimated PCWP, and subsequent 
reductions in cardiac pressures occurred after treatment. The remaining 16 acute HF-related 
events were adjudicated to be due to hypovolaemia, hypotension and/or prerenal azotaemia.  
Hypovolaemic presentations were associated with reduced estimated PCWP. Patients who did 
not have a HF-related event did not have significant changes in their central cardiac pressures. 
 
1.2.2  Volume status as a mechanistic target for prognostic treatment 
 
Furthermore, the presence of abnormal volume status in LVSD is also associated with an 
independently poor prognosis. The presence of symptoms and clinical signs of volume 
overload, raised cardiac filling pressures and increased blood/plasma volume, are all 
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predictors of increased morbidity and mortality in LVSD [Androne et al., 2004; Drazner et al., 
2001]. On the other hand, hypovolaemia, mainly in the context of diuretic overuse, is 
associated with detrimental neurohormonal activation and poorer renal function with 
increasing diuretic dosage, these also being adverse prognostic markers in LVSD [Eshaghian 
et al., 2006; Dries et al., 2000]. 
 
The mechanisms by which therapeutic strategies in LVSD improve prognosis range from 
effects on cardiac remodelling, prevention of progression of atheroslecrosis, blocking 
detrimental neurohormonal activation and reduction of oxidative stress and inflammation 
[Pfeffer et al., 2006; Francis et al., 1995; Trachtenberg
 
 et al., 2009; Brauwnwald, 2008]. 
However, the complex mechanism of abnormal volume status in LVSD remains poorly 
understood and the prevention of abnormal volume status as a prognostic target has not been 
fully evaluated to date. Given the significant role of abnormal volume status in 
decompensated HF, specific treatments aimed at maintaining optimal volume status could 
result in reduced morbidity and mortality.  
 
1.3  Determinants of volume status 
1.3.1  Volume compartments of relevance in LVSD  
 
In the context of LVSD, volume status is a term used to describe whether a patient is 
hypervolaemic, hypovolaemic or euvolaemic. Thus hypervolaemia or volume overload tends 
to describe a state of excessive salt and water retention manifesting as increased jugular 
venous pressure (increased circulatory volume) and/or dyspnoea, rales, dependent oedema 
and ascites (increased interstitial space volume). However, each of the above states of volume 
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can occur with or without redistribution of fluid between volume compartments secondary to, 
for example, changes in vascular tone, such that an acute presentation with signs and 
symptoms of volume overload may not necessarily be secondary to excessive salt and water 
retention, but may be due to volume redistribution between the interstitial and intravascular 
spaces [Cotter et al., 2008]. Thus, an understanding of the dynamic interplay between the 
volume compartments of body water and the factors that influence them is crucial in order to 
gain insight into the determinants of abnormal volume status in LVSD.   
 
The composition of body water is illustrated in Figure 1.1, with the compartments of most 
relevance in LVSD highlighted. Determinants of stroke volume include cardiac preload, 
afterload and contractility. Extracellular volume constitutes of intravascular volume [also 
termed blood volume, circulatory volume, or plasma volume (non-cellular component of 
intravascular volume)] and interstitial volume. The exchange of fluid across the vascular 
capillary bed between intravascular volume and the interstitial space is under the influence of 
Starling’s law, the balance between hydrostatic pressure (determined by systemic vascular 
resistance or cardiac afterload) and colloid oncotic pressure. The majority of intravascular 
volume (70-85%) lies within the venous compartment due to the larger capacitance of this 
compartment compared to the arterial compartment. Fluid volume within the venous 
compartment contributes to the venous return to the heart or the cardiac preload, measured as 
LV filling volume or LV filling pressure at the end of diastole [LV end diastolic volume 
(LVEDV) and LV end diastolic pressure (LVEDP) respectively]. LVEDP is equivalent to left 
atrial pressure in the absence of mitral valve disease; this can in turn be estimated by the 
PCWP. Fluid volume within the arterial compartment is responsible for perfusion of 
peripheral organs.   Another relevant compartment in LVSD is red cell volume which is 
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relatively reduced in the presence of increased plasma volume resulting in haemodilutional 
anaemia, a predictor of poor outcome in LVSD [Androne et al., 2003]. 
 
Figure 1.1 Volume compartments of relevance in LVSD.  
 
Under normal physiological conditions, extracellular water constitutes one-third of total body water (about 15 
L), of which 4/5 is interstitial fluid and 1/5 is intravascular fluid. [Guyton, 2000; Gelman et al., 2008; Braunwald 
et al., 2004; Adlbrecht et al., 2008].  
 
1.3.2       Pathophysiology of abnormal volume status in LVSD 
 
The active reabsorption of sodium and water by the kidneys is determined mainly by volume 
alterations in the arterial component of circulatory volume [Schrier, 1990].  A drop in cardiac 
output, such as occurs in LVSD, is sensed by baroreceptors and results in activation of the 
integrated neurohormonal response. Sympathetic nervous system (SNS) activation results in 
vasoconstriction and increased heart rate and cardiac contractility, and subsequent activation 
of the renin angiotensin aldosterone system (RAAS), responsible for increased renal 
reabsorption of salt and water and further vasoconstriction. Antidiuretic hormone (ADH) 
   7 
 
secretion is induced by osmotic and non-osmotic (SNS) stimuli causing renal retention of 
water independent of sodium reabsorption. The natriuretic system modulates the effects of the 
other hormones by causing vasodilatation and natriuresis.  The net effect of neurohormonal 
activation is increased sodium and water retention in order to maintain cardiac output and 
maintain arterial pressure. At this stage, LVSD patients are compensated, and have either no 
symptoms, or have stable symptoms. 
 
1.3.2.1  Haemodynamic disturbances 
 
These compensatory mechanisms only have a finite capacity to sustain cardiac output in the 
presence of chronic systolic pump failure, such that decompensation eventually ensues. 
Chronic retention of salt and water results in firstly, elevation of LVEDV and LVEDP, 
manifesting clinically as elevated jugular venous pressure and hepatomegaly; and secondly to 
increased capillary hydrostatic pressure resulting in exudation of fluid into the interstitial 
space, thus producing dependent oedema, pleural effusion, ascites and pulmonary oedema. 
Furthermore, an inappropriate or sustained increase in vascular resistance may lead to both 
reduced venous capacitance in the large veins and increased arterial resistance.  The former 
leads to increased venous return or cardiac preload, coupled with net movement of fluid into 
the interstitial space, and the latter to increased afterload, both potentially detrimental to the 
failing LV. 
 
The haemodynamic sequelae of decompensation are illustrated in the small early study by 
Anand et al. [1989], who compared six patients with untreated LVSD with clinical signs of 
volume overload and 11 healthy controls.  They demonstrated increased right atrial pressure 
   8 
 
and PCWP, and increased systemic and pulmonary arterial resistances in the decompensated 
patients.  The excess total body water (TBW) determined by radionuclide techniques in the 
decompensated patients was 16% above controls (about 4L per patient).  This excess TBW 
was almost entirely in the extracellular space (ECW), with both extravascular and 
intravascular components increasing proportionately (total extravascular volume rose by 33% 
and plasma volume rose by 34%).     
 
Similarly, in more contemporary treated patients with severe LVSD who were in cardiogenic 
shock and awaiting cardiac transplantation, James et al. [1996] found a mean increase in 
plasma volume of 23% above normal reference values; this was accompanied by similarly 
increased mean right and left atrial pressures, and reduced cardiac index. In response to 
treatment interventions, plasma volume reduced to an excess of around 15% of normal values. 
Much earlier, Davidov et al. [1967] also demonstrated response of plasma volume to 
treatment in the form of a 25% reduction from baseline in plasma volume following 
intravenous administration of furosemide in decompensated LVSD patients. Interstital space 
volume was not assessed in these studies. 
 
On the other hand, Henning et al. [1978] showed that acute cardiogenic pulmonary oedema 
was associated with increased LVEDP and PCWP in combination with either normal or 
reduced plasma volume and increased interstitial volume determined by radionuclide 
techniques. After treatment with the peripheral arterial vasodilator phentolamine, plasma 
volume increased rather than decreased, with fluid shift from the interstitial space into the 
intravascular space. Shuster et al.[1994] also showed that there was no significant change in 
plasma volume in critically ill patients with pulmonary oedema being treated with intravenous 
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diuretics and who experienced marked diuresis, suggesting that plasma volume expanded (due 
to fluid shift from the interstitial space as a result of vasodilatation) at a rate approximating 
the volume removed by diuresis.  In patients who failed to respond to diuresis, plasma volume 
continued to expand despite intravenous diuretic, suggesting movement of fluid from the 
interstitial space into the intravascular space, which was not then removed by the kidneys.  
 
The above data therefore support the fact that acute cardiogenic pulmonary oedema is 
associated with the extravasation of large quantities of plasma from the intravascular 
compartment into the interstitial compartment and subsequent contraction of the intravascular 
plasma volume. The treatment of acute cardiogenic pulmonary oedema is then associated with 
the return of fluid from the interstitial compartment back into the intravascular compartment 
with expansion of plasma volume and reduction of colloid osmotic pressure. Thus, the 
disagreement between the changes in plasma volume as a result of decompensation and 
treatment observed in the above studies may simply reflect the dynamic interplay between 
volume compartments which is involved in volume redistribution; different cohorts of 
patients may have simply been at different stages of decompensation or improvement with 
potentially differing renal responses and capacity to effectively excrete excessive salt and 
water. 
 
1.3.2.2  eurohormonal abnormalities 
 
The baseline neurohormonal tone in decompensated and compensated (with or without 
baseline angiotensin converting enzyme (ACE) inhibitor treatment) patients is higher than in 
normal individuals, and the effects of the RAAS predominate over the effects of the 
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natriuretic system [Volpe et al., 1992; Anand et al., 1989]. Furthermore, LVSD patients fail to 
escape from the sodium-retaining effect of aldosterone compared to normal subjects despite 
normalisation of sodium balance [Hensen et al., 1991] due to reduced sodium delivery to the 
distal tubule and collecting ducts as a result of increased sodium reabsorption in the proximal 
tubule [Boerrigter
 
et al., 2004; Chen, 2007]. Baroreceptor-mediated non-osmotic release of 
ADH overrides the osmotic regulation of ADH in LVSD patients [Francis et al., 1990], such 
that the resulting high baseline ADH levels further enhance water retention [Szatalawicz et 
al., 1981].  The neurohormonal consequence in LVSD is thus a paradoxical state whereby the 
kidneys, even with apparently normal function, continue to retain sodium and water despite an 
increased plasma volume thus spiralling into worsening of the clinical syndrome of HF.  
 
1.3.2.3  Cardiorenal syndrome 
 
The kidney receives 20-25% of total cardiac output, this constituting the highest blood flow 
per gramme of body weight in the human body. This is not mainly for the metabolic needs of 
the kidney but in order to maintain glomerular filtration rate (GFR). It is therefore the organ 
the most likely to be compromised by a true or relative reduction in perfusion pressure which 
results from the haemodynamic consequences of LVSD.  
 
Renal dysfunction is common in patients with LVSD. Only 26% of a cohort of stable LVSD 
patients had normal renal function as defined by a GFR of >90 mL/min/1.73 m
2
; the majority 
of these patients (44%) had mild renal impairment (GFR 60-90 mL/min/1.73 m
2
), and the 
remaining 30% had moderate to severe renal impairment (GFR <60 mL/min/1.73 m
2
) [Reis et 
al., 2009]. The incidence of renal impairment in other groups of LVSD patients has varied 
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depending on criteria used for the definition of renal impairment, but has nevertheless been 
consistently high [Silverberg et al., 2000; Smith et al., 2006]. There is also evidence of 
subclinical kidney injury in the form of elevated renal tubular markers even in the presence of 
normal renal function as estimated by conventional measures of renal function such as serum 
urea and creatinine (sCreatinine) and GFR [Damman et al., 2008]. The incidence of renal 
impairment appears higher in hospitalised HF patients compared to outpatients, with 32% of 
hospitalised patients having moderate to severe renal impairment compared to only 10% of 
outpatients in one cohort [Smith et al., 2006]. 
 
The presence of significant renal impairment confers a poor prognosis in HF in both the acute 
and chronic settings [Silverberg et al., 2000; Heywood et al., 2007]. One-year mortality of 
LVSD patients with any renal impairment is around 38%, reaching 51% for patients with 
moderate to severe renal impairment. The degree of renal impairment also worsens with LV 
ejection fraction (LVEF) and NYHA class. Worsening renal failure also results in diuretic 
resistance and is a poor prognostic marker in both acute and chronic HF [Hillege et al., 2000; 
Metra et al., 2008]. 
 
This close relation between renal impairment and LVSD has been termed the cardiorenal 
syndrome [Ronco et al., 2008]. The most obvious mechanism for renal dysfunction involves 
reduced renal perfusion [Damman et al., 2007] secondary to reduced cardiac output and/or the 
impact of cardiorenal drug therapy.  Renal blood flow is the most important determinant of 
GFR. With very low systemic blood pressure, GFR is no longer able to be maintained by 
autoregulatory mechanisms [Smilde et al., 2009], resulting in sodium and water retention.  
Other mechanisms that may precipitate renal dysfunction in LVSD include renal hypoxia; 
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activation of the neurohormonal system with ensuing vasoconstriction, sodium and water 
retention, and increased venous pressure; immune-mediated damage through endothelial 
dysfunction and inflammation; the presence and progression of acquired risk factors such as 
atherosclerosis and hypertension; and anaemia [Damman et al., 2009; Vaidya et al., 2008]. 
Consequently, a vicious circle of worsening renal and cardiac function ensues, regardless of 
the initial mechanism, where the result is the same: critically reduced GFR and deranged 
volume homeostasis.   
 
1.4  Therapeutic manipulation of volume status in LVSD 
 
Given the number of symptomatic and prognostic interventions currently available or under 
investigation for the treatment of LVSD, it is foreseeable that specific treatments may be 
tailored for each individual patient in order to achieve optimal volume status. While RAAS 
blockade impacts on volume status by modulating neurohormonal status [Pfeffer et al., 2006; 
Dickstein et al., 1995; Shyu, 2005; Pitt et al., 1999; Pitt et al., 2003], other treatments have a 
more direct impact on volume status, such as by their effects on the kidneys and 
haemodynamic tone, and will be discussed below.  
 
1.4.1  Diuretics 
 
The thiazide, loop and potassium-sparing diuretics act on different sites of the neprhon and by 
varying mechanisms to increase sodium and water excretion [Jentzer et al., 2010]. The loop 
diuretic furosemide, is actively secreted by the proximal tubules into the urine, and acts on the 
ascending limb of the loop of Henle by inhibiting the NA-K-Cl2 transporters. Loop diuretics 
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are a mainstay of treatment in LVSD guidelines, having the most perceived impact on 
symptoms of acute and chronic volume overload [Dickstein et al., 2008].  90% of patients 
admitted with decompensated HF are treated with loop diuretics, and the dose of loop 
diuretics is frequently titrated against clinical signs and symptoms of congestion in chronic 
HF patients [Peacock et al., 2009]. In the congested LVSD patient, administration of 
intravenous furosemide results in rapid reduction in LV filling pressures and improvement in 
cardiac output, as well as an almost immediate  relief of symptoms of decompensation 
[Dikshit et al., 1973; Verma et al., 1987]. These effects are secondary to a rapid venodilatory 
effect resulting in net movement of fluid from the interstitial space (most critically that 
involved in compromising gas exchange in the alveoli) back into the intravascular 
compartment [Pickkers et al., 1997]. The resulting increase in overall plasma volume and 
relief of hypoxic renal vasoconstriction can then contribute to increased natriuresis and 
diuresis, which occurs within 30 minutes of intravenous administration, and peaks at 1.5h 
[McMurray et al., 2009].  
 
There is no doubt that background diuretic treatment is paramount to long term care of a 
substantial proportion of LVSD patients. Braunschweig et al. [2002], using continuous 
haemodynamic monitoring in a small cohort of stable LVSD patients in whom oral diuretics 
were withdrawn for six weeks, showed significant deterioration of haemodynamic parameters 
and worsening of symptoms. These returned to baseline values with reinstitution of chronic 
oral diuretic therapy. 
 
Combination therapies are routinely applied in clinical practice in the congested patient 
[Jentzer et al., 2010]. However, administration of incremental doses or combinations of 
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diuretics in non-congested LVSD patients who are already on maintenance oral diuretic can 
result in reduced intravascular volume. Thus, while plasma volume is fundamentally 
expanded in untreated LVSD patients, and for an unknown proportion of symptomatically 
decompensated LVSD patients, Feigenbaum et al. [2000] determined that plasma volume in 
clinically stable LVSD patients on chronic diuretic therapy was in fact contracted by 
approximately 23% when compared to known euvolaemic controls. Although Bonfils et al. 
[2010] demonstrated no significant difference between plasma volume and extracellular 
volume in stable LVSD patients compared to healthy volunteers, they showed a significant 
tendency towards a contraction in plasma volume with increasing furosemide dose in their 
LVSD patients. 
 
Diuretic-induced intravascular contraction results in inappropriate RAAS and SNS activation 
over and above that which can be suppressed by routine neurohormonal antagonist therapies 
resulting in further deterioration of cardiac performance [Francis et al., 1985].  Volume 
independent mechanisms can also play a role in this inappropriate neurohormonal activation, 
such as direct stimulation of renin release by blocking sodium uptake at the macula densa and 
upregulation of renin gene expression in the kidney, thus blocking the tubuloglomerular 
feedback [Ellison et al., 2001]. 
 
Intravascular volume contraction can also be linked to declining renal perfusion secondary to 
reduced renal blood flow and GFR, such that the emergent cardiorenal syndrome in fact can 
be due to the therapy as much as the disease. In the SOLVD study, patients taking diuretics 
had higher sCreatinine levels compared to patients not taking diuretics [Dries et al., 2000]. 
Furthermore, higher doses of loop diuretic are linked to  worse renal function in LVSD 
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patients, patients with pre-existing renal dysfunction requiring higher doses of loop diuretic to 
achieve adequate trans glomerular concentration of drug in the urine in order to reach their 
site of action in the kidney [Neuberg et al., 2002; Gottlieb et al., 2002]. The recognition and 
definition of mechanism of this renal resistance to diuretic treatment is a major problem in 
LVSD management [MacFadyen et al., 2003; Brater, 1994].  
 
Loop diuretic therapy has no controlled trial evidence of prognostic benefit in LVSD patients. 
Whether loop diuretics may improve prognosis in LVSD by their mode of action on abnormal 
volume status thus remains unclear. Indirectly, there is evidence that patients taking non-
potassium sparing diuretics have a worse prognosis compared to patients who are not treated 
with diuretics or patients who are on a potassium-sparing diuretic [Domasnki et al., 2003; 
Domanski et al., 2006]. There is a dose-related relationship with increasing mortality, and 
patients with the most altered doses of diuretics are also most likely to die [Eshaghian et al., 
2006].  These of course can be patients with inadequate treatment or those whose treatment is 
uptitrated due to worsening of their underlying HF; either can play a variable role in emergent 
mortality. 
 
1.4.2  Vasodilators 
 
Despite being used as cornerstones in the treatment of acute decompensated LVSD, the use of 
vasodilators is based on evidence from small studies focusing mainly on their acute 
haemodynamic effects and symptomatic benefit [Metra et al., 2009; Dickstein et al., 2008]. In 
patients with acute pulmonary oedema, vasodilators produce almost immediate symptomatic 
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benefit and improvement in central haemodymanic indices by volume compartment 
redistribution [Jugdutt, 1994].  
 
The use of vasoldilators in chronic LVSD, particularly in combination with hydralazine, 
although resuling in improved symptomatic benefit and increased exercise tolerance and 
LVEF compared to ACE inhibitors, does not confer the same mortality benefit as ACE 
inhibitors [Pfeffer et al., 2003; Cohn et al., 1991].
   
Thus the vasodilator combination is 
reserved for patients who are still symptomatic on ACE inhibitors, who are intolerant to ACE 
inhibitors and ARB, and in Afro-Caribbean patients where haemodynamic responses to both 
beta-blockers and ACE inhibition are attenuated [Taylor et al., 2004].  
 
1.4.3  Ultrafiltration (UF) 
 
UF filters plasma directly across a semi-permeable membrane in response to a transmembrane 
pressure gradient, resulting in ultrafiltrate that is isoosmotic compared with plasma. Its use is 
advocated for diuretic-resistant fluid overloaded patients in the acute setting in whom it 
produces greater weight and fluid loss, reduces hospital stay and readmission rates for HF 
compared to optimal doses of intravenous diuretics [Costanzo et al., 2008; Costanzo et al., 
2007].  During acute UF, mean right atrial pressure and PCWP reduce progressively resulting 
in increased cardiac output in the short-term.  Overall intravascular volume remains stable 
throughout UF with no suggested haemodynamic instability, suggesting movement of fluid 
from a congested interstitial space into the circulatory space [Marenzi et al., 2001; Marenzi et 
al., 1998].  Limited data also suggests that UF is able to remove more sodium and less 
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potassium for an equivalent amount of fluid removal when compared to traditional high-dose 
diuretic therapy. 
 
In the chronic setting, moderate LVSD patients without fluid overload have been randomised 
to either traditional diuretic based fluid management strategy or had in addition one single 
session of UF.  The latter patients showed predictable marked reduction in right atrial pressure 
soon after UF, and had significant improvements in clinical and functional status at 6 months 
compared to the control group [Agostoni et al., 1993]. Further studies are needed to establish 
the clinical applicability of UF beyond the acute setting, especially due to its high financial 
costs, and the fact that it may not have long-term reno-protective effects and indeed could 
exacerbate renal injury by abrupt fluid flux. 
   
1.4.4  Therapies under investigation  
 
The vasopressin antagonists conivaptan (V1/V2-receptor antagonist) and tolvaptan (specific 
V2-receptor antagonist) are currently being evaluated for their use in LVSD in view of their 
ability to increase net water loss and reduce hyponatraemia [Russell et al., 2003].  So far, they 
have shown significant reduction in cardiac preload and body weight, with increased urine 
output and consequent improvement in oedema [Udelson et al., 2008]. Increased serum 
sodium levels in conjunction with a reduced urinary osmolality and increased net water loss 
have also been demonstrated [Rossi et al., 2007]. 
 
A1 adenosine-receptor antagonists have the potential to block the vasoconstrictive effect of 
A1-receptor activation on the afferent renal arteriole.  This should in theory increase renal 
   18 
 
blood flow and GFR, thus reducing sodium reabsorption by the proximal tubule. So far, they 
have been shown to produce a potassium-neutral diuresis while maintaining renal function.  
Furthermore, their use may potentiate the effect of diuretics [Cotter et al., 2008]. 
Unfortunately the net effect of the primary agent in this group, rolofylline, has been 
discontinued due to lack of efficacy and adverse effects in blinded acute studies. Although 
several other agents in this class are available, the clinical outlook for these agents in LVSD 
with concomitant renal impairment seems poor [Massie et al., 2010]. 
 
1.5  Conclusion 
 
Predicting acute HF decompensation is an important clinical goal in LVSD, and abnormal 
volume status is an important determinant of decompensation. However, volume homeostasis 
has not been fully evaluated as a prognostic marker in LVSD nor has it yet been shown to be a 
target for prognostic treatment. Further studies are needed to explore the value of current and 
future therapies that impact directly or indirectly on volume status as a means of prolonging 
life and preventing decompensation in patients with LVSD.   
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Chapter Two 
 
Current Means of Defining Volume Status in Left 
Ventricular Systolic Dysfunction 
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2.1  Introduction 
 
In an attempt to prevent acute decompensation in LVSD, it is vital for the clinician to be able 
to assess the volume status of each individual patient accurately. In current clinical practice, 
the assessment of volume status in LVSD is challenging.  Furthermore, progressive 
abnormalities in volume status can occur prior to symptomatic or clinical recognition, such 
that the assessment of patients’ volume status encouraged through patterns of self-monitoring 
or regular clinical review is limited [Dickstein et al., 2008].  This Chapter will discuss 
currently available means that can potentially enable the clinician to assess volume status. A 
number of these means of volume assessment can be used routinely during inpatient and 
outpatient monitoring, while others have not made their way into routine clinical practice due 
to factors such as the complexity of their measurement, their costs, and risks of complications. 
In general, the routine non-invasive means of volume assessment tend to be cheap and more 
accessible, but have low specificity and/or low sensitivity, whereas the more complex and 
invasive means tend to be more accurate but may be associcated with more complications. 
 
2.2  Clinical symptoms  
 
The sensitivity and specificity of symptoms at estimating fluid status in LVSD are in general 
poorly defined.  Perceived exertional symptoms or scores (e.g., as assessed by NYHA 
functional class) poorly reflect exercise capacity, which may be regarded as a surrogate 
measure of cardiac output and thus of volume status.  In patients with reduced LVEF, there is 
only a weak association between peak exercise VO2 and NYHA functional class [Smith et al., 
1993], and no correlation of perceived exercise intolerance and peak VO2 or PCWP [Wilson 
et al., 1995].   
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2.3   Clinical signs  
 
Routine assessment of both acute and chronic LVSD includes a range of clinical signs on 
physical examination, documentation of which is highly dependent on the skill and technique 
of the operator.  While signs of hypervolaemia particularly during acute decompensation have 
some prognostic association [Drazner et al., 2003], the sensitivity of these signs at detecting 
abnormal volume status in chronic stable patients is low. On the basis of the 
pathophysiological model of dynamic volume redistribution in HF, it is not surprising that 
only 24% of stable LVSD patients with PCWP ≥18 mmHg had pulmonary rales in one study 
[Butman et al., 1993].  In a series of 52 HF patients referred for cardiac transplantation 
assessment, radiographic pulmonary congestion was absent in 53% patients with PCWP of 
16-29mmHg, and in 39% of patients with PCWP ≥30 mHg [Chakko et al., 1991].  Stevenson 
et al. [1989] found that the combination of rales, dependent oedema and elevated JVP only 
had a 58% sensitivity but a specificity of 100% in predicting PCWP ≥22 mmHg.   
 
2.4  Blood Volume Analysis 
 
Blood volume analysis forms the main basis of our understanding of the pathophysiological 
mechanisms involved in abnormal volume status in LVSD.  It constitutes a gold standard 
against which other means of volume assessment are compared in multiple clinical studies 
[Anand et al., 1989; Henning et al., 1978; Feigenbaum et al., 2008].  The volumes of each 
body water compartment as described in Figure 1.1 can be calculated based on dilution and 
equilibrium principles using appropriate radioactive or non-radioactive tracers.  These are 
distributed and diluted in the various fluid compartments, and their radioactive activity or 
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concentration levels can be measured at specific times so that volume of specific 
compartments can be determined by extrapolation [Veall et al., 1980].  Thus specific tracer 
characteristics are applied to measure a specific volume compartment, e.g., a tracer to 
measure ECW should diffuse freely across the capillary membrane, should not penetrate the 
cellular membrane barrier and should have a relatively slow rate of elimination from the 
system [Albert et al., 1968].  Single or multiple tracers can be used at the same time for 
simultaneous measurement of different volume compartments. 
 
Thus, the standard method to determine plasma volume is iodine-labelled human serum 
albumin (
125
I-HSA) [International Committee for Standardisation in Haematology, 1980].  
Alternative non-radioactive methods to determine plasma volume are less accurate and 
include Evans Blue dye dilution, Indocyanine green dilution, high molecular weight dextran 
and an extrapolated calculation of blood volume based on concomitant haemoglobin and Hct 
concentrations [Kalra et al., 2002]. For red cell volume estimation, use of sodium 
radiochromate (
51
Cr) or sodium pertechnetate (Tc-99m) is advocated [International 
Committee for Standardisation in Haematology, 1980].  The performance of radiosulfate (
35
S) 
is reliable for ECW estimation [Albert et al., 1968], and with simultaneous estimation of 
blood volume, allows the determination of interstitial fluid. TBW can be determined by using 
tritiated water. 
 
While sensitive and specific for volume status in LVSD, and useful as a standard against 
which other methods can be compared, blood volume analysis is not routinely applied in the 
care of LVSD patients due to the complexity of its measurement and necessary exposure to 
radioisotopes [Brown et al., 1992]. 
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2.5  Body weight monitoring 
 
HF guidelines routinely advocate daily weight monitoring in LVSD patients as an index of 
volume status [Dickstein et al., 2008].  Patients are in general advised to contact medical or 
nursing personnel or to temporarily increase their diuretic dosing if they develop a weight 
gain of 2 Kg over stable body weight over a period of 48-72h.  While this practice potentially 
motivates and empowers individual patients to take control of their own disease management, 
and is linked to reduced mortality, data linking changes in body weight to volume status is 
fundamentally lacking, and can only be interpolated from studies linking serial weight gain 
and acute decompensation [Chaudhry et al., 2007].  
 
In a multi-centre randomised controlled trial of a technology-based automated daily weight 
and symptom-monitoring system of advanced LVSD patients, there was no difference in the 
primary end-point of re-hospitalisation between the intervention group and the control group. 
However, mortality at 6 months was lower by 56% in the overall intervention group 
[Goldberg et al., 2003]. Similarly, in the larger TEN-HMS study, telemonitoring of body 
weight and other variables did not improve the hospitalisation end-point but was associated 
with improved survival [Cleland et al., 2005].  Lewin et al. [2005] demonstrated that the 
commonly used ≥2 Kg weight gain over 48-72h has a very low sensitivity at detecting clinical 
deterioration (only 9%), however, in common with many measures in proven LVSD it has a 
high specificity (97%).  Thus, weight gain, however defined, is insensitive to acute 
decompensation, and patients also have to be reminded that lack of weight change does not 
exclude impending clinical deterioration.  
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2.6     Invasive haemodynamic monitoring  
2.6.1     1on-ambulatory invasive haemodynamic monitoring 
 
Invasive haemodynamic monitoring by right heart or pulmonary artery catheterisation is 
commonly used in acute decompensated HF to estimate cardiac preload, cardiac ouput and 
systemic vascular resistance in order to guide treatment.  Surrogate measures of cardiac 
preload include LVEDP, LVEDV, left atrial pressure and PCWP [also known as pulmonary 
artery occlusion pressure (PAOP)]. These left sided haemodynamic measures  are closely 
related to right-sided filling pressures, i.e., central venous pressure or right atrial pressure, 
pulmonary artery systolic pressure (PASP) and pulmonary artery mean pressure 
(mPAP)[Drazner et al., 1999, Rhode et al., 2002], right-sided pressures being more readily 
measured clinically.  
 
There is also fair correlation between haemodynamic variables and blood volume. In one 
small open study of 17 stable LVSD subjects [Androne et al., 2004], a PCWP of ≥15mmHg 
had a sensitivity and specificity of 0.85 and 0.75 respectively for predicting a total blood 
volume of > 8% from predicted normal value. However, blood volume estimates reflect 
indices of cardiac function more accurately than either left or right-sided filling pressures in 
mechanically ventilated patients or in patients with potentially large fluid volume shifts 
(iatrogenic or pathophysiological) [Brock et al., 2002, Sakka et al., 1999].   
 
Catheter-titrated intravenous diuretic and vasodilator therapy in refractory HF enabled the 
achievement of low to normal LV filling pressures while maintaining low peripheral systemic 
resistance [Rohde et al., 2002], resulting in improved cardiac output and functional class. 
Steimle et al. [1997] showed similar haemodynamic and sustained clinical improvement in 
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patients referred for cardiac transplantation.  Repeat right heart catheterisation performed at 8 
±6 months in survivors showed sustained increase in stroke volume on unchanged chronic 
therapy.  LVEF improved and the severity of mitral regurgitation fell. Similarly, in the 
ESCAPE trial, treatment guided by pulmonary artery catheterisation compared to clinical 
assessment in decompensated LVSD patients resulted in a trend towards significant 
improvement in quality of life and exercise capacity both in-hospital and at one month post 
discharge [Binanay et al., 2005].   However, use of pulmonary artery catheterisation did not 
improve mortality figures and rates of hospitalisation, and was associated with predictably 
higher incidence of catheter-related adverse events such as bleeding and infection. Thus, the 
use of invasive non-ambulatory haemodynamic monitoring is limited by the need for 
intensive observation, additional costs and an association with increased adverse events.  It is 
also impractical in the follow up of ambulatory chronic LVSD patients.  
  
2.6.2     Ambulatory invasive haemodynamic monitoring 
 
Ambulatory monitoring of right ventricular pressures is feasible and safe by means of 
implantable haemodynamic monitors, whose use currently is still at an investigational stage
 
[Zile et al., 2008].  This method provides continuous haemodynamic data that is potentially 
more reliable than isolated static readings from a right heart catheter.  Current implantable 
haemodynamic monitors consist of a programmable device that processes and stores 
information and is similar in appearance to a pacemaker pulse generator, and a transvenous 
lead with a sensor near its tip to measure intracardiac pressure.  Variables such as heart rate, 
body temperature, patient activity, right ventricular systolic and diastolic pressure, rate of rise 
of ventricular pressure (dP/dt),  and estimated pulmonary artery diastolic pressure (ePAD) can 
be continuously monitored and stored [Bourge et al., 2008]. The ePAD is defined as the right 
   26 
 
ventricular pressure at the time of pulmonary valve opening, which occurs at the time of 
maximal dP/dt [Reynolds et al., 1995]. A strong correlation exists between ePAD and actual 
pulmonary artery pressures measured under a variety of physiological conditions [Magalski et 
al., 2002; Ohlsson et al., 1995; Chuang et al., 1996].  
 
Braunschweig et al. [2002] demonstrated a potential clinical utility of an implantable 
haemodynamic monitor in adjusting diuretic dose in patients with HF, linking right 
ventricular pressure to volume changes induced by diuretic manipulation. During 
haemodialysis in 5 patients with systolic or diastolic dysfunction (EF 20-50%), ePAD 
dropped by a mean  50 % , with the lowest pressures recorded during the first 90 minutes of 
dialysis[Braunschweig et al., 2006]. Long-term haemodynamic monitoring unmasked severe 
volume overload in one patient, in whom dry weight was kept constant despite a decrease in 
lean body mass. A study by Adamson et al. [2003] showed that continuous haemodynamic 
monitoring in 32 patients with LVSD revealed increased right ventricular pressures  4 ±2 days 
prior to exacerbations requiring hospitalisation in 9 out of 12 cases.  
 
On a larger scale, however, the use of implantable haemodynamic monitor-guided 
management compared to conventional management in 277 stable patients with severe HF, 
did not meet the primary efficacy end-point of reduction of HF-related events, defined as 
hospitalisations and emergency or urgent care visits requiring intravenous therapy [Bourge et 
al., 2008].  However, further analysis showed that there was a non-significant 21% reduction 
in total event rates and a non-significant 36% reduction in the relative risk of a first HF-
related hospitalisation.  The study may have been underpowered to show significant 
difference in event rates, and event rates in the control group may have been much lower than 
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expected for conventionally treated patients due to intensification of their contact schedule to 
match that of the implantable monitor-guided group.  
 
2.7  Bioimpedance analysis 
2.7.1  Definition and techniques  
 
Impedance (Z) is a measure of overall resistance of a body to an alternating current. Several 
techniques enable the estimation of measures relevant to volume status by integrating 
impedance values into regression equations validated against gold standards such as 
radioisotope techniques, densitometry, dual-energy absorbtiometry, thermodilution studies or 
the Fick principle [Sodolski et al., 2007].  Bioimpedance analysis (BIA) is a technique which 
applies the difference in impedance to different current frequencies to estimate body water 
composition based on the principle that electrolyte-containing water (a better conductor) has 
lower impedance than fat (a worse conductor).  Low frequency currents are unable to 
penetrate cell membranes, thus they enable approximation of ECW, whereas higher frequency 
currents are able to penetrate cell membranes, and give an approximation for total body water 
[Kyle et al., 2004].  Intracellular water (ICW) can then be estimated from subtracting ECW 
from TBW. 
 
Impedance cardiography and impedance tomography are techniques utilising the change in 
impedance with every cardiac cycle secondary to a change in intravascular volume to estimate 
haemodynamic variables. Common haemodynamic variables derived include cardiac output, 
stroke volume, systemic vascular resistance, thoracic fluid content, velocity index, pre-
ejection period, LV ejection time and heart rate.  Furthermore, bioimpedance variables can be 
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derived either across the whole body or across a specific area of interest, so called segmental 
bioimpedance. In addition, although most impedance analysis is performed non-invasively via 
surface electrodes (current electrodes delivering the current and voltage electrodes detecting 
the temporary changes in voltage), impedance-derived information can also be obtained 
invasively by integration of current fields into implantable cardiac devices. A device will 
typically measure the impedance between the right ventricular lead and the generator, thus 
giving regional information about lung and cardiac impedance. 
 
In LVSD, bioimpedance has been applied in an attempt to determine body water composition 
using BIA, or to provide estimates of haemodynamic variables using impedance cardiography 
(either non-invasively by means of surface electrodes across the chest, or invasively by means 
of cardiac devices).  
 
2.7.2  Diagnosis of systolic HF and prediction of acute decompensation 
 
The earliest potential application of bioimpedance was to diagnose systolic HF.  Using 
electrical impedance tomography in a group of 20 patients with acute pulmonary oedema, 
Noble et al. [1999] showed that lung impedance was lower compared to controls, and 
increased in response to treatment during the admission, at the same time as radiographic 
improvement on serial chest radiographs.   
 
Impedance reduces for some time prior to the onset of clinical pulmonary oedema, and thus 
may predict acute decompensation.  Repeated non-invasive thoracic impedance was 
performed in 328 patients admitted with an acute coronary syndrome without acute 
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pulmonary oedema [Shochat et al., 2006].  In 37 patients who subsequently developed 
cardiogenic pulmonary oedema, impedance decreased by more than 12% at least 30 minutes 
prior to the development of symptomatic cardiogenic pulmonary oedema. Similarly, Charach 
et al. [2001] demonstrated a significant decrease in non-invasive thoracic impedance in 30 
patients developing cardiogenic pulmonary oedema compared to patients who did not develop 
cardiogenic pulmonary oedema in a critical care setting.  The decrease in impedance values 
preceded the appearance of symptoms and signs by approximately 1h, and impedance values 
started to rise 1h prior to the resolution of clinical pulmonary oedema. 
 
In the chronic ambulatory setting, Yu et al. [2005] performed the first study to demonstrate 
the feasibility and potential clinical usefulness of intra-thoracic impedance monitoring in 
stable LVSD.  33 patients were implanted with an implantable cardioverter-defibrillator 
device which was also capable of measuring intrathoracic impedance. Of the 10 patients 
hospitalised for HF decompensation, intrathoracic impedance decreased by an average of 
12.3% over an average of 18.3 days prior to the admission. Reduction in the mean value of 
impedance values started on average 15.3 days prior to the onset of symptoms.  Similarly, a 
small scale study of 212 stable LVSD patients showed that higher composite scores for non-
invasively determined impedance parameters predicted the likelihood of a related cardiac 
event (death or a clinical HF presentation) within the next 14 days [Packer et al., 2006].
 
 
Currently, invasive intra-thoracic impedance monitoring can be performed using the 
Medtronic OptiVol
® 
which is integrated within implantable cardiac devices. A reference 
impedance line is derived from the individual patients’ continuous data 34 days after implant 
to allow for pocket oedema to settle and for lead maturation to take place. A combination of 
deviation from this reference line and the duration of this deviation in days constitutes the 
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fluid index measure, above which an audible alert will be triggered. The fluid index is 
physician-programmable and can be tailored to individual patients.  Ypenburg et al. [2007] 
showed that an impedance index threshold of 120 Ohm.day had a sensitivity of 60% and 
specificity of 73% for decompensated HF.  
 
2.7.3           Correlation with invasive haemodynamic indices 
 
The correlation of bioimpedance measures with gold standard measures is variable.  In 25 
healthy volunteers, a weak correlation was seen between cardiac output estimated by non-
invasive impedance cardiography and that estimated by echocardiography when the 
volunteers were at rest, with a percentage error of 53% between the two readings [Fellahi et 
al., 2009].  Following haemodynamic load challenge, there was no statistically significant 
relationship between percentage change in cardiac output determined by the two methods. 
Similarly, in 13 patients post cardiac surgery [Simon et al., 2009], good correlation was 
demonstrated between cardiac output determined by impedance cardiography and pulmonary 
artery catheterisation, however, the percentage error between the 2 methods was 49%. In 
patients hospitalised with decompensated HF, haemodynamic measures using non-invasive 
impedance cardiography had poor correlation with invasively measured PCWP and cardiac 
output [Kamath et al., 2009].  On the other hand, during acute decompensation, an inverse 
correlation was found between intrathoracic impedance determined from an implantable 
cardioverter-defibrillator device and invasively measured PCWP, and between intrathoracic 
impedance and net fluid loss during hospitalisation [Yu et al., 2005].   
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This variability between bioimpedance systems may stem from the use of widely varying 
regression equations, calibration against differing gold standards,  definitions made in widely 
variable reference populations, the use of whole-body versus segmental measurements, and 
whether algorithms are used to subtract the greater skin-electrode impedance values in non-
invasive systems [Yamamoto et al., 1976; Smye et al., 1993].  Furthermore, other 
confounders can cause changes in routine impedance values, such as infection, non-specific 
pyrexial illnesses, electrolyte abnormalities, conduction of current by sweat and electrode 
paste, electrode application errors and/or pocket infection in device-based estimates, 
significant aortic regurgitation, septic shock, arterial hypertension, extremes of body 
dimensions (height and weight), use of an intra-aortic balloon pump and some arrhythmias 
[Sodolski et al., 2007, Yamamoto et al., 1986].
 
 
 
Despite these limitations, in a small prospective observational study, clinicians felt that 
impedance cardiography helped them with clinical decisions and enabled them to avoid the 
use of invasive haemodynamic parameters in decompensated HF [Silver et al., 2004].  This 
highlights the fact that interpretation of trends rather than absolute values of derived or raw 
variables may be more clinically relevant.  The DOT-HF trial is currently in progress to 
address the impact of continuous intrathoracic impedance measured from an implanted device 
to detect increases in pulmonary fluid retention early and to facilitate timely treatment 
interventions. The primary end-point will be all-cause mortality and hospitalisation. 
Secondary end-points will also include quality of life and cost-effectiveness in this study 
aiming to involve 2400 patients [Braunschweig et al., 2008]. 
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2.8   Echocardiography 
 
The primary aim of echocardiography in the routine assessment of patients with LVSD is to 
establish LV size and function and to determine the aetiology or classification of LV 
impairment.  However, despite not being used routinely for the purposes of volume 
assessment, some echocardiographic indices can provide estimates of cardiac preload and of 
cardiac performance. 
 
2.8.1   Pulsed wave Doppler and Tissue Doppler indices 
 
 
Pulsed wave mitral inflow indices correlate significantly with invasive estimates of LV filling 
pressures such as PCWP in LVSD [Bartel et al., 1996].  In a study comparing the relation of 
mitral flow indices to left atrial pressure in patients with LVSD and patients with hypertrophic 
cardiomyopathy, left atrial pressure determined by angiography was directly related to the 
ratio of the early transmitral velocity (MVE) to the late transmitral velocity (MVA) (MVE/A), 
and inversely related to the early deceleration time (MVDT) in the LVSD group [Nishimura 
et al., 1996].  The sensitivity and specificity of an MVDT <180m/s which indicated a mean 
left atrial pressure of ≥ 20mmHg in this group were both 100%. However, there was no 
significant correlation between mean left atrial pressure and MVDT in patients with 
hypertrophic obstructive cardiomyopathy, suggesting this correlation may only be valid in 
patients with LVSD. This may be secondary to impaired myocardial relaxation in patients 
with hypetrophic obstructive cardiomyopathy. Similarly, the use of pulsed wave Doppler 
mitral inflow indices also provides only limited haemodynamic information in patients with 
sinus tachycardia, a prolonged PR interval, diastolic HF and primary abnormal left atrial 
dysfunction [Pozzoli et al., 2000].  The clinical utility of a combination of serial weekly 
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measures of mitral inflow indices (MVE/A, MVDT, and PASP) used in conjunction with 
raised B-type natriuretic peptide (BNP) levels and high NYHA functional class was 
demonstrated by Ben Driss et al. [2007], with a 100% sensitivity in retrospectively predicting 
acute decompensation in LVSD patients during beta-blocker initiation or up titration. 
 
Tissue Doppler imaging assesses the regional LV myocardial tissue velocities during diastole. 
The early diastolic mitral annular velocity (Ea) is a relatively load-independent measure of 
myocardial relaxation in patients with cardiac disease and does not correlate with mean 
PCWP. However its combination with MVE (E/Ea ratio) correlates well to invasively 
measured PCWP both in patients with normal and reduced LVEF [Dokainish et al., 2004; 
Nagueh et al., 1995]. Varying degrees of correlation have been found for E/Ea measured at 
the septal (E/Ea(s) and lateral (E/Ea(l) walls, and for the average of these two measurements. 
Furthermore, changes in PCWP in critically ill patients following treatment with intravenous 
inotropes and diuretics correlated well with changes in E/Ea [Dokainish et al., 2004]. 
However, the accuracy of E/Ea as a measure of  LV filling pressure appears to be limited in 
patients with restrictive heart disease; chronic resynchronisation therapy, significant mitral 
regurgitation, or in advanced LVSD with extensive LV remodelling [Mullens et al., 2009].  
The presence of regional wall motion abnormalities is also problematic, especially when 
measuring E/Ea(s).  E/Ea (s) did not correlate to LV filling pressures in patients with basal 
septal wall abnormalities following a myocardial infarction, whereas E/Ea(l) correlated with 
LV filling pressure, regardless of the location of the regional wall motion abnormality [Lim et 
al., 2009].  In patients with normal to low-normal LVEF, however, some authors have 
demonstrated better correlation of E/Ea(s) to PCWP [Arteaga et al., 2008; Drighil et al., 
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2008],  whereas others have shown that E/Ea(l) performs better at predicting  LV filling 
pressures [Rivas-Gotz et al., 2003].
 
 
Pulsed wave Doppler assessment of pulmonary vein flow provides yet another potentially 
useful estimate of LV filling pressure.  The pulmonary vein Doppler spectrum reflects the 
phasic change of left atrial filling and is highly load dependent [Tabata et al., 2003].  Several 
studies have found close correlations between the pulmonary systolic velocity /pulmonary 
diastolic flow velocity ratio of the pulmonary vein Doppler spectrum and LV filling pressure 
in the perioperative setting and in patients undergoing elective cardiac catheterisation 
[Kuecherer et al., 1990; Rossvol et al., 1993].  In patients undergoing haemodialysis, this ratio 
outperformed other mitral inflow indices in its correlation with changes in ECW as assessed 
by BIA [Wu et al., 2004].  Confounding factors between fluid status and pulmonary vein 
Doppler parameters are age, sex, body surface area and LV diastolic function [Gentile et al., 
1997].   
 
2.8.2           Inferior vena cava indices 
 
 
The inferior vena cava (IVC) is easily imaged and is a highly compliant vessel whose size and 
dynamics change with changes in central venous pressure and volume, and with the 
respiratory cycle.  The retrohepatic or superior part of the IVC is most commonly imaged, 
with good correlation between measurements using 2-D and M-mode imaging in the long and 
short-axis, and with little intra and inter-observer variability [Moreno et al., 1984].   
 
IVC diameter and percentage collapse is recommended in echocardiography guidelines for the 
routine estimation of right atrial pressure [Lang et al., 2006], using a variety of equations with 
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differing cut-off values for IVC diameters to estimate right atrial pressure. Several studies 
have demonstrated varying degrees of correlations of IVC indices to invasively measured 
haemodynamic variables. IVC diameter has a curvilinear correlation with pulmonary artery or 
right atrial pressures measured during cardiac catheterisation in varied groups of normal 
volunteers, patients with predominantly right-heart disease, and patients with left-sided 
cardiac disease [Moreno et al., 1984].  This may be due to the reduced distensibility of the 
vein at larger diameters.  IVC collapsibility index (IVCCI), defined as [(IVC diameter on 
expiration – IVC diameter on inspiration) / IVC diameter on expiration] × 100, also correlated 
well with these invasive haemodynamic parameters, supporting the recommendations for the 
use of this variable as an estimate of right atrial pressure [Natori et al., 1979].   In view of the 
large variation in body weight and composition of patients with varying pathologies, IVC 
diameters are commonly indexed to increase their accuracy at estimating haemodynamic 
variables or blood volume. Thus, IVC diameter corrected for body surface area (IVCD) 
correlated well with both invasively-measured mean right atrial pressure and blood volume in 
haemodialysis patients without cardiac or pulmonary disease [Cheriex et al., 1989].  There 
was also good correlation between changes in IVCD and changes in blood volume. Although 
there was also good correlation between IVCCI and mean right atrial pressure in this group of 
patients, IVCCI did not correlate to blood volume, suggesting that IVCD is pressure and 
volume-related, whereas IVCCI is pressure-related only. Similarly, in a cohort of 100 dilated 
cardiomyopathy patients, IVC diameters on inspiration and expiration, and IVCCI correlated 
with right atrial pressure before and after loading manipulations.  Furthermore, the increase in 
IVC diameter from baseline in patients with acute decompensated HF reflected the increase in 
body weight from baseline to that on admission [Sasaki et al., 2001].  In an attempt to ensure 
that the assumption that IVC indices are indeed indicative of LV filling pressures, as studies 
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up to then had only compared IVC indices to right-sided pressures, Blair et al. [2009] 
evaluated the ability of IVC diameter and IVCCI to predict an increased PCWP.  The 
respective sensitivities for this prediction were 75% for an IVC diameter of >2.0 cm, and 83% 
for an IVCCI of <45%. 
 
IVC enlargement alone can be a non-specific finding, with a degree of overlap between 
normal subjects, patients with right-sided and left-sided HF [Rein et al., 1982].  However, 
increased IVC diameter on admission and at discharge for acute HF was a reasonable 
predictor of subsequent adverse events [Goonewardena et al., 2008].  Similarly, in stable 
patients with varying comorbidities attending routinely for an echocardiogram, larger IVC 
diameter with reduced collapsibility was a predictor of poorer outcome.  A reduced IVCCI 
had 92% sensitivity and 84% specificity for the diagnosis of HF in patients who presented to 
hospital with shortness of breath [Blehar et al., 2009].   
 
2.9   Blood biomarkers  
2.9.1   1atriuretic peptides (1P) 
 
B-type natriuretic peptide (BNP) and its inactive form N-terminal pro-BNP (NTproBNP), the 
B-type NP, and to a lesser extent, atrial natiuretic peptide (ANP) and its inactive form N-
terminal pro-ANP (NTproANP), the A-type NP, have been widely studied in terms of their 
sensitivity as indices in both the diagnosis and prognosis of LVSD, in addition to their 
potential utility in mapping response to treatment [Maisel et al., 2007]. The routine use of 
BNP and NTproBNP, for which there are commercially available assays for point of care 
measurement, is endorsed in HF guidelines as adjuncts in HF diagnosis [Dickstein et al., 
2008].
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BNP and NTproBNP have a useful role in the diagnosis of LVSD in unselected patients 
presenting with breathlessness [Januzzi et al., 2005, Mueller et al., 2006; Moe et al., 2007].  
Furthermore, admission and discharge BNP and NTproBNP levels have good prognostic 
value for future adverse events [Maisel et al., 2004; Fonarow et al., 2007; Dokainish et al., 
2005; Logeart et al., 2002]. BNP and NTproBNP seem to have more prognostic power in the 
short term compared to ANP and NTproANP [Yan et al., 2005].
 
 
Data on the use of NP to diagnose acute decompensation of chronic LVSD is less robust than 
its utility during an index presentation of acute LVSD [Maisel et al., 2008].  Although NP 
levels correlate well to left atrial and LV dimensions, LVEF and symptoms [Pfisterer et al., 
2009; Iwanaga et al., 2006], data regarding the correlation of NP levels with invasive 
estimates of LV filling pressures are inconsistent. In acute decompensation, point 
measurements of BNP do not correlate to right atrial pressure or PCWP, although BNP and 
NTproBNP levels tend to be increased in patients who have high LV filling pressures 
[O’Neill et al., 2005; Dokainish et al., 2004; Shah et al., 2007]. Serial BNP levels then 
decrease significantly following HF treatments, similarly to invasive haemodynamic indices, 
however, changes in levels of the respective variables do not correlate well with each other.  
BNP decreases in response to effective diuresis in refractory LVSD within 6 days [Salvatore 
et al., 2005], but not within 24h of acute treatment where it correlates poorly to either blood 
volume or haemodynamic measurements [James et al., 2005].
 
 BNP levels, however, seem 
more responsive to rapid haemodynamic changes in acute HF compared to NTproBNP [Mair 
et al., 2007]. Thus, BNP and NTproBNP measures may be better measures of medium to 
longer-term haemodynamic changes [Braunschweig et al., 2006]. 
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ANP and NTpro-ANP appear more sensitive to acute volume loading in both normal 
volunteers and haemodialysis patients with normal LV function [Corboy et al., 1994; 
Herringlake et al., 2004]. 
 
In these studies ANP and NTproANP are both more sensitive in 
terms of onset of response, time for achieving peak levels and time for levels to return to 
baseline compared to both BNP and NTpro-BNP. In LVSD patients, data regarding this 
comparative responsiveness is more limited.  In small scale studies, acute volume load in 
stable HF was accompanied by acute increases in ANP levels [Uretsky et al., 1990; 
Rodeheffer et al., 1991; Gabrielsen et al., 2001].  Similarly, in LVSD patients receiving 
vasodilator therapy, ANP levels reduced quickly, with subsequent modest increase over a 24h 
period (mirroring PCWP), whereas BNP levels reduced more slowly and correlated better 
with systemic vascular resistance [Larsen et al., 2006].  
 
This difference in sensitivity of the A-type and B-type NP to acute volume changes may be 
due to differing dynamic responsiveness and release, and metabolism and excretion of each 
NP [Yoshimura et al., 1993].  ANP is present in the atria and to a lesser extent in the 
ventricles and is released in response to both atrial and ventricular stretch [Yasue et al., 1994]. 
BNP on the other hand is present in the ventricles only and is released in response to 
ventricular stretch, but may also be released in response to ventricular damage or injury due to 
the cardiotoxicity of other processes such as other neurohormones or production by cardiac 
fibroblasts [Maeda et al. 1998]. Furthermore, the A-type NP are released from granlues in the 
atrial myocardium in a rapid process, whereas only small amounts of B-type NP are prestored 
in the ventricles. The response of B-type NP is thus dependent on upregulation at the level of 
gene activation for secretory adjustments of BNP, which would take longer to occur [Yasue et 
al., 1994]. It is also plausible that the atria, being more distensible than the ventricles, are 
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stretched to a larger extent by the same mechanical or pressure stimulus compared to the less 
distensible ventricles. This results in faster and proportionally larger release of A-type NP 
compared to B-type NP [Ogawa et al., 1996].Furthermore, whereas a difference between the 
renal clearance of A-type and B-type NP remains to be clarified, there is a difference in the 
circulatory metabolism and pulmonary clearance of the NP [Smith et al., 2000; Yoshimura et 
al., 2000]. B-type NP are more resistant to clearance by peptidase in the ciruclation, and their 
metablic clearance in the pulmonary circulation occurs to a lesser extent than for A-type NP.  
 
There is conflicting evidence that BNP-guided or NTproBNP-guided treatment of HF on an 
outpatient basis compared to treatment guided by clinical assessment alone produces better 
outcome, and whether this may be secondary to optimisation of volume status. 
 
In the TIME-
CHF study where NTproBNP-guided treatment was compared to standard symptom-guided 
management and therapy in a randomised controlled trial, no significant differences were 
found for the primary outcomes of survival free of hospitalisations and quality of life over a 
follow up period of 18 months [Pfisterer et al., 2009]. Doses of drugs with proven prognostic 
efficacy were up titrated to a significantly greater extent in the NTproBNP-guided group, this 
being mainly driven by the significantly higher use of aldosterone receptor blockers and 
number of dose increases of beta-blockers. Changes in diuretic, ACE inhibitor and 
angiotensin receptor blocker use did not differ between the groups. Levels of NTproBNP and 
symptoms were also not significantly different between the two groups. A similar pattern of 
drug changes was found in the STARS-BNP study [Jourdain et al.,  2007], whereas 
Troughton et al. [2000] demonstrated significantly higher titration of ACE inhibitors, 
aldosterone antagonists and diuretics only to achieve very similar levels of BNP in both BNP-
guided and standard management groups. Both studies however, showed positive outcomes 
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with BNP-guided treatment versus standard management. Thus, it is still not clear which 
specific treatment would confer benefit guided by NP levels.   
 
2.9.2   Haematocrit (Hct) 
 
Hct (red cell volume) is the percentage of red blood cells as a proportion of total blood 
volume. This is perhaps the simplest of blood biomarkers applicable to variations in blood 
volume, and it can be simply measured by automated analysers [Lewis et al., 2001]. Hct 
levels can be an indirect measure of blood volume in patients with HF, thus increasing due to 
haemoconcentration in hypovolaemia, and reducing due to haemodilution secondary to 
circulatory volume expansion. Strauss et al. [1951] proposed the use of Hct and haemoglobin 
levels before and after an intervention to alter plasma volume in order to estimate the 
percentage change in plasma volume.  Thus, percentage change in plasma volume was 
calculated as 100 × [Haemoglobin (before)/Haemoglobin (after)] × [1-Hct (after)/1-Hct 
(before)] –100.   
 
However, a low Hct in patients with LVSD can be due to either an increased plasma volume 
(haemodilution), and/or from reduced red blood cell volume (true anaemia) [Ng Kam Chuen 
et al. 2007].  Determination of red cell and plasma volume is important in this circumstance to 
differentiate between the two.  Anaemia, defined as a low Hct level, is relatively common in 
patients with chronic LVSD, and is a strong predictor of adverse outcome [Kosiborod et al., 
2005].  Anaemia in chronic LVSD may be due to chronic disease, bone marrow depression 
from excessive cytokine production, malnutrition, concomitant or related renal disease, and/or 
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drug therapy. This complicates the use of Hct as a practical measure of volume status, and 
makes it non-specific. 
 
When isolated point measured samples are compared, haemodilution can be present in up to 
46% of anaemic patients with LVSD [Androne et al., 2003].  Patients with low Hct due to 
haemodilution have poorer outcome compared to patients with a true anaemia. Similarly acute 
HF patients who are subsequently stabilised show lower BNP and NTproBNP levels which 
inversely correlate with haemoglobin and Hct. The association between simple Hct and 
progression of disease from asymptomatic LVSD to symptomatic HF in 2,281 patients from 
the SOLVD trial showed that patients with the lowest Hct quartile were at increased risk for 
the development of HF symptoms, first hospitalisation due to HF, and death compared with 
patients in the highest Hct quartile [Das et al., 2005].  
 
Boyle et al. [2006] proposed that haemoconcentration could be used as a surrogate marker to 
indicate that plasma refill rate has been exceeded by the rate of fluid removal during UF in the 
treatment of acute decompensated HF. Hct can be easily and continuously measured by using 
an on-line Hct sensor during UF therapy. Thus, the rate of volume extraction could be 
adjusted to approximate plasma refill rate so that complete decongestion can be reached when 
haemoconcentration is observed at minimal rates of volume extraction. On-line Hct 
monitoring has enabled the above principle to be applied to haemodialysis patients prone to 
dialysis-related hypotension with some evidence of efficacy [Schroeder et al., 2004].  One 
potential advantage of Hct measures is that while low Hct levels would suggest developing 
hypervolaemia, alternatively a high Hct might indicate dehydration thus allowing a potentially 
damaging therapy to be balanced.  As with other biomarkers the change in measured value 
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and direction of change may be the key in clinical application. The best setting for Hct 
measuresmay lie in repeatedly monitoring acute volume changes, as many other factors may 
affect Hct levels in the longer term. 
 
2.10   Summary 
 
In the management of individual LVSD patients, the accurate non-invasive definition of 
volume status remains severely problematic. Despite large resources being placed in systems 
of care designed to optimise therapy and prevent decompensation, a suitably sensitive and 
specific non-invasive biomarker for detecting changes in volume status, whether at a clinical 
or preclinical stage in LVSD has not yet been defined.  
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Chapter Three 
 
Defining the Source of Variance of Blood 
Biomarkers Relevant to the Pathophysiology of 
Abnormal Volume Status in Left Ventricular 
Systolic Dysfunction 
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3.1   Characteristics of a clinically useful biomarker for the  
  monitoring of volume status in LVSD 
 
A biomarker is an objectively measured indicator of normal biological or pathogenic 
processes, or response to a therapeutic intervention, and can consist of blood, urine or tissue 
constituents or physical biomeasures [Biomarkers Definitions Working Group, 2001]. In 
utilising biomarkers to track changes in volume status in LVSD, the clinician needs to be 
aware of the characteristics required of clinically useful biomarkers for this purpose, the 
sources of their measurement variance, and principles to minimise this. These issues will be 
discussed in this Chapter, with particular emphasis on the specific blood biomarkers which 
will be studied in this thesis. Despite this Chapter focusing on blood biomarkers, the 
principles described here will also apply to the physical biomeasures studied in this thesis. 
 
In general, a candidate biomarker will only have clinical utility if it can be measured by the 
clinician, if it adds new information, and if it helps the clinician to manage the patient, over 
and above any tests currently available and in addition to clinical acumen [Morrow et al., 
2007].   To be readily measured by the clinician, its measurement must be accurate, 
reproducible, rapid and cost-effective.  The results must be easy to interpret, and undergoing 
the test must be acceptable to the patient [Malino et al., 2003]. The properties of biomarkers 
will vary with the sample frame of their intended use [Vasan et al., 2006]. In the context of 
monitoring of volume  status in LVSD, not only do the biomarker levels need to correlate to 
spot measures of gold standards for volume status, more importantly, changes in their levels 
need to have high sensitivity and specificity for changes in volume status. Thus, their levels 
need to change rapidly and to an appreciable extent with changes in volume status, unlike for 
diagnostic biomarkers, where sustained elevated levels are an advantage. Narrow within-
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subject variability is required, although between-subject variance is less important as each 
patient will serve as his/her own control. Because biomarker levels for monitoring need to be 
performed on a regular basis, tolerability and cost effectiveness are also important features.  
 
3.2  Sources of variance of blood biomarkers 
 
When using a biomarker to guide patient management, clinicians must appreciate that a point 
measurement of the biomarker is an estimate of its absolute value; this estimate needs to be 
interpreted in the context of the normal variance both within an individual and between 
individuals [MacFadyen, 2006]. The normal variance of a biomarker is a measure of the 
range of measured values from the absolute value, and is also termed the total variance of that 
biomarker (CVt). Thus, for blood, urine or tissue biomarkers, normal variance is affected by 
pre-analytical, analytical and post-analytical factors, as outlined in Figure 3.1. Similar 
principles apply to physical biomeasures, with intra and inter-observer variability determing 
their analytical and post-analytical variance. 
 
Pre-analytical variance refers to inherent biological variability (CVi) and sample handling, in 
other words the stability of the biomarker depending on conditions under which it is sampled 
and stored.  While the latter component of pre-analytical variance can be minimised to non-
significant values by taking steps such as ensuring that steady state is reached prior to 
sampling, good training of staff and good adherence to standard operating procedures, 
biological variability can be very large for some biomarkers, and generally constitutes the 
largest source of variance [Fraser, 2009].
 
Biological variability is determined by several 
factors as outlined in Figure 3.1.  Within an individual, it can be considered as a random 
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fluctuation around a homeostatic set point, which tends to be constant over time, geography, 
methodology and in health and chronic disease. This is termed the within-subject biological 
variation. However, individual homeostatic set points vary between individuals; this 
difference between individuals is termed the between-subject biological variation. The former 
is generally much smaller than the latter for most biomarkers. 
 
Figure 3.1.  Potential sources of pre-analytical, analytical and post-analytical variance of 
blood biomarkers [Vasan 2006; Fraser, 2009].
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Analytical variability relates to the assay performance in the laboratory, and post- analytical 
factors include the processes of approval and transmission and the appropriate display of test 
results with the use of the laboratory’s information management systems. Post-analytical 
sources of variance can also in practice be minimised to non-significant levels. 
 
Thus, the main determinants of the total variance (normal variance) of a biomarker within an 
individual (CVtws) consist of the within-subject biological variance (CViws) and analytical 
variance (CVa) [Fraser, 2001]. CVtws of a biomarker over a specific period of time can be 
calculated from several measured values of the biomarker over that specific time period by 
determining the coefficient of variation [(standard deviation/mean) × 100] of values measured 
over that time period within an individual. The longer the time period over which values are 
measured, the larger the CVtws will tend to be. Analytical variance can be calculated generally 
by determining the coefficient of variation of several measurements of quality control 
specimens with pre-determined values using one assay (intra-assay CVa) or using different 
assays (inter-assay CVa). The within-subject biological variability (CViws) can then be 
determined by using the equation CViws = √ (CVtws
2 
–CVa
2
) [Bruins et al., 2004]. The 
between-subject total variance (CVtbs) can also be calculated using the same equation as for 
the determination of CVtws[(standard deviation/mean) × 100], but applying population means 
and standard deviations for the calculation of the CVtbs. CVibs can thus be derived in the same 
way to CViws, by applying the equation CVibs=√ (CVtbs
2 
–CVa
2
).  
 
To the clinician, whose role it is to diagnose and monitor disease or response to treatment, it 
is the within-subject and between-subject total variance that are of most relevance in the 
context of interpreting biomarker levels released by the laboratory and relating this to the 
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clinical state of the individual patient. The between-subject total variance can be very large for 
some biomarkers, such that a reported biomarker level may be highly unusual for a patient, 
but may still lie below conventional cut-off points or within conventional population-based 
reference ranges. This may explain the controversies surrounding for example, the use of NP, 
namely the false positive and false negative rates for diagnosis of HF [Tang et al., 2003],
 
and 
the ongoing debate about whether biomarker-guided treatment is beneficial over and above 
treatment guided by clinical assessment [Berger et al., 2010].  
 
In an attempt to solve this problem, some authors advocate the use of reference change values 
(RCV) [Harris, 1979]. The RCV of a biomarker is defined as that measured value which 
indicates a difference between two consecutive measures that is statistically significant and 
links to a significant change in a patient’s health status; it is usually expressed as a percentage 
of a baseline value. It can be calculated simply by using the following equation:  
RCV= √2 × Z × √ (CVa2 + CVi2), or RCV=√2 × Z × CVt, where Z is the number of standard 
deviations appropriate to the desired probability, e.g., 1.96 for p<0.05 and 2.58 for p<0.01.  
However, there is still current debate around the clinical application of this principle, and the 
statistical calculation of RCV for non-normally distributed data, which is the case for a large 
number of biomarkers relevant to LVSD [Fokkema et al., 2006; Omar et al., 2008]. 
 
Some 
authors advocate using a log-normal approach , producing two different RCV for increasing 
and decreasing values, e.g., RCV for BNP: +198% and –66% from baseline measure [Wu et 
al., 2009].  
 
An alternative way of using the principle of using a difference between two measured values 
within an individual for detecting a significant change in that individual’s clinical status 
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involves mapping the within-subject normal variance at times of clinical stability by means of 
repeated measures assessment.  With continuous/intermittent monitoring, the onset of acute 
exacerbation of disease would be identified as a significant and sustained deviation from this 
within-subject normal variance, as illustrated in Figure 3.2.  This principle is currently 
employed in implantable haemodynamic monitors or bioimpedance sensors within 
implantable cardiac devices; the clinical validity of its use still being under investigation 
[Braunschweig et al., 2006]. Importantly, these principles potentially enable the identification 
of the subclinical phase of disease, such that in theory, treatment can be intensified and 
hospital admissions avoided.  
 
Figure 3.2.  Potential patterns of deviation from within-subject normal variance for the 
prediction of a clinical event. 
 
Reproduced with the author’s permission from J Human Hypertension 2006; 20: 383-6. [MacFadyen, 2006]. 
 
3.3   Blood biomarkers relevant to LVSD to be studied in this thesis 
 
The panel of blood biomarkers to be studied in this thesis was selected based on their current 
availability and ongoing application in routine clinical practice, and includes NP, cardiac 
troponin peptides, ischaemia modified albumin and Hct. The next section will discuss the 
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sources of variance of these blood biomarkers which can be directly controlled, and thus 
mininised by the clinician, namely pre-analytical variance. 
 
3.3.1            1atriuretic peptides 
 
3.3.1.1            Biological variance 
 
NP levels are affected by a number of physiological and non-physiological conditions (Table 
3.1), which if present concurrently with LVSD may confound their monitoring capacity. 
 
Table 3.1.  Physiological and non-physiological states associated with changes in 
natriuretic peptide levels [Maisel et al., 2008; McDonagh et al., 2007].
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physiological states 
Increased 
•    Children 
•    Old age 
•    Female 
Decreased 
•    Increasing body mass index 
 
• Left atrial size  
• Pulse pressure 
• Genetic 
 
1on-physiological states 
Cardiac causes 
Increased 
• Systolic heart failure  
• Diastolic heart failure 
• Left ventricular hypertrophy 
• Coronary artery disease 
• Right ventricular dysfunction 
1on cardiac causes 
Increased 
• Pregnancy-related hypertension 
• Chronic renal impairment 
Decreased 
• Uncomplicated diabetes  
• Obesity 
 
 
• Hypertension  
-with or without LVH 
• Valvular heart disease 
• Cardiac allograft rejection 
• Hypertrophic obstructive cardiomyopathy 
 
 
• Primary pulmonary hypertension 
 
 
• Pulmonary embolism 
• Subarachnoid haemorrhage 
Effect of treatment 
Increased 
•
 Beta-blockers (short-term)  
Decreased 
• Beta-blockers (long-term)  
• Diuretics 
• ACE inhibitors 
 
• Digoxin 
 
• Angiotensin II receptor blockers 
• Spironolactone 
• Cardiac resynchronisation therapy  
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Table 3.2. Within-subject total variance (CVtws), analytical variance (CVa), within-
subject biological variance (CViws) and reference change values (RCV) of natriuretic 
peptides.  
Population Biomarker Time period CVtws (%) CVa (%) CViws (%) RCV (%) 
Bruins et al., 
2004
  
Stable HF 
(n=43)
  
BNP 
 
 
 
NTproBNP
 
2° for 8h 
Daily for 5 days 
Weekly for 6 wks 
 
2° for 8h 
Daily for 5 days 
Weekly for 6 wks 
 
12.0 
27.0 
41.0 
 
9.1 
20.0 
35.0 
8.4 
8.4 
8.4 
 
3.0 
3.0 
3.0 
8.2 
25.0 
40.0 
 
8.6 
20 
35
 
32.0 
74.0 
113.0 
 
25.0 
55.0 
98.0
 
Wu et al., 
2003 
NV (n=12)
  
 
Stable HF 
(n=5) 
 
Unstable HF 
(n=11)
 
 
 
BNP 
NTproBNP 
 
BNP 
 
BNP 
NTproBNP 
 
 
 
4 samples every 
alternalte week 
 
2° for 24 h 
 
Daily during acute 
admission 
 
 
NA 
NA 
 
NA 
 
NA 
NA 
 
 
8.6 
1.6 
 
8.6 
 
8.6 
1.6 
 
 
43.6 
33.3 
 
24.0 
 
NA 
NA 
 
 
NA 
NA 
 
NA 
 
130.0 
90.0 
 
O’Hanlon et 
al., 2007
  
Stable HF 
(n=45) 
 
BNP 
 
 
NTproBNP 
 
1 hour apart 
1 week apart 
 
1 hour apart 
1 week apart 
 
 
14.6 
28.4 
 
6.9 
21.1 
 
13.7 
13.7 
 
2.8 
2.8 
 
5.0 
24.8 
 
6.3 
20.9 
 
34.0 
66.2 
 
16.1 
49.2 
 
McDowell et 
al.,2002 
NV (n=10)
  
 
 
Stable HF 
(n=10) 
 
 
 
ANP 
NTproANP 
 
ANP 
NTproANP 
 
 
 
Every 2 min for 90 
min 
 
Every 2 min for 90 
min 
 
 
 
65.0 
8.9 
 
51.0 
3.6 
 
 
 
8.0 
5.9 
 
8.0 
5.9 
 
 
 
NA 
NA 
 
NA 
NA 
 
 
 
NA 
NA 
 
NA 
NA 
NV: normal volunteers; NA: not documented by authors. 
 
NP have large within-subject and between-subject normal variance. In a cohort of 558 LVSD 
patients, up to one-fifth of symptomatic but clinically stable patients (NYHA class II-III) had 
BNP levels of <100pg/mL, whereas asymptomatic patients’ BNP levels ranged from 5-572 
pg/mL, with a median value of 147pg/mL [Tang et al., 2003]. The large within-subject normal 
variance of NP has been demonstrated in a number of studies in a variety of populations, as 
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shown in Table 3.2.
 
The amplitude of this variance has not been consistent in different 
studies, such that considerable uncertainty remains regarding these estimates.  This within-
subject normal variance has been shown to be independent of factors such as renal function, 
age or gender [O’Hanlon et al., 2007].
 
NP levels in both diastolic and systolic HF have 
reduced within-subject normal variance compared to levels measured in healthy individuals 
[Kjaer et al., 2005]. Furthermore, within-subject normal variance for NP reduces with 
advancing severity of HF and increasing NP levels [Araújo et al., 2006]. 
 
Thus, current consensus recommendations are that NP levels are interpreted as a continuous 
variable so that the higher the NP value, the higher the likelihood of the presence of HF, and 
that two cut-off values are used to rule in and rule out HF [Maisel et al., 2008].  For BNP, cut-
off values of <100 pg/mL and >400 pg/mL have high sensitivity and specificity at ruling out 
and in a diagnosis of HF respectively [Mueller et al., 2004].  For NTproBNP, the 
recommended cut-off point to rule out a diagnosis of HF is <300 pg/mL, whereas different 
age-dependent cut-off values for ruling in HF include >450 pg/mL (<50 years), >900 pg/mL 
(50-75 years) and >1800pg/mL (>75 years) [Januzzi et al., 2005; McDonagh et al., 2004].  
Nevertheless, considerable error may be encountered when trying to diagnose HF in a 
particular individual while trying to apply this population-generated approach.   
 
The large within-subject and between-subject total variance of NP makes their measured point 
values difficult to interpret in the context of diagnosing an acute decompensation of LVSD; 
some authors recommend the use of RCV, which can be as high as 130% in the case of BNP. 
 
This makes the interpretation of results from studies implying significant treatment benefit 
with reductions of NTproBNP and BNP levels of up to 35% and 50% respectively, difficult. 
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Furthermore, in clinical practice, total variability of NP levels is likely to be much more than 
that established in selective clinical studies, as many precautions taken for granted in the 
former setting to actively minimise biological and analytical error are not followed in routine 
practice. Currently, some opinion advocates that a rise of >50% of NP values should draw the 
clinician to consider increasing the patient’s diuretic dose, in the absence of symptoms of 
volume overload [Maisel et al., 2008], a practice which would be entirely flawed in the light 
of the above discussion. 
 
3.3.1.2           Sampling and storage 
 
The half-lives of ANP, NTproANP, BNP and NTproBNP are 2-3 minutes, 16-24 minutes, 20 
minutes and 70 minutes respectively.  Thus, ideally, sampling should take place after steady 
state is reached (5-6 half-lives) [Fraser, 2004], which for BNP would require 100-120 
minutes.  Most clinical studies take blood for measurement after resting supine for 30 
minutes, and in busy outpatient departments, patients are very rarely rested and supine before 
drawing blood.   
 
NP in plasma or serum is degraded by proteolysis, occurring within 24h of separation of 
plasma or serum from whole blood, progressing on refrigeration or freezing.  Stabilisation of 
NP in vitro can be achieved by collection into EDTA tubes [Belenky et al., 2004, Dupuy et 
al., 2006; van der Merwe et al., 2004; Sokoll et al., 2002], and by adding protease inhibitors 
such as aprotinin, benzamidine and D-Phe-Phe-Arg-chloromethylketone to reduce ex-vivo 
degradation of NP [Belenky et al., 2004].
 
The latter seems the most effective, whereas 
aprotinin, which has been used extensively in many studies, is more widely available.  
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In general, quick centrifugation of NP samples is recommended, with storage of whole blood 
at 4°C until this takes place.  The separated sample should then be stored at temperatures of 
around –70°C. Furthermore, repeat freeze-thaw cycles should be avoided; this can result in 
BNP loss ranging from 10-36%, independent of the type of assay used [Mueller et al., 2004].
 
 
 
3.3.2           Cardiac troponin peptides (cTn) 
 
The role of cTn in the diagnosis of acute coronary syndromes is well established; both 
troponin I (cTnI) and troponin T (cTnT) are very sensitive and specific markers of myocardial 
damage [Alpert et al., 2009].  Disease progression in LVSD even in the absence of overt 
ischaemia is associated with ventricular remodelling and myocyte loss as illustrated by 
indium anti-myosin antibody imaging in patients with dilated cardiomyopathy [Cohn et al., 
2000; Matusmori et al., 1993].  In theory, the cTn, in ischaemic cardiomyopathy at least, 
could map disease status, response to treatment and prognosis by providing a measure of 
myocyte injury secondary to LV stretch or dilatation as a result of ventricular remodelling in 
response to abnormal volume status. Other mechanisms leading to myocyte injury could 
include inflammatory, oxidative stress and neurohormones [Braunwald, 2008]. 
  
In stable LVSD, modest elevations of cTn are found even in the absence of ischaemia or acute 
symptomatic decompensation in around half of patients being studied [La Vecchia et al., 
1997; Horwich et al., 2003]. 
 
Incremental increases in, and higher cTn levels are linked to 
increasing mortality, rates of hospitalisation, declining LVEF, worse haemodynamic variables 
and higher BNP levels [Miller et al., 2007; Miller et al., 2009].
  
Latini et al. [2007] showed 
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that using a high sensitivity-assay, a higher proportion (92%) of stable HF patients had 
elevated cTnT, compared to only 10.4% of patients identified by a standard cTnT assay.  
After adjustment for baseline variables and BNP level, the detection of cTnT by means of the 
high-sensitivity assay was still associated with an increased risk of death. 
 
Similarly, increased cTnT levels were found in 9.2% of patients being admitted with acute 
decompensated HF in whom there was no evidence of ischaemia or coronary disease 
[Peacock et al., 2008].  Patients who had positive cTnT levels had lower LVEF and higher in-
hospital mortality. Serial cTn measures could provide useful information regarding clinical 
improvement in acute decompensation.  39 decompensated LVSD patients had elevated cTn 
levels on admission; these levels then fell at the time of hospital discharge to their values 
during a compensated state, and were maintained at several weeks after discharge [Biolo et 
al., 2009].  Gheorghiade et al. [2005] established prospectively the pattern of cTn variance in 
patients with acute decompensated ischaemic LVSD where decompensation was not due to 
ischaemia. During periods of stable disease, 73.9% of patients had detectable levels of cTnI, 
and 43.5% had detectable cTnT levels.  Median concentrations of both cTn remained 
unchanged 0-32h from decompensation but rose between 32-56h.  cTnT levels eventually 
plateaued until discharge, whereas cTnI levels decreased back to baseline values by 80h. Chen 
et al. [1999] also demonstrated raised cTnI levels in 89% of patients with acute 
decompensation.  cTnI levels fell in patients who improved clinically, while a deteriorating 
clinical profile was associated with increasing cTnI. However, only cTnI drawn at the time of 
first haemodynamic measurements correlated weakly with right atrial pressure in 
decompensated HF [Shah et al., 2007].  
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3.3.2.1           Biological variance 
 
Table 3.3 summarises a number of physiological and pathological conditions in which cTn 
can be elevated. The first study to establish the normal variance of cTnI in healthy volunteers 
was performed by Wu et al. [2009], who collected repeated blood samples hourly over 4h, 
and on alternate weeks over 8 weeks.  Using a high-sensitivity assay, they found within-hour 
within-subject and between-subject normal variance to be 9.7% and 57% respectively, and 
between-day within-subject and between-subject normal variance to be 14% and 63% 
respectively. RCV were calculated using a lognormal approach as the cTnI values were 
skewed to the right.  Lognormal within-day values were +46% and –32%, between-day values 
were +81 and –45%. The normal variance of cTn in LVSD patients has not been defined. 
 
 
Table 3.3.  Physiological and non-physiological states associated with elevated cardiac 
troponin [Kelly et al., 2009; Ammann et al., 2004]. 
Physiological 
• Strenuous exercise - Amateur and professional 
Cardiac diseases 
• Acute coronary syndromes 
• Heart failure (systolic and diastolic) 
• Myocarditis 
• Pericarditis 
• Arrhythmias 
• Valvular heart disease 
• Congenital heart disease 
• Coronary vasospasm 
• Cardiac amyloidosis 
1on cardiac diseases 
• Critically unwell patients 
• Renal failure  
• Sepsis 
• Pulmonary embolism 
• Pulmonary hypertension 
• Subarachnoid haemorrhage 
• Stroke 
• High dose chemotherapy 
Cardiac interventions 
• Percutaneous coronary intervention 
• Cardiac surgery 
• DC cardioversion 
• ICD implantation 
• Closure of atrial septal defects 
• Cardiac transplantation 
• Radiofrequency ablation 
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3.3.2.2          Sampling and storage 
 
The half-life of cTnI is much shorter than that of cTnT, and is around 24h in patients with 
normal renal function. Collection of blood samples in heparin tubes, although allowing more 
rapid analysis of cTn, results in reductions of up to 15% in measured cTn values compared to 
serum tubes [Gerhardht et al., 2000].  Measured concentrations of cTn also decreases with 
increasing heparin concentrations added to sera [Speth et al., 2002].  Similar tubes should thus 
be used for repeated cTn analysis in an individual patient. cTn samples should also either be 
analysed immediately or stored in serum at –70°C and analysed within a year. There were no 
significant changes in cTnT levels stored up to 12 months, whereas at 24 months, there was a 
significant decrease from baseline levels [Basit et al., 2007].   
 
3.3.3   Ischaemia modified albumin (IMA) 
 
IMA is a marker of acute ischaemia whose levels rise within minutes of the onset of 
ischaemic chest pain [Sinha et al., 2004]. Of the large number of potential biomarkers of 
ischaemia, it is the only biomarker in addition to the cTn to have reached the clinical 
validation stage [Var-Or et al., 2000].  Percutaneous coronary intervention, as a model of 
transient reversible ischaemia [Sinha et al., 2003],  reveals an IMA response in 18 out of 19 
patients sampled immediately and 30 minutes post procedure, with levels returning to 
baseline by 12h. This occurs in the absence of cTn elevation. IMA levels correlate with the 
severity of ischaemia, being higher in patients with more balloon inflations, higher pressure 
inflations, and longer inflation times [Quiles et al., 2003], and lower in patients with collateral 
circulation [Garrido et al., 2004].  
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IMA thus appears to be a more sensitive marker of reversible ischaemia in the absence of 
myocardial necrosis in this respect, distinguished from cTn which is a better marker of micro 
necrosis but a poorer marker of true reversible ischaemia. IMA was more sensitive at ruling 
out a non-ischaemic cardiac cause in patients presenting with symptoms of acute chest pain, 
although it fared poorer as a discriminator of ischaemia with and without infarct [Bhagavan et 
al., 2003].  IMA levels performed within 3h of the onset of chest pain had a sensitivity of 82% 
for a final diagnosis of ischaemic chest pain, compared to a markedly poorer sensitivity of 
45% and 20% for admission ECG and cTnT respectively [Sinha et al., 2004].  Furthermore, 
IMA levels, used in conjunction with cTnI levels were found to be useful in the triage of 
patients presenting with undifferentiated chest pain [Collinson et al., 2006].  Admission IMA 
levels in patients presenting within 3h of the onset of chest pain suggestive of cardiac 
ischaemia were also predictive of poor short and medium-term prognosis [Consuegra-Sanchez 
et al., 2008]. 
 
With respect to biomarker utility in LVSD, IMA may only be relevant in those individuals 
with underlying reversible ischaemia.  While recurrent ischaemia is a potential mechanism of 
worsening systolic function, it is rarely well defined in routine clinical practice. However, it 
may also reflect the process of relative myocyte ischaemia as part of the process of cardiac 
remodelling (regardless of epicoronary stenosis as a cause of LVSD). In the same respect that 
cTn changes might sensitively define the cardiac remodelling process and thus might indicate 
abnormal volume status compromising myocyte stretch, IMA, if suitably sensitive, might also 
reflect the impact of abnormal volume status as sub-clinical ischaemia via increased wall 
stress. Alternatively, it might reflect the other processes involved in the pathogenesis of HF, 
such as oxidative stress, inflammation or neurohormonal activation acting detrimentally on 
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the myocyte [Braunwald, 2008; Sbarouni et al., 2008]. These issues have not been examined 
thus far. 
 
In end-stage renal failure, raised IMA levels associate with larger LV, lower LVEF, higher 
echocardiographic estimates of LV filling pressures and objective evidence of reversible 
ischaemia as evidenced by stress echocardiography and coronary angiography, as well as a 
worse prognosis during a follow up period of 2.25 years [Sharma et al., 2006].  In patients 
with ST-elevation myocardial infarction undergoing primary percutaneous coronary 
intervention, serum IMA concentrations measured 15 minutes post-procedure are significantly 
related to LVEF, and represent early markers of the development of clinical HF during the 
admission [Dominguez-Rodriguez et al., 2008].  Similarly, in stable dilated cardiomyopathy, 
IMA levels were found to be significantly negatively correlated to LVEF, and levels differed 
significantly between NYHA functional classes [Sbarouni et al., 2009].  However, IMA levels 
in these stable patients were no different compared to age-matched healthy volunteers. On the 
other hand, in stable LVSD patients about to undergo chronic resynchronisation therapy, IMA 
levels were approximately 24% higher compared to age-matched healthy volunteers, and were 
not significantly different between patients with ischaemic cardiomyopathy and dilated 
cardiomyopathy [Franceschi et al., 2009].  Furthermore, IMA levels correlated with BNP 
levels, and could thus be a potential biomarker of volume status. The difference in observed 
levels of IMA in the latter two studies may be due to varying severity of LV dysfunction, and 
suggests that in stable patients with a non-ischaemic aetiology for LVSD and with milder 
degrees of LV dysfunction, lower levels of IMA may prevail in the same way that only 
modest elevations of cTn are present in a large proportion of stable LVSD patients with no 
evidence of ongoing ischaemia [Latini et al., 2007].  Further studies are needed to establish 
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prognostic utility in HF as well as relationships to other measures of HF progression such as 
volume status. 
 
3.3.3.1           Biological variance 
 
Measured IMA levels are not cardiospecific; Table 3.4 shows a number of physiological and 
non-physiological conditions that can affect IMA levels. Only one study so far has established 
the normal variance of IMA levels in normal volunteers. Blood samples were taken weekly 
over a 5-week period at the same time and by the same phlebotomist [Govender et al., 2008].  
Within-subject and between-subject normal variance were 2.89% and 6.76% respectively. 
 
Table 3.4  Physiological and non-physiological conditions affecting ischaemia modified 
albumin levels
 
[Sbarouni et al.,  2008; Sbarouni et al.,  2009; Kaefer et al.,  2009; Haklıgör
 
 et 
al., 2009; Turedi et al., 2009; Gundez et al., 2009; Guven et al., 2009]. 
Physiological 
Increased 
• Increasing age 
Reduced 
• Increasing albumin 
 
• Strenuous exercise 
 
• Increasing lactate 
1on-physiological 
Increased 
• Cardiac ischaemia 
• Ischaemic stroke 
• Skeletal muscle ischaemia 
• Intra uterine ischaemia 
• Right ventricular dysfunction 
• Pulmonary hypertension 
 
 
• End stage renal failure 
• Peripheral vascular disease 
• Gastrointestinal ischaemia 
• Pulmonary embolus 
• Diabetes mellitus 
Cardiac interventions (increased) 
• Percutaneous coronary intervention 
• Permanent pacemaker intervention 
• Radiofrequency ablation 
• Internal cardio defibrillator implantation 
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3.3.3.2           Sampling and storage 
 
Blood has been collected in serum or heparinised tubes in several studies [Christenson et al., 
2001; Bhagavan et al., 2003].  Gidenne et al. [2004] observed that paired samples of 
heparinised plasma or serum were not equivalent, but only reported results for serum 
specimens as the assay they used was validated for commercial use for serum samples only.  
Limited studies have revealed small but significant differences in IMA dependent on 
specimen storage, real time analysis or analysis after freezing [Christenson et al., 2001]. 
Samples stored at -20°C show minimal variation in IMA (-2.7 to +4.7%) from immediate 
analysis provided frozen tubes are thawed at 4°C for 20 minutes, whereas thawing at room 
temperature for 20 minutes increased measured IMA by 15% [Gidenne et al., 2004] .
 
   
 
3.3.4   Haematocrit 
3.3.4.1  Biological variance 
 
Hct levels increase with age and in association with male gender [Cheng et al., 2004].  They 
vary with ethnicity, genetics, exercise training, living at high altitude for prolonged periods 
and other environmental factors [Lugada et al., 2004].  Hct shows small seasonal within-
subject normal variance of 3-7%. From 12 studies of 638 normal healthy adults, sampling 
between daily to 2 months gave a within-subject normal variance of Hct of about 3% [Thirup, 
2003].  
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3.3.4.2  Sampling and storage 
 
Hct values are significantly higher if collected into sodium EDTA tubes compared to 
potassium EDTA tubes [Chen et al., 1999]. Under-filling of tubes results in lower estimates 
for Hct, with values of Hct determined on 2mL sample volume significantly lower than those 
from a 5mL sample volume. Sequential rise in Hct occurs between 1, 8 and 12h from 
collection.  Storage of samples at room temperature results in a gradual increase in Hct up to 7 
days after collection [Gulati et al., 2002]. Thus, collection of serial blood samples for Hct 
measures should be in similar tubes, and analysis should take place within the same time 
frame for all measurements. 
 
3.4   Summary 
 
In this chapter, a range of biologically plausible blood biomarkers with potential for 
monitoring volume status in LVSD have been highlighted.  They all have potential clinical 
application in the routine management of LVSD in terms of their current availability to the 
physician on a routine basis. However, it is essential that clinicians understand the potential 
sources of variance and take steps to minimise them in order to successfully utilise these 
biomarkers in routine patient care.  
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Chapter Four 
 
Hypotheses, Experimental Design, Rationale for 
Selection of Biomarkers and Pre-analytical and 
Analytical Methods Outline  
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4.1  Introduction 
 
The main aim of this thesis was to investigate the potential utility of repeated measures 
assessment of relevant biomarkers as non-invasive means of defining changes in volume 
status in different volunteer groups with a view to applying the principles tested to the 
situation in LVSD. Changes in each biomarker studied will be considered as potentially 
reflecting changes within specific compartments of volume status or depicting a specific 
pathophysiological step in LVSD, and will be interpreted in the context of its within-subject 
and between-subject normal variance, a concept which is rarely applied in routine clinical 
practice. ‘Biomarkers’ will be the collective term used for all biomarkers studied, which will 
include blood and urine biomarkers, and physical biomeasures.  
 
4.2   Hypotheses (H1) 
 
My general hypotheses (H1) were: 
• Repeated measures of relevant blood and urine biomarkers, and physical biomeasures 
might provide a non-invasive means of assessment of changes in volume status by 
their response to induced volume changes. 
• Changes in specific biomarkers might reflect changes in specific components of 
volume status, such as specific volume compartments, haemodynamic and renal 
variables. 
• Changes in repeated measures of biomarker levels as a result of volume changes 
might be described above the within-subject normal variance for these biomarkers.  
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• Changes in repeated measures of biomarker levels in response to volume changes 
may occur without the development of symptoms (these may precede the 
development of symptoms or occur subclinically), and could thus have the potential 
to predict decompensation in LVSD. 
• The mechanism for ongoing cardiac ischaemia or injury in LVSD may be secondary 
to volume overload. This might be reflected by an increase in biomarker measures of 
ischaemia in LVSD patients in response to volume expansion.  
• The mechanism of renal tubular dysfunction in LVSD may be secondary to abnormal 
volume status. This might be reflected by changes in markers of renal tubular 
function following induced volume changes in LVSD patients.  
 
4.3   Aims and experimental design 
 
While mainly interested in the clinical application of repeated measures of non-invasive 
biomarkers to predict changes in volume status in stable LVSD patients, this group of patients 
would be unlikely to tolerate large changes in volume without the risk of decompensation. It 
was therefore possible that some of the less sensitive biomarkers being studied here may not 
show significant response to the small asymptomatic volume changes that were planned in 
this group of patients in an outpatient setting. In order to still be able to demonstrate the 
principle that a suitable biomarker of volume change has to show significant deviation from 
its within-subject normal variance, a principle that could then be applied to other biomarkers 
in future studies, protocols to study larger induced volume changes in decompensated HF and 
normal volunteers were also devised. Furthermore, the principle of significant deviation from 
within-subject normal variance in response to induced volume changes would in theory, be 
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more readily demonstrated in normal volunteers due to the likelihood of a more stable steady 
state with the distribution of most biomarkers likely to be non-skewed, and more control of 
the start of volume stimulus. Physiological responses to induced volume changes are different 
in LVSD patients compared to normal volunteers [Volpe et al., 1995], as are patterns for 
within-subject normal variance [Wu et al., 2003], such that induced volume changes in normal 
volunteers could not be directly compared to the situation in LVSD. However, studies in 
normal volunteers could potentially highlight abnormal responses in LVSD patients.   
 
A three-stage plan of investigation was therefore devised, consisting of an observational study 
of repeated measures of physical biomeasures in patients with decompensated HF receiving 
intravenous furosemide (Chapter Five); repeated measures assessment of blood biomarkers 
and physical biomeasures in normal volunteers receiving controlled acute volume loading 
(Chapter Six); and repeated measures assessment of blood and urine biomarkers, and physical 
biomeasures in stable chronic LVSD patients who underwent temporary diuretic-induced 
volume changes (Chapter Seven).  Respective biomarkers studied will be outlined in more 
detail in the latter sections of this chapter, and more detailed description of experimental 
protocols will be outlined in each respective chapter. 
 
4.3.1   Studies in patients with decompensated heart failure 
 
Pilot studies of repeated measures of physical biomeasures were completed in volunteers who 
were in decompensated HF.  These were individuals who were admitted with acute 
cardiogenic pulmonary oedema being treated with high-dose intravenous furosemide (ivF) 
and they were predicted to have significant drug-induced changes in volume status. The main 
aim of this observational study was to establish the feasibility of performing repeated timed 
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physical biomeasurements in a group of unstable patients in a set pattern or systematic way in 
an attempt to reduce measurement error of physical biomeasures, to assess whether these 
measures were well tolerated by patients, and to define the response pattern of physical 
biomeasures to acute drug-induced volume changes.  This experiment did not involve blood 
or urine biomarker analyses. Physical biomeasures measured at different time points consisted 
of: 
Echocardiographic measures 
• Mitral inflow indices 
• Tricuspid inflow indices 
• IVC indices 
 BIA measures 
• Whole-body (distal) BIA 
• Trunk (proximal) BIA   
• Right-lung BIA (anterior-posterior electrode placement) 
 
4.3.2   Studies in normal volunteers 
 
Normal volunteers received differential acute volume loading protocols from a stable baseline 
under controlled conditions. The main aim of this stage of investigation was to establish the 
within-subject and between-subject normal variance of selected blood biomarkers and 
physical biomeasures in normal volunteers, and to define their response patterns to differential 
volume loading protocols as a deviation from their within-subject normal variance pattern. 
 
Biomarkers determined in this study were: 
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Estimated blood volume 
Blood biomarkers 
• NP (ANP and BNP) 
• Hct 
Echocardiographic measures 
• Mitral Doppler indices 
• IVC indices 
BIA measures 
• Whole-body (distal) BIA 
• Trunk (proximal) BIA 
• Right-lung BIA (anterior-posterior and sternum-rib electrode placements) 
 
4.3.3   Studies in stable chronic LVSD patients 
 
Stable LVSD patients on chronic oral diuretic treatment underwent controlled manipulation of 
volume status by changes to their stable diuretic therapy over a 7-day period. Patients took 
their usual oral diuretic on Day 1, omitted their diuretic on Days 2, 3 and 4 (diuretic 
withdrawal phase), and resumed their oral diuretic on Days 5, 6 and 7 (diuretic resumption 
phase).The longitudinal response of bioamarkers could thus be established as a result of 
volume changes induced by diuretic manipulation. Furthermore, the normal variance of 
bioamakers could be established over an 8h monitoring period on Day 1. On Day 4 of the 
protocol, after 0h measures, a bolus of ivF was given to re-equilibrate volume status following 
maximal volume expansion associated with diuretic withdrawal, following which they were 
monitored under controlled conditions for 8h.  
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The variables assessed by repeated measures were: 
Blood biomarkers 
• NP (ANP and BNP) 
• Hct 
• Markers of ischaemia (cTnI and IMA) 
• Markers of renal function [serum creatinine (sCreatinine) and serum NGAL (sNGAL)] 
 
Urine biomarkers of renal tubular function 
• Kidney injury molecule-1 (uKIM-1) 
• Neutrophil gelatinase-associated lipocalin (uNGAL)  
• N-acetyl-beta-D-glucosaminidase (uNAG) 
• Urinary creatinine (uCreatinine) 
Echocardiographic measures 
• Mitral Doppler indices 
• IVC indices 
BIA measures 
• Whole-body (distal) BIA 
• Trunk (proximal) BIA 
• Right-lung (anterior-posterior and sternum-rib electrode placement) BIA 
 
4.4   Rationale for selection of biomarkers to be studied 
 
A panel of blood and urine biomarkers and physical biomeasures was selected on the basis of 
the relevance in the potential depiction of different components of volume status and on the 
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background of previously documented sensitivities to volume change.  Furthermore, the ease 
of availability of their measurement during both my study protocol and in routine clinical 
practice in terms of accessibility, reliability and practicality was a deciding factor.  The 
emphasis was to study parameters with potential relevance for current clinical utility as 
opposed to biomarkers which were still at an experimental stage.  
 
4.5   Blood and urine biomarkers 
 
4.5.1   Indicators of intravascular volume change through haemoconcentration  
  or haemodilution 
 
Hct is potentially the simplest measure of haemoconcentration or haemodilution if 
normovolaemic Hct values are known [Androne et al., 2003].  As discussed in Chapter Three, 
the most useful setting for applying changes in Hct levels to track intravascular volume 
changes would be in the short-term monitoring of either acute or chronic LVSD [Valeri et al., 
2006].
 
 This is because of its low sensitivity for haemodilution or haemoconcentration in the 
long term due to the wide range of pathological processes associated with the progression of 
LVSD [Ng Kam Chuen et al., 2007]. 
 
These processes are unlikely to develop over the short 
time course of this study protocol, and changes in Hct levels in my volunteers are therefore 
likely to reflect primarily changes in intravascular volume secondary to the experimental 
volume manipulations. Hct levels are thus expected to fall following IV Saline infusion in the 
normal volunteers study and during diuretic withdrawal in the stable LVSD study, and to 
increase following diuretic reinitiation in the stable LVSD study.  Furthermore, the within-
subject normal variance of Hct will be established in stable volunteers at baseline, and the key 
element being studied here is the use of repeated measures to detect deviation from normal 
variance in response to volume manipulation.  
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Due to its simplicity and potential for in line continuous assessment, Hct has potential utility 
as it can be routinely and easily measured in clinical practice as part of the full blood count 
analysis.  If repeated measures were sensitive to volume changes, Hct would constitute a 
cheap biomarker for routine repeated measures use in clinical practice that would accurately 
reflect changes in intravascular volume.  
 
4.5.1.1  Estimation of blood volume using Hct measures 
 
In the absence of invasive measures of intravascular volume, the regression equation for the 
calculation of estimated blood volume from Nadler et al. [1962] was used in an attempt to 
approximate a gold standard to which changes in suitable non-invasive biomarkers to 
different protocols could be correlated. This equation is based on body weight and height, and 
has been shown to have good correlation with radioisotope measures of blood volume in 
normal volunteers.  
 
Thus, in my cohort of normal volunteers, blood volume at Time 0h (BV0) was estimated using 
Nadler’s formula: BV0 (L) = 0.0329 × BW0 + 0.3669 × Ht
3
 + 0.6041, where BW0 is the body 
weight in Kg at Time 0h, and Ht is the height in m. 
 
Unlike in normal volunteers, there is no validated equation for the estimation of plasma/blood 
volume in LVSD patients based on body weight, height and percentage change of Hct.  It 
would be inappropriate to use such equations which have been applied in normal volunteers, 
especially in a group of HF patients in whom gradual but dynamic fluid shifts would be 
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induced, and who were on multiple vasoactive treatments. Thus, no estimates of blood 
volume were calculated for stable LVSD patients. 
In normal volunteers, the equations from Lobo et al. [2010] were used to then derive blood 
volume in litres at each time point by applying percentage changes in Hct values at each 
respective time point to determine percentage change in blood volume from baseline. 
 
The percentage change in Hct at time t (∆Hctt) was determined by the following equation: 
∆Hctt (%) = [(Hct0 - Hctt) / Hct0] × 100, where Hct0 is the Hct at 0h, and Hctt  is the Hct at 
time t. 
 
Thus, the percentage change in blood volume at time t (∆BVt) can be calculated using the 
following formula: ∆BVt (%) = {[100 / (100 - ∆Hctt)] × 100} – 100. 
 
Blood volume at time t, BVt, can thus be calculated by applying the formula:  
BVt (L) = [(BV0 × (100 + ∆BVt)] / 100. Blood volume change (in L) from baseline can then 
be derived as follows: BVt (L) = BVt – BV0. 
 
4.5.2   Indicators of venous compartment of intravascular volume/cardiac  
  preload change through myocyte stretch 
 
As previously discussed, the linkage of a range of NP to cardiac preload and myocyte stretch 
is well established. Consequently, the repeated measures sensitivity of ANP and BNP was 
evaluated in the studies in this thesis as potential indicators of cardiac stretch in response to 
the differential volume manipulation protocols which would induce changes in intravascular 
volume and thus affect cardiac preload.   
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ANP and BNP have shorter half-lives than their respective inactive forms, NTproANP and 
NTproBNP.  A shorter half-life incorporates a greater ability to respond to acute changes in 
volume status, but is reflected in the greater observed variability over time of ANP and BNP 
compared to their inactive forms [McDowell et al., 2002; Bruins et al., 2004]. While increased 
variability might reduce the effectiveness of these markers when used simply as one-off 
diagnostic measures, this need not be a limitation for the use of repeated measures assessment 
during the short term observations planned during my studies as changes in ANP and BNP 
response to volume manipulation will be interpreted in the context of their baseline within-
subject variance. 
 
While ANP appears to be potentially more responsive to acute intravascular volume changes 
and haemodynamic changes [Gabrielsen et al., 2000; Herringlake et al., 2004; Maisel et al., 
2002; James et al.,  2005],  BNP is certainly the more widely studied and more easily 
measured NP biomarker. Thus, ANP might increase in response to IV Saline infusion in the 
normal volunteers study and during the diuretic withdrawal phase in the stable LVSD study, 
and might reduce following diuretic reinitiation in the stable LVSD study. On the other hand, 
BNP was not expected to respond to the acute volume changes in the normal volunteers study. 
However, its levels might increase during the less acute diuretic withdrawal phase and reduce 
during diuretic resumption in the stable LVSD patients. 
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4.5.3   Potential indicators of cardiac preload/cardiac remodelling through  
  myocardial ischaemia or necrosis 
 
As previously outlined, ongoing myocyte injury is part of the cardiac remodelling process in 
LVSD occurs in both ischaemic and non-ishaemic cardiomyopathy [Matsumori et al., 2993], 
and is not necessarily linked to overt ischaemia [Sato et al., 2001]. The mechanisms for this 
process likely involve oxidative stress, inflammation, neurohormonal activation [Braunwald, 
2008], but may also involve increased cardiac preload inducing myocyte stretch and 
subclinical injury. 
 
cTnT and cTnI, as the most robust markers of myocyte death, are the obvious choice of blood 
biomarkers in an attempt to track these processes in my cohort of stable LVSD patients. 
However, their long half-lives [Ellis et al., 2001] are likely to explain their lack of 
responsiveness to acute changes in blood volume and haemodynamic indices in acute HF 
[Shah et al., 2007].  In this context, cTnI appears to be the more responsive of the two cTn 
[Gheorghiade et al., 2005], and would therefore be more likely to track small subclinical 
volume changes in my stable HF volunteers than cTnT. IMA, however, as an early marker of 
ischaemia whose levels appear within minutes of the onset of cardiac ischaemia with levels 
normalising rapidly [Sinha et al., 2003],
 
and whose levels correlate with non-invasive 
measures of LV filling pressure [Sharma et al.,  2006] could outperform the cTn as a more 
sensitive marker of volume changes.  Thus, IMA levels might increase in response to diuretic 
withdrawal and reduce in response to diuretic reinitiation in the stable LVSD patients, 
whereas cTn levels may not change significantly. These biomarkers were not tested in the 
setting of volume expansion in normal volunteers as their baseline levels would likely be 
undetectable using the available assays. 
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4.5.4   Potential indicators of intravascular volume change through markers of  
  renal tubular function 
 
As discussed in Chapter One, the relationship between cardiac and renal function is critical in 
the maintenance of volume homeostasis.  The potential mechanisms of renal injury as a direct 
haemodynamic consequence of reduced cardiac output in HF include reduction of renal blood 
flow resulting in reduced GFR, renal hypoxia, drug-induced dehydration or renal damage; and 
activation of the neurohormonal axis causing sodium and water retention with increased 
venous pressure [Ronco et al., 2008].  Increased CVP, right atrial pressure or physical signs of 
venous congestion are associated with reduced GFR in a range of stable patients with or 
without impaired LVEF, regardless of cardiac output [Damman et al., 2009; Nohria et al., 
2008]. Particularly in the presence of reduced renal blood flow, increased CVP is associated 
with further reductions in eGFR.  Furthermore, increased CVP associates with worsening 
renal function in acute HF [Mullens et al., 2009]. While the mechanisms for this interaction 
between venous congestion and renal impairment has not been fully elucidated, it is possible 
that increased venous congestion causes renal dysfunction by increasing renal venous 
pressures with subsequent reductions in renal blood flow [Mullens et al., 2009], or that 
impaired kidneys as a result of multiple pathophysiological mechanisms associated with HF 
are unable to excrete salt and water appropriately.  Regardless of whether the mechanism of 
renal dysfunction related to increased central pressures is causative, consequential or merely 
associative, markers of renal damage could potentially also act as markers of changes in 
central venous pressure, and thus of cardiac preload. Furthermore, markers of renal damage 
could potentially also act as direct measures of renal perfusion, and thus of reduced cardiac 
output. 
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Renal damage in the context of LVSD can occur via a number of cellular mechanisms, 
namely, tubular dysfunction, cell death by apoptosis and necrosis contributing to intratubular 
obstruction, and tubulointerstitial inflammation [Vaidya et al., 2008].  The final common 
pathway for kidney injury may involve renal hypoxia, especially in the proximal tubules 
which utilise the largest amount of oxygen [Nangaku et al., 2006].  Renal impairment is 
traditionally defined by reduced GFR, elevated sCreatinine or blood urea nitrogen levels, with 
changes in these markers occurring hours or days after the inciting event.  However, the 
process of renal impairment is a continuous process as described by the RIFLE criteria, which 
ranges from initial risk of kidney dysfunction to renal injury through damage of renal 
structures which eventually results in failure of kidney function, loss of kidney function 
(reduced GFR) and eventually kidney failure (end-stage kidney disease) [Bellomo et al., 
2004].
 
 There is a delicate and dynamic relationship between tissue repair and progression or 
regression of renal injury, where each of the steps within this continuum from renal injury to 
failure could be potentially reversible. Thus, whereas measures of reduced GFR would 
identify the latter stages of this process and reflect functional failure of the kidneys, 
biomarkers identifying structural damage at the earlier stages of this process could not only 
identify early kidney dysfunction at a reversible stage, but also identify the potential sites and 
severity of the injury, and the mechanism of the injury [Vaidya et al., 2008].  Therefore, while 
reduced GFR may coexist with raised markers of morphological damage to the kidneys, it is 
likely that in a large number of patients, there is subclinical renal dysfunction manifesting as 
increased markers of structural/morphological damage with normal GFR, serum urea and 
serum creatinine (sCreatinine) levels. 
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In this respect, a range of candidate renal biomarkers of tubular function have been defined 
whose levels increase within hours of acute kidney injury and have been shown to have 
diagnostic and prognostic value for renal damage. 
 
N-actetyl-β-glucosaminidase (uNAG) is a proximal tubule lysozyme which is shed into the 
urine during subtle alterations in the epithelial cells of the proximal tubules.  The amount of 
enzyme shed can be directly correlated to tubular injury, and has thus been shown to be a 
sensitive, persistent and robust indicator of tubular injury in several contexts including 
cardiopulmonary bypass procedures [Vaidya et al., 2008].
 
 uNAG levels are highly sensitive 
at detecting acute kidney injury in critically ill adult patients, increased levels preceding 
increases in sCreatinine by 12h to 4 days [Westhuyzen et al., 2003].  Poorer outcome, as 
determined by death in hospital and requirement for long-term renal replacement therapy, was 
associated with high levels of uNAG on admission to a renal care unit compared to normal 
uNAG levels [Chew et al., 1993].  
 
Kidney Injury Molecule-1 (uKIM-1) is a renal tubular glycoprotein whose ectodomain is shed 
into the urine following proximal tubular kidney injury; this can then be measured by means 
of an ELISA. Its levels are also elevated within 12h after an initial ischaemic renal insult, 
prior to the appearance of casts in the urine, and its levels correlate with tubulo-interstitial 
fibrosis and inflammation. uKIM-1 seems to be most sensitive to ischaemic injury to the 
proximal tubules, its levels being most elevated in ischaemic acute tubular necrosis compared 
to other mechanisms of injury [Han et al., 2005]. There is also evidence that its levels are the 
most elevated compared to other biomarkers following kidney injury. uKIM-1 and uNAG 
levels in acute kidney injury were significantly associated with the clinical composite end-
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point of death or dialysis requirement, even after adjustment for disease severity and co-
morbidities [Liangos et al., 2007].   
 
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein initially identified 
bound to gelatinase in specific granules of the neutrophil. It is normally secreted in small 
amounts in lungs, kidney, trachea, stomach and colon tissue. Normal adults only have 
undetectable to low levels of serum and urinary NGAL (sNGAL and uNGAL); however their 
levels are elevated in various pathological states [Vaidya et al., 2008].
 
 In renal failure, both 
sNGAL and uNGAL levels rise markedly following the same trends. A prospective study of 
paediatric patients without pre-existing renal failure undergoing cardiopulmonary bypass 
found both sNGAL and uNGAL to be powerful early markers of acute kidney injury, levels 
being raised within 2h after bypass, and preceding any increase in sCreatinine by 1-3 days 
[Mishra et al., 2005].  A similar study in adult patients showed uNGAL levels at 1, 3 and 18h 
after cardiac surgery to be significantly higher in patients who went on to develop clinically 
significant acute kidney injury [Wagener et al., 2006].  Damman et al. [2008] demonstrated 
for the first time, increased levels of uNGAL in LVSD patients compared to controls, thus 
indicating the presence of tubular damage in LVSD. Both sCreatinine and eGFR were 
significantly correlated to uNGAL levels in their cohort of patients. However, it is unclear as 
to how many patients with normal eGFR and urinary albumin excretion had increased 
uNGAL. uNAG and uKIM-1 levels have so far not been established in HF populations. 
 
Thus, based on the diuretic-induced volume manipulation protocol in my cohort of LVSD 
patients, I hypothesised that renal injury might occur in clinically dehydrated patients as a 
result of chronic diuretic treatment. This might improve following diuretic withdrawal, thus 
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causing a reduction in levels of the renal tubular markers, and worsen following diuretic 
resumption, causing an increase in renal tubular marker levels. On the other hand, renal injury 
might occur secondary to increased central venous pressure and could potentially be reflected 
by increased levels of these sensitive renal tubular markers in response to diuretic withdrawal.  
 
4.6   Physical biomeasures 
4.6.1   Echocardiographic variables: Indicators of intravascular volume/cardiac 
  preload change through estimates of LV filling pressure 
 
 As outlined in chapter Two, transthoracic echocardiography is used in HF patients mainly as 
a diagnostic tool to assess LV function and to determine the aetiology of a HF presentation. 
Although many individual measures have been linked to a variety of invasively measured 
haemodynamic indices of cardiac preload [Mansencal et al., 2007], these are not routinely 
repeated as a measure of volume status to guide treatment decisions.  However, as with Hct, 
potential echocardiographic indicators of volume status have considerable interest as they are 
freely available as part of a routine comprehensive study.   
 
The utility of echocardiographic measures is limited by their inter-observer and intra-observer 
variability, and more fundamentally by subject echogenicity.  These are perhaps less 
important in the application of routine echocardiography in a simple diagnostic role to address 
the presence or absence of LVSD.  However, these principles become key aspects of utility 
where any echocardiographic measure is to be used as a repeated measure of volume status 
within an individual. 
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Repeated measures assessment by a single operator has the potential to reduce measurement 
error and improve sensitivity. Thus, echocardiograms were performed by only one operator 
(MJNKC), to eliminate inter-observer variability. All patients were screened prior to 
enrolment to ensure adequate echocardiographic windows and to determine LVEF using the 
biplane modified Simpson’s rule. A GE Vivid 3 portable platform (General Electric Medical 
Systems, Solingen, Germany) was used for the study in patients with decompensated HF in an 
in-patient setting; and a GE Ving Med System 5 platform (GE Medical Systems Ltd, Slough, 
UK) was used for the normal volunteers and stable LVSD studies in the study centre location.   
A 2.5 MHz transducer probe was used.  Relevant echocardiographic windows were stored on 
video for the former, and on optical disc for the latter, for off-line, anonymised and blinded 
analysis using the Echopac system. Measurements were made according to the 
recommendations of the American Society of Echocardiography [Lang et al., 2006; Quinones 
et al., 2002]. 
 
Following literature review of potential echocardiographic measures of LV filling pressure 
(Chapter Two), markers which are easily obtainable and whose documented time for 
measurement and intra- and inter-observer variability were small were selected [Khan et al., 
2004; Rijsterborgh et al., 1990]. These comprised mitral Doppler indices, tricuspid inflow 
indices and IVC indices.  Pulmonary vein Doppler indices, right atrial volume, LV end 
diastolic and end systolic dimensions and volume and contractility indices which have also 
been correlated to changes in cardiac prelaod, were not incorporated into the repeated 
measures assessment due to time constraints of repeated measurement and volume 
manipulation, which would compromise the accuracy of their measurement, and also due to 
large measurement variation even under optimal conditions [Gordon et al., 1993].  
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Furthermore, these particular indices are affected by accurate wall detection and echogenicity 
within a subject, again affecting their accuracy. The reported success rates for obtaining 
echocardiographic measures in 80 patients were 100% for mitral inflow indices compared to 
only 46-73% for pulmonary vein Doppler indices, the inter-observer variability being reported 
as 2-5% for mitral inflow indices, increasing slightly to 2-9% after Valsalva manoeuvre, 
compared to 3-12% without Valsalva manoeuvre for pulmonary vein Doppler indices [Khan 
et al., 2004].  Furthermore, the time taken to record mitral inflow indices was 29-36 seconds, 
compared to 81 seconds for pulmonary vein Doppler indices. 
 
Mitral and tricuspid inflow indices were assessed with and without the Valsalava manoeuvre 
on expiration to minimise their respiratory variation.  The strain phase of the Valsalava 
manoeuvre results in an acute increase in intra-thoracic pressure and decreased stroke volume 
as a result of decreased venous return [Hamilton et al., 1994].  Thus, during the strain phase, 
the expected reduction in cardiac preload is likely to attenuate the mitral and tricuspid inflow 
responses, such that greater sensitivity would be indicated for variables whose levels still 
change significantly following a particular volume stimulus during the manoeuvre (rather than 
only changing significantly without the Valsalava manoeuvre).  Patients were instructed to 
perform the Valsalava manoeuvre at the end of a normal inspiratory effort, and the Valsalava 
manoeuvre was judged adequate if accompanied by the development of florid facies, 
distended neck veins and increased abdominal wall muscle tone [Zema et al., 1984].  Relevant 
echocardiographic windows for each variable were optimised before strain; strain was then 
maintained for the duration of acquisition of images which in general lasted less than 10 
seconds.    
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4.6.1.1  Mitral Doppler indices 
 
Mitral inflow pattern, as illustrated in Figure 4.1, consists of MVE, MVDT and MVA, from 
which MVE/A was calculated.  As outlined in Chapter Two, MVE, MVDT and MVE/A 
correlate to invasive measures of LV  filling pressure in patients with depressed LV systolic 
function, to a lesser extent, in subjects with normal LVEF [Nishimura et al., 1996; Szatajzel et 
al., 1993; Kinet et al., 1982; Hurrell et al., 1997]. 
 
Figure 4.1.  Mitral inflow indices.  
                            
MVE: early peak transmitral velocity; MVA: late peak transmitral velocity; MVDT: transmitral deceleration 
time. 
 
 
E/Ea indices correlate to varying extents to PCWP and LVEDP in a wide variety of cardiac 
conditions and were also used as estimates LV filling pressure [Nagueh et al., 1997; Mullens 
et al., 2009; Arteaga et al., 2008].  
 
Ea was measured at the lateral and septal walls (Figure 
4.2), enabling the calculation of E/Ea(l) and E/Ea(s) respectively.  
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Figure 4. 2.  Tissue Doppler early diastolic mitral annular velocity at the lateral wall 
[Ea(l)] and at the septal wall [Ea(s)]. 
                                  
 
 
4.6.1.2  Tricuspid inflow indices 
 
Tricuspid inflow indices (Figure 4.3) including early peak transmitral velocity (TVE), early 
deceleration time (TVDT), late peak transmitral velocity (TVA) and the ratio of early to late 
peak mitral velocities (TVE/A) were also measured to establish whether changes in right 
ventricular inflow indices would be more sensitive to volume changes, the right ventricle 
being a much more distensible structure than the LV and thus possibly less likely to be 
affected by relaxation compared to preload. Changes in tricuspid inflow velocities have not 
been studied extensively in relation to cardiac preload changes, but TVE has been correlated 
to right atrial pressure [Harada et al., 1994; Bartel et al., 1996].  In atrial fibrillation, all 
transtricuspid and transmitral measures were measured three times and averaged. 
 
 
 
   84 
 
Figure 4.3.  Tricuspid inflow indices.   
  
TVE: early peak transtricuspid velocity; MVA: late peak transtricuspid velocity; MVDT: transtricuspid 
deceleration time. 
 
4.6.1.3   Inferior vena cava indices 
 
As described in Chapter Two, several IVC indices correlate to invasive haemodynamic 
measures of LV filling pressures or blood volume in a number of conditions [Cheriex et al., 
1989; Blair et al., 2009; Capomolla et al., 2000].  The difficulty with interpreting and 
applying these findings to routine clinical practice is that different studies of IVC have 
employed varying views (long-axis verus short-axis), modes of measurement (2-D versus M-
mode) and states of IVC (in expiration, inspiration, deep inspiration or after a sniff) in a wide 
variety of conditions with varied volume manipulation protocols (haemodialysis patients, 
patients awaiting cardiac transplant, normal volunteers). Furthermore, the timing of IVC 
measurement in relation to the cardiac cycle is not standardised. I therefore aimed to 
systematically measure all IVC indices used in previous studies in order to provide a direct 
comparison of the potential performance of these markers in mapping changes in volume 
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status within the venous compartment and LV filling pressure within the same volunteer 
group.  
 
The 2-D image was firstly optimised in the long-axis view, and the M-mode cursor was 
placed 2 cm from the junction between the IVC and the right atrium. Following the long-axis 
M-mode measures, the probe was turned by 90 degrees from the previous 2-D long-axis view 
in order to produce the short-axis view, as in the study by Brennan et al. 2007. The M-mode 
cursor was placed in the centre of the IVC image, and further M-mode measures were made. 
Thus, IVC was measured by M-mode in expiration (e), inspiration (i) and maximal inspiration 
(mi) in long (Figure 4.4) and short-axis views (Figure 4.5).   IVC was measured before the P 
wave on the ECG to avoid the A wave, or before the QRS complex in atrial fibrillation. IVC 
was corrected for body surface area (IVCD) and the IVC collapsibility index (IVCCI) was 
calculated using the equations: IVCCIi = [(IVCe-IVCi) / IVCe] × 100; IVCCImi= [(IVCe-
IVCmi) / IVCe].   
 
E/Ea indices could not be performed in the cohort of patients with decompensated HF as the 
portable Vivid 3 platform used in this study did not have tissue Doppler modality.   
Furthermore, tricuspid Doppler indices were not analysed in the normal volunteers and stable 
LVSD cohort as the tricuspid pulsed wave signals from the study in patients with 
decompensated HF were not well defined for the majority of volunteers and were therefore 
felt to significantly affect the accuracy of measures in subsequent studies.  
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Figure 4.4.  Long-axis inferior vena cava diameter in expiration (IVCe), inspiration 
(IVCi) and maximal inspiration (IVCmi).   
            
 
Figure 4.5.  Short-axis inferior vena cava diameter in expiration (IVCe), inspiration 
(IVCi) and maximal inspiration (IVCmi).      
          
 
4.6.2   Bioimpedance analysis: Indicators of volume change through changes in 
  estimates of extracellular volume (intravascular and interstitial) and total 
  body water 
 
Given increasing commercial interest in bioimpedance, largely without predefined sensitivity 
and specificity, BIA could potentially be a useful, cheap and non-invasive means of tracking 
volume changes in the models of volume manipulation defined here. Furthermore, it 
constituted the only variable of the biomarkers selected for the study which has been shown to 
change reliably prior to the onset of symptoms of HF, and could thus potentially be the most 
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sensitive to the planned subclinical volume changes.
 
Although sophisticated and expensive 
devices could provide estimates of haemodynamic measures such as cardiac output, these are 
all reliant on regression equations validated against gold standards in specific populations 
[Sodolski et al., 2007].  The chosen device for my studies would be used in different study 
populations, where the regression equations would have variable accuracy.  The emphasis 
therefore, was on obtaining raw impedance values, with the assumption that impedance would 
decrease with increasing volume [Kyle et al., 2004].
 
 
 
 A commercially available multi-frequency BIA device (Bodystat Quadscan 4000, Isle of 
Man, UK) was therefore chosen which would measure body water compartments and raw 
impedance values (BIA measures) using tetrapolar electrodes.  Impedance values to currents 
of 5, 50, 100 and 200 kHz (Z5kHz, Z50kHz, Z100kHz, Z200kHz respectively), and estimated body 
water composition (TBW, ECW and ICW) were all collectively obtained in one measurement.  
The device has been calibrated against under-water weighing for percentage fat, tritium 
dilution techniques for TBW estimation, and NaBr dilution technique for estimation of ECW; 
ICW is then estimated as the difference between TBW and ECW (personal communication 
from manufacturer). According to the product literature, Z50kHz maps ECW (current at low 
frequency unable to penetrate cell membrane), and Z200kHz maps TBW (high frequency able to 
penetrate cellular membrane).  The most useful marker would potentially be impedance at 
lower frequency currents as this would be a measure of the ECW (intravascular plus 
interstitial spaces), the compartment most likely to be affected by the relatively acute stimuli 
generated by volume manipulation.   
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Whole-body (distal), trunk (proximal) and right-lung BIA measures were documented. 
However, whereas estimates of body water composition were derived by the device for 
whole-body and trunk measurements, no derivation equation was available from the 
manufacturer for use of the right-lung impedance values. In fact, electrode position for right-
lung BIA was only recommended by the manufacturer after the study in the patients with 
decompensated HF was completed. 
 
Whole-body BIA was measured by connecting the electrodes to the right wrist and ankle, 
trunk BIA by electrode placement to the suprasternal notch and right knee.  Right-lung 
impedance was measured by using the manufacturer-recommended electrode placements to 
the suprasternal notch and intersection of right anterior axillary line and lower rib (sternum-
rib), and by my own devised electrode placement to the anterior fourth and fifth ribs and to 
the posterior scapula (anterior-posterior), as shown in Figure 4.6. 
 
Figure 4.6.  Bioimpedance analysis across whole body (a), trunk (b), right lung with 
electrodes in anterior-posterior position (c) and sternum-rib position (d).   
 
 b   
 
 
 
 
 
 
 
a b 
c d
a 
d
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4.7   Pre-analytical and analytical methods for blood and urine  
  biomarkers 
 
Based on the discussions in Chapter Three, steps to minimise pre-analytical and analytical 
variance of blood and urine biomarkers are described below. 
 
4.7.1  Blood biomarkers 
 
Blood for Hct was collected into EDTA tubes (1.5mg/mL) and kept at room temperature.  
Analysis was carried out using the Bayer ADVIA 120 Haematology System (Siemens 
Medical Solutions Diagnostics Ltd, Newbury, Berks, UK) at the Centre for Cardiovascular 
Sciences within 2h of collection.  Blood was well mixed prior to analysis. The intra- and 
inter-assay coefficients of variation were 1.5% and 2.3% respectively. 
 
For ANP and BNP, blood was collected into chilled EDTA and aprotinin (500i.u./mL, 
Trasylol, Bayer, Newbury, Berks, UK) tubes. Samples were kept on ice until they were 
centrifuged at 4°C at 1200 rpm for 20 minutes within 2h of collection. Samples were 
aliquoted into respective plastic tubes and stored at -70°C for subsequent analyses.  Samples 
were gently thawed and vortexed prior to analysis and all samples from the same patient were 
analysed in the same batch to minimise analytical error. ANP was analysed by ELISA (USCN 
Life Science Inc., Wuhan, China) at St George’s Hospital by Dr David C. Gaze and Dr Paul 
O. Collinson.  Intra-assay coefficient of variation was <5%, inter-assay CV was <14%, the 
assay range was 0-25 ng/mL. BNP was measured using the ADVIA Centaur
TM 
automated 
chemiluminescence system (Siemens Medical Solutions Diagnostics, Newbury, Berks, UK).  
BNP values were converted from pmol/L to pg/mL by dividing by 0.289 [Gabriel et al., 2008; 
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Kroll et al., 2007] in order to standardise values to previous studies. The inter-assay 
coefficient of variation was 13.6% for low (4.26 pg/mL), 10.0% for medium (36.9 pg/mL) 
and 11.2% for high (133.0 pg/mL) BNP values.  The intra-assay coefficient of variation was 
22.3% for low, 10.9% for medium and 11.6% for high values. The quality control analyses 
were performed in between the study sample analyses.  The sensitivity of the assay was 6.9 
pg/mL and the upper detection limit was 17301 pg/mL. A BNP value of >100 pg/mL was 
considered as elevated (specificity >95% and above the upper confidence interval of 95
th
 
percentile of healthy reference population). Normal range of ANP was considered to be 10-70 
pg/mL.  
 
Blood was also collected in serum separator tubes at room temperature and centrifuged at 4°C 
at 1200 rpm for 20 minutes. Samples were aliquoted into respective plastic tubes and stored 
within 2h at -70°C for cTnI , cTnT and sNGAL, and at -20°C or less for IMA for subsequent 
analyses.  Similar precautions as for ANP and BNP were taken prior to analysis to minimise 
pre-analytical and analytical error. cTnI was measured using the ADVIA Centaur 
TM  
automated chemiluminescence system (Siemens Medical Solutions Diagnostics, Newbury, 
Berks, UK) in the Biochemistry Department at Sandwell Hospital.   The lower detection limit 
was 0.010 ng/mL, and a cTnI value of >0.040 ng/mL was considered as elevated.  The intra-
assay coefficient of variation was 5.6% for low (0.051 ng/mL), 1.13% for medium (0.894 
ng/mL), and 0.47% for high (29.7 ng/mL) quality control values.  The inter-assay coefficient 
of variation was 1.49% for low, 0.78% for medium and 1.13% for high cTnI quality control 
values.  
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cTnT was measured by Bayer autoanalyser at Sandwell Biochemistry Laboratory.  The 
detection limit of cTnT was 0.010 ng/mL, with a cTnT value of >0.010 ng/mL considered as 
elevated.  100 random samples from the cohort of chronic LVSD patients were initially 
analysed.  Only 3 produced detectable results (0.012, 0.020 and 0.011 ng/mL respectively).  
The remaining samples had undetectable cTnT levels (<0.010 ng/mL).  I therefore felt that the 
majority of LVSD patients would have undetectable levels of cTnT by our available 
autoanalyser, and no further cTnT analyses were carried out. 
 
IMA was analysed at St George’s Hospital by Dr Paul O. Collinson and Dr David C. Gaze 
using a colorimetric assay, the ACB (Albumin Cobalt Binding) test (Inverness Medical 
Innovations, Inc., Massachussets, USA) on the Roche Cobas Mira platform. The normal range 
was 0-85 U/mL. Intra-assay coefficient of variation at low IMA value (75.9 U/mL) was 2.2% 
and high IMA value (119.9 U/mL) was 2.1%.  Inter-assay coefficient of variation at low IMA 
value (75.9 U/mL) was 5.4% and high IMA value (119.9 U/mL) was 4.4%. 
 
4.7.2   Urine biomarkers 
 
Urine samples were stored in plastic tubes at room temperature.  They were frozen at -70°C 
within 2h of collection until the time of analysis, at which point they were gently thawed and 
vortexed. uKIM, uNGAL, sNGAL, uNAG, sCreatinine and uCreatinine were analysed in 
Groningen by Dr Kevin Damman and Prof Dirk J. van Veldhuisen. NGAL was determined by 
means of a commercially available ELISA test kit from Antibody Shop (Gentofte, Denmark). 
Samples were diluted 500 times in dilution buffer supplied with the test kit. uNAG was 
evaluated using the substrate p-nitrophenyl -acetyl-β-D-glucosaminide (Sigma, St Louis, 
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MO) in citrate buffer at pH 4.5. After 60 minutes at 37
o
C, 1 M Na2CO3 was added to the 
mixture to terminate the reaction and to develop a yellow colour released from the converted 
substrate. Controls were obtained from each sample by addition of Na2CO3 at time=0h. The 
colour was measured at 405 nm by a microtitre plate reader and controls were subtracted. A 
standard curve was made with -acetyl-β-D-glucosaminidase. uKIM-1 measurements were 
performed using microsphere-based Luminex xMAP technology with polyclonal antibodies 
raised against the human KIM-1 ectodomain. For measurements, 30 µl of urine samples were 
analyzed in duplicate. The lowest limit of detection for this assay is 0.125 ng/ml. The inter- 
and intra-assay variability for these biomarkers was <20%. uNGAL, uNAG and uKIM-1 
levels were corrected for urinary concentration by dividing their values by corresponding 
uCreatinine concentration, and expressed as /gram urinary creatinine (/gCr). 
 
4.8   Body weight and height 
 
Body weight was recorded to the nearest 0.1 Kg using a Seca 761 mechanical medical scale 
(Seca Ltd, Birmingham, UK), and height was recorded to the nearest 0.01 m. 
 
4.9   Statistical analysis 
 
Normally distributed data were presented as means (SD), and non-normally distributed data as 
median (IQR). Mean, median and standard deviation values, as well as histograms and the 
Kolmogorov-Smirnow test were used to define whether data was normally or non-normally 
distributed. Specific statistical analyses for each study are discussed in the respective 
chapters. A p value of ≤0.05 was significant. Data were analysed using SPSS 14.0 for 
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Windows (SPSS Inc., Chicago, Illinois, USA). Graphs were created using GraphPad Prism 
Software (GraphPad Software Inc., San Diego, CA, USA). 
 
4.10  Ethical approval 
 
The Sandwell and West Birmingham Local Research Ethics Committee granted ethical 
approval for all studies reported in this thesis.  All volunteers gave written informed consent 
to study procedures. 
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Chapter Five 
 
Studies in Patients with Decompensated Heart 
Failure 
 
Performing Repeated Measures of 1on-invasive 
Physical Biomeasures of Volume Response to 
Intravenous Furosemide: a Feasibility Study 
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5.1   Introduction 
 
A study investigating the performance of repeated measures of physical biomeasures in 
tracking volume changes relies on all repeated measures being collected and analysed under 
optimal conditions to minimise measurement error, but equally, on it being feasible for all 
repeated measures to be consistently recorded at all time points.  This is in the context of 
repeated measures having to be performed within the time constraints of the study protocols, 
with the onset of intervention being staggered between individual patients to allow 
optimisation of operator use of resources and time.  
 
Thus, only a limited period of time would be available to the operator to collect the planned 
series of physical biomeasures before either the next series of measures is due (whether in the 
same volunteer or a different volunteer), or the volume change at a particular time point is 
missed, for example, the 0.5h measures still being collected at 1h into the protocol. This was 
particularly relevant for echocardiographic measures which are time consuming and 
dependent on both the skills of the operator, speed of acquisition and patient factors such as 
tolerability of the measures, echogenicity, optimal position (e.g., left lateral position for mitral 
and tricuspid inflow indices, but supine for IVC measures), and compliance with instructions, 
such as ability to perform the Valsalva manoeuvre and control of respiration. These factors 
would all contribute to measurement error. Thus, in a similar way to taking steps to minimise 
the sources of variance of the selected panel of blood biomarkers as outlined in Chapters 
Three and Four, there was also a need to explore ways in which measurement variance for 
physical biomeasures could be minimised.  
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A set pattern of measuring physical biomeasures in a systematic way was therefore devised 
which would optimise both operator and patient factors as well as time resources. To 
eliminate inter-observer variability, the physical biomeasures were performed by only one 
operator (MJNKC). A readily available group of volunteers to perform a pilot study for the 
feasibility of this pattern of measuring physical biomeasures consisted of hospitalised patients 
who were admitted with acute cardiogenic pulmonary oedema, and who were undergoing 
intravenous diuresis for the treatment ofdecompensated HF. Performing the pilot study in this 
group of patients would not involve any additional attendance or intervention to their routine 
medical care. These patients would by definition, have abnormal volume status, with at least 
increased interstitial water as evidenced by the clinical signs of pulmonary oedema, peripheral 
oedema or ascites, with potentially variable volume status in their intravascular space, this 
being predefined by their underlying neurohormonal status and current and previous 
treatments, in particular prior doses of diuretics[Cotter et al.].  Fluid redistribution, and 
diuresis and natriuresis were expected to occur on a significant scale as a result of intravenous 
diuretic administration.  
 
5.2   Hypotheses (H1) 
 
I hypothesised that it would be feasible to perform repeated measures of physical biomeasures 
consistently in a systematic way by a single operator in this potentially unstable group of 
patients, that the repeated assessments would be well tolerated by the patients, and that 
practice of and increased familiarity with the set pattern of measurement would reduce the 
measurement error of echocardiographic measures.  Furthermore, I hypothesised that physical 
biomeasures that changed the most from baseline measures following intravenous diuresis 
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would potentially be the most sensitive physical biomeasures at tracking volume changes in 
response to intravenous diuresis in this group of patients. 
   
5.3   Methods 
 
5.3.1   Study population 
 
Patients were recruited from the Coronary Care Unit, Post Coronary Care Unit and the 
Cardiology ward at City Hospital who had been admitted with a clinical diagnosis of acute 
cardiogenic pulmonary oedema, defined as the presence of acute symptoms and signs, as well 
as radiological evidence of lung congestion.  In addition, these patients had other symptoms 
and signs of decompensated HF such as lethargy, raised jugular venous pressure, peripheral 
oedema, third heart sound and ascites to varying extents. They were all receiving bolus doses 
of intravenous furosemide (ivF) up to twice daily. Exclusion criteria included patients who 
were too clinically unstable and unable to cooperate or consent to repeated measures 
assessment, and patients receiving more than their 10
th
 dose of ivF. Patient demographic 
details were documented.  
 
5.3.2   Set pattern for collection of repeated measures of physical biomeasures 
 
Physical biomeasures were performed at baseline (0h), then at 0.5, 1, 2 and 3h after ivF. At 
each time point, BIA measures were performed first, with patients lying supine. Prior to the 
0h measures, the relevant areas of skin were prepared by shaving and by applying alcohol 
wipes, followed by positioning of respective electrodes, as described in Chapter Four. The 
BIA device was then connected, in the following order, to electrodes placed distally to 
determine whole-body BIA, then to proximal electrodes to determine trunk BIA and finally, 
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to electrodes placed in the antero-posterior position to determine right-lung impedance. The 
latter electrode position was my own devised position, as the manufacturer had not devised 
their recommended electrode position for right lung BIA measurements at the time of this 
study. The BIA device was then disconnected, followed by connection of the ECG monitor on 
the echocardiography platform. IVC measures on expiration, inspiration and maximal 
inspiration were then performed with the patient still lying supine.  The patient was then 
turned to the left lateral position for the remaining echocardiographic assessment.  Mitral 
inflow indices with and without the Valsalva manoeuvre and tricuspid inflow indices with and 
without the Valsalva manoeuvre were then performed. BIA pmeasures determined included 
Z5kHz, Z50kHz, Z100kHz, Z200kHz TBW, ECW and ICW across the whole-body and the trunk.  
Only impedance values were available from the right-lung measures. Echocardiographic 
measures that were collected consisted of MVE, MVDT, MVE/A, TVE, TVDT, and TVE/A 
with and without the Valsalva manoeuvre, and IVC indices on expiration, inspiration and 
maximal inspiration in both long-axis and short-axis views.   
 
5.3.3   Determination of intra-observer variability for physical biomeasures 
 
 
The intra-observer variability for echocardiographic measures and the intra-device variability 
for BIA measures were determined by performing 10 repeated measures on one healthy 
individual and calculating the coefficient of variation before the start of the study. This 
process was then repeated for echocardiographic measures after completion of the study to 
assess whether intra-observer variability would reduce after practice and increased familiarity 
with the process of repeated measures assessment. The first set of measures was performed 
using the GE Vivid 3 portable platform, which was used in the current study, and the second 
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set of measures were performed using the GE VingMed System 5 platform which would be 
used in the studies in normal volunteers and stable LVSD patients. 
 
5.3.4   Statistical analysis 
 
General linear model repeated measures one-factor ANOVA was used to establish the 
response of variables to ivF against time, and Bonferroni post-hoc analysis was performed to 
identify the time points between which the significant changes in biomarker measurement 
took place.   The Bland-Altman method was used to assess the agreement between the 
measurement of IVC diameters using the long-axis and short-axis views.There is no precedent 
to this study investigating the acute effects of ivF on mitral and tricuspid inflow indices, IVC 
indices or BIA measures, thus data are lacking to estimate power for these markers.  
However, based on the study by Dikshit et al. [1973], a sample size of 30 patients would give 
a power of > 85% to detect a 30 % reduction in LV filling pressure in response to ivF. 
 
5.4   Results 
 
Patients were recruited over a 6-month period.  Of the 31 patients enrolled, 61% were male.  
Table 5.1 illustrates their demographic details. The predominant cause for acute cardiogenic 
pulmonary oedema was cardiac ischaemia. 14 (46%) patients were receiving between their 
first to third dose of ivF, and 14 (46%) patients were receiving their fourth to sixth dose of 
ivF.  13 (42%) patients had LVEF < 40%; 9 (29%) patients had LVEF 40-50%, and 9 (29%) 
patients had LVEF of >50%. 12 (39%) patients had renal dysfunction, as evidenced by a 
serum creatinine level of > 1.20 mg/dL. 
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Table 5.1.  Demographic details of patients with decompensated heart failure. 
Variable Value 
Male (%) 19 (61)  
Age (yrs) 72 (12) 
Systolic BP (mmHg) 122 (22) 
Diastolic BP (mmHg) 71 (11) 
Heart rhythm 23 sinus rhythm; 8 atrial fibrillation 
Body mass index (Kg/m
2
) 28.6 (5.5) 
Body surface area (m
2
) 1.9 (0.2) 
Left ventricular ejection fraction (%) 43 (14) 
Haemoglobin (g/dl) 12.2 (2.2) 
Haematocrit (%) 36.8 (6.3) 
Urea (mmol/L) 9.7 (6.2) 
Serum Creatinine (mg/dL) 
 
1.21 (0.92-1.67) 
Aetiology, n(%) 
   Ischaemia  
   Valvular heart disease  
   Arrhythmia 
   Hypertension  
   Renal disease  
   Non ischaemic cardiomyopathy  
   Others  
 
  
12 (39) 
3 (10) 
3 (10) 
1 (3) 
5 (16) 
2 (7) 
5 (15) 
Dose of IV furosemide  given (mg) 40-50 mg: n=14 
80-100 mg: n=17 
Total daily dose of IV furosemide (mg) 120 (40); range 50-200 
n
th
 dose of IV furosemide  1
st
-3
rd
: n=14  
4
th
-6
th
: n=14  
7
th
-10
th
: n=3 
 
5.4.1   Feasibility and tolerability 
 
Repeated measures of echocardiographic and BIA indices were well tolerated by patients and 
were feasible at all time points in all patients by applying the devised pattern of measurement.  
Preparation of the skin and placement of all BIA electrodes took less than one minute. The 
combined set of BIA results across each region was obtained collectively within 20-30 
seconds each, such that the entirety of BIA variables was obtained within three minutes in 
general. The complete set of echocardiographic measures was collected within 10 minutes. 
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Overall, each timed collection of measures took an average of 15 minutes. I observed that 
tricuspid inflow traces, although collected at each time point, were not as well defined as the 
mitral inflow indices. 
 
5.4.2   Intra-observer/intra-device variability 
 
Table 5.2 shows the intra-observer variability for echocardiographic measures before and 
after completion of the study in one normal volunteer. Intra-observer variability generally 
reduced after completion of the study. Table 5.3 shows the intra-device variability of BIA 
measures, which was much smaller compared to that of the echocardiographic measures.  
 
Table 5.2. Intra-observer variability of echocardiographic variables before and after 
completion of the study in patients with decompensated HF. 
Variable Intra-observer 
variability (%) 
Variable Intra-observer 
variability (%) 
 Before After  Before After 
MVE (m/s) 5.5 3.4 vTVDT 23.1 19.5 
MVDT (ms) 16.5 14.0 vTVA 13.6 9.4 
MVA (m/s) 12.6 5.6 E/Ea (l) NA 5.4 
TVE (m/s) 7.7 6.2 E/Ea (s) NA 7.8 
TVDT (ms) 22.6 9.1 LIVCe  5.0 4.2 
TVA (m/s) 11.3 5.9 LIVCi 14.5 7.8 
vMVE (m/s) 7.1 7.5 LIVCmi 14.5 13.8 
vMVDT (ms) 11.1 5.9 SIVCe 6.7 2.7 
vMVA (m/s) 15.3 10.1 SIVCi 9.5 7.3 
vTVE (m/s) 10.6 7.3 SIVCmi 12.1 5.7 
MV: transmitral; TV: transtricuspid; E: early peak velocity; A: late peak velocity; DT: 
deceleration time; Ea: Tissue Doppler early peak mitral annulus velocity; l: lateral wall; s: 
septal wall; IVC: inferior vena cava diameter; IVCD: IVC corrected for body surface area; S: 
short axis; L: long axis; e: expiration; i: inspiration; mi: maximal inspiration; v: Valsalva 
manoeuvre; NA: not assessed. 
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Table 5.3.  Intra-device variability for bioimpedance measures. 
Variable Intra-device 
variability (%) 
Variable Intra-device 
variability (%) 
dTBW (%) 0.22 pZ50 kHz (Ω) 0.47 
dECW (%) 0.22 pZ100kHz (Ω) 0.50 
dICW (%) 0.36 pZ200kHz (Ω) 0.50 
pTBW (%) 0.22 srZ5kHz (Ω) 2.62 
pECW (%) 0.35 srZ50 kHz  (Ω) 2.1 
pICW (%) 0.51 srZ100kHz (Ω) 2.4 
dZ5kHz (Ω) 0.54 srZ200kHz (Ω) 2.85 
dZ 50 kHz (Ω) 0.63 apZ5kHz (Ω) 0.82 
dZ100kHz (Ω) 0.43 apZ50 kHz (Ω) 0.95 
dZ200kHz (Ω) 0.34 apZ100kHz (Ω) 1.69 
pZ5kHz (Ω) 0.74 apZ200kHz (Ω) 1.10 
d: whole-body;  p: trunk; sr: right lung with sternum-rib electrode position; ap: right-lung with anterior-
posterior electrode position; Z: impedance; 5-200 kHz: current frequency; ECW: extracellular water; 
ICW: intracellular water; TBW: total body water. 
 
5.4.3   Changes in echocardiographic measures in response to ivF 
5.4.3.1  Mitral and tricuspid inflow indices 
 
Table 5.4 shows changes in mitral and tricuspid inflow indices that occurred in response to 
ivF, with the maximal percentage change of these variables from baseline and the time point 
at which they occurred.  Following ivF, there were statistically significant reductions in 
vMVE and TVE, and statistically significant increase in MVDT , with maximal change for 
TVE occurring earlier than corresponding left-sided variables. Figure 5.1 illustrates the large 
between-subject variance not only in baseline measures, but also in response pattern to ivF of 
individual patients.    
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Table 5. 4.  Changes in mitral and tricuspid inflow indices following ivF. Mean (SD).  
Variable Baseline Maximal 
response 
Maximal 
change 
(% baseline) 
Maximal 
response 
time (h) 
p value 
MVE (m/s)  1.15 (0.27) 1.09 (0.30) 5.2 (10.2) 3 0.105 
vMVE (m/s) 1.10 (0.30) 0.99 (0.25) 8.8  (18.6) 2 0.012 
MVDT (ms) 204 (75) 245 (94) 20.1 (34.3) 3 0.030 
vMVDT (ms) 211 (75) 219 (79) 3.8 (6.4) 1 0.883 
MVE/A 1.88 (0.81) 1.81 (0.94) 3.7 (5.3) 1 0.611 
vMVE/A 
 
2.02 (0.80) 1.90 (0.73) 5.9 (9.9) 1 0.870 
TVE (m/s) 0.77 (0.23) 0.68 (0.21) 11.7 (13.9) 1 0.010 
vTVE (m/s) 0.67 (0.21) 0.61 (0.18) 9.0 (12.0) 1 0.362 
TVDT (ms) 222 (81) 246 (120) 10.8 (15.3) 3 0.069 
vTVDT (ms) 215 (59) 235 (94) 9.3 (15.2) 1 0.250 
TVE/A 1.63 (0.45) 1.55 (0.47) 4.9 (6.5) 1 0.683 
vTVE/A 1.50 (0.53) 1.45 (0.50) 3.3 (5.4) 0.5 0.259 
MV: mitral inflow; TV: transtricuspid; DT: Deceleration time; E: early peak velocity; A: late peak velocity; v: 
Valsalva manoeuvre. p value calculated from repeated measures one-factor ANOVA of variables at 5 time 
points in response to ivF. 
 
 
Figure 5. 1.  Changes in mitral valve early peak velocity with Valsalva manoeuvre 
(vMVE) and tricuspid valve early peak velocity (TVE) following ivF. 
 
Red line denotes mean change in response to ivF. p value calculated from repeated measures one-factor ANOVA 
of variables at 5 time points in response to ivF. 
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5.4.3.2  Inferior vena cava indices 
 
There was a positive bias (mean difference) between IVC diameters measured in the long-axis 
and short-axis as shown in Figure 5.2.  This was particularly large for the measurement of 
IVCe (bias of 0.19 cm), but small for the measurement of IVCmi (bias of 0.03 cm). However, 
the variability of measures using both methods appeared consistent regardless of the vessel 
diameter. 
 
Figure 5.2. Bland-Altman plots of long-axis and short-axis measures of IVC diameters. 
 
L: long-axis; S: short-axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal 
inspiration; mean: mean difference between LIVC and SIVC measures; SD: standard deviation of the mean. 
 
 
 
Table 5.5 shows maximal changes in IVC indices following ivF. For the majority of variables, 
these maximal changes occurred at the 3h measures. There were statistically significant 
reductions in SIVCe and SIVCi, and their corresponding indexed measures (SIVCDe and 
SIVCDi). Figure 5.3 illustrates the SIVCDe and SIVCDi responses of individual patients to 
ivF. 
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Table 5.5. Changes in IVC indices following ivF. Mean (SD). 
Variable Baseline Maximal 
response 
Maximal 
change 
(% baseline) 
Maximal 
response 
time (h) 
p value 
SIVCe (cm) 2.23 (0.58) 2.08 (0.56) 5.1 (21.5) 3 0.039 
SIVCi (cm) 1.96 (0.53) 1.78 (0.54) 6.4 (26.6) 3 0.020 
SIVCmi (cm) 1.69 (0.55) 1.58 (0.47) 6.5 (25.1) 3 0.306 
SIVCDe (cm/m
2
) 1.23 (0.33) 1.14 (0.31) 5.1 (21.5) 3 0.032 
SIVCDi (cm/m
2
) 1.08 (0.30) 0.98 (0.27) 6.4 (26.6) 3 0.016 
SIVCDmi (cm/m
2
) 0.93 (0.32) 0.87 (0.24) 6.5 (24.3) 3 0.288 
SIVCCIi (%) 12.8 (9.1) 15.5 (6.8) 21.1 (30.2) 2 0.417 
SIVCCImi (%) 
 
24.8 (13.4) 25.9 (12.9) 4.4 (8.2) 1 0.783 
LIVCe (cm) 2.43 (0.53) 2.30 (0.54) 5.3 (12.3) 3 0.172 
LIVCi (cm) 2.06 (0.51) 1.90 (0.50) 7.8 (15.2) 3 0.111 
LIVCmi (cm) 1.71 (0.51) 1.59 (0.51) 7.0 (13.2) 1 0.450 
LIVCDe (cm/m
2
) 1.34 (0.30) 1.26 (0.28) 6.0 (14.9) 3 0.121 
LIVCDi cm/m
2
) 1.14 (0.31) 1.04 (0.26) 8.8 (15.8) 3 0.088 
LIVCDmi cm/m
2
) 0.95 (0.28) 0.87 (0.28) 8.4 (13.2) 1 0.472 
LIVCCIi (%) 15.9 (9.7) 17.8 (9.0) 11.9 (23.0) 1 0.404 
LIVCCImi (%) 29.6 (13.3) 29.9 (13.6) 1.0 (4.6) 3 0.766 
S: short-axis; L: long-axis; IVC: inferior vena cava diameter; IVCD: IVC corrected for body surface area; 
IVCCI: IVC collapsibility index; e: expiration; i: inspiration; mi: maximal inspiration. p value calculated from 
repeated measures one-factor ANOVA of variables at 5 time points in response to ivF. 
 
 
Figure 5.3.  Changes in short-axis inferior vena cava diameter corrected for body 
surface area in expiration (SIVCDe) and inspiration (SIVCDi) in response to ivF.  
 
Red line denotes mean changes in response to ivF. p value calculated from repeated measures one-factor 
ANOVA of variables at 5 time points in response to ivF. 
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5.4.4   Changes in bioimpedance measures in response to ivF 
 
Whole-body measures of Z at similar frequency currents were observed to be larger than 
trunk measures, which in turn were larger than right-lung measures, as shown in Figure 5.4. 
Furthermore, estimated body water composition was generally smaller when measured 
proximally compared to distally, e.g., mean baseline ECW estimated using distal electrode 
placement was 24.9 (3.6)%, compared to 23.9 (3.8)% when estimated using proximal 
electrode placement. For TBW estimation, the difference in readings was >5%.  
 
Figure 5.4. Impedance values at 50kHz frequency current (Z50kHz) measured across the 
whole body, trunk and right lung: between-subject variability and response of to ivF  
 
Red line denotes mean changes in response to ivF 
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Table 5.6 shows maximal changes in BIA measures following ivF. All components of body 
water composition reduced and Z values increased following ivF, reaching maximal change 
from baseline at between 2-3h post dosing, although not all changes in variables showed 
statistical significance.  Figure 5.5 illustrates the changes in whole-body Z5kHz and Z50kHz 
following ivF in individual patients, as well as the mean change within the cohort.  
 
Table 5. 6.  Changes in bioimpedance measures following ivF. Mean (SD).  
Variable Baseline Maximal 
response 
Maximal 
change 
(% baseline) 
Maximal 
response 
time (h) 
p value 
d ECW (%) 24.9 (3.6) 24.4 (3.4) 2.1 (3.0) 3 0.001 
d ICW (%) 30.2 (4.9) 29.4 (3.8) 2.6 (3.4) 1 0.309 
d TBW (%) 55.8 (9.1) 54.8 (8.9) 1.8 (2.3) 3 0.058 
d Z5kHz  (Ω) 486 (138) 506 (150) 4.2 (6.1) 3 <0.0001 
d Z50kHz (Ω) 442 (122) 457 (130) 3.7 (7.2) 3 0.006 
d Z100kH (Ω) 423 (118) 438 (122) 4.4  (9.6) 3 0.010 
d Z200kHz (Ω) 404 (115) 418 (115) 3.5 (5.3) 3 0.051 
 
p ECW (%) 23.9 (3.8) 23.3 (3.8) 2.3 (5.9) 3 0.052 
p ICW (%) 26.6 (4.1) 26.1 (3.3) 1.9 (4.2) 3 0.381 
p TBW (%) 50.5 (7.5) 49.3 (7.0) 2.4 (4.9) 3 0.121 
p Z5kHz  (Ω) 95 (23) 100 (25) 5.3 (7.3) 2 0.115 
p Z50kHz (Ω) 85 (20) 89 (22) 4.0 (6.0) 3 0.039 
p Z100kH (Ω) 81 (19) 84 (20) 3.7 (5.2) 3 0.323 
p Z200kHz (Ω) 77 (18) 79 (19) 2.5 (5.1) 3 0.377 
 
apZ5kHz  (Ω) 49 (16) 53 (17) 7.8 (13.0) 2 0.054 
apZ50kHz (Ω) 42 (13) 45 (13) 10.5 (17.9) 1 0.016 
apZ100kHz (Ω) 40 (13) 43 (13) 9.7 (19.0) 1 0.068 
apZ200kHz (Ω) 38 (12) 41 (13) 10.2 (18.8) 3 0.036 
d: whole-body; p: trunk; ap: right-lung with anterior-posterior electrode position; Z: impedance; 5-200 
kHz: current frequency; ECW: extracellular water; ICW: intracellular water; TBW: total body water. p 
value calculated from repeated measures one-factor ANOVA of variables at 5 time points in response 
to ivF. 
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Figure 5. 5.  Whole-body impedance (Z) at 5 kHz and 50 kHz frequency currents in 
response to ivF. 
 
Red line denotes mean changes in response to ivF. p value calculated from repeated measures one-factor 
ANOVA of variables at 5 time points in response to ivF. 
 
 
5.5   Discussion 
5.5.1   Feasibility and minimisation of measurement error 
 
Determining the feasibility of consistently performing and obtaining physical biomeasures at 
each time point was a crucial step for the assessment of biomarker sensitivities in the future 
planned study protocols in normal volunteers and stable LVSD patients. The accurate 
assessment of biomarker sensitivities would be reliant on the availability of all measures at 
each specific time point for subsequent analysis. The time scale in which the collection of 
biomeasures was achieved confirmed that my choice of echocardiographic variables and of 
BIA device was appropriate. In accordance with previous studies, mitral inflow traces were 
consistently adequate, and were obtained in a small amount of time [Khan et al., 2004]. IVC 
indices were also easy to measure, with adequate images in all patients. However, traces for 
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tricuspid inflow indices were not as consistently clear as the mitral inflow indices and may 
have contributed to their documented high intra-observer variability.  
 
The tolerability of the repeated measures was the next crucial step as this would be a major 
factor determining the comfort and compliance of volunteers, thus affecting measurement 
variance. The fact that the repeated measures assessment was well tolerated in this potentially 
unstable group of patients implied that normal volunteers and stable LVSD patients would 
also tolerate repeated measurements using this set pattern well.  
 
A reduction was observed in intra-observer variability for most echocardiographic measures, 
in some cases by approximately 100%, following practice and increased familiarity with the 
devised pattern for collecting repeated measures of biomarkers. The fact that a different 
echocardiographic platform was used before and after completion of the study may be a 
confounding factor, however, the images obtained were of similar quality with similar settings 
used to optimise images. Furthermore, the studies in normal volunteers and stable LVSD 
patients would be performed using the GE VingMed System 5 platform, thus, determining the 
intra-observer variability using that particular platform was more appropriate to enable 
accurate interpretation of results for the studies in these volunteer groups.  
 
The intra-observer variability of MVE determined in this Chapter (3.4%) was higher than that 
documented by Rijtsterborgh et al. [1990] (1%). However, the reported inter-observer 
variability for MVE in the latter study was 6.5% compared to 2% reported by Khan et al. 
[2004]. Furthermore, I observed much larger intra-observer variability for MVDT (14%) 
compared to the inter-observer variability in the study by Khan et al. of 5% (intra-observer 
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variability not reported). This illustrates the fact that intra- and inter-observer variability will 
vary depending on a number of factors such as the clinical settings (mitral valve disease or 
replacement in the former study, unselected population in the latter study), echocardiography 
platforms and experience of the operator. These factors need to be considered when 
interpreting results from studies involving echocardiographic measures, or indeed when using 
echocardiographic measures as a monitoring tool in practice. I observed increased intra-
observer variability of mitral and tricuspid inflow indices when measured with the Valsalva 
manoeuvre compared to without the Valsalva manoeuvre, in accordance with findings from 
the above studies.  
 
The intra-observer variability of IVC indices is not well documented. I found that in general, 
it increased the smaller the IVC diameter being measured, i.e., that of IVCe being the smallest 
and that of IVCmi being the largest.  The measurement of IVC diameters using the long-axis 
and short-axis views in this cohort of patients had a clinically significant bias, particularly 
when measuring the IVC in expiration. IVC diameter measurement using these two views is 
thus not interchangeable in this group of patients, and when used in the monitoring of 
individual patients, should be obtained using the same view each time to allow direct 
comparison of IVC measures. Although the intra-device variability for BIA measures was 
very small, it tended to increase the smaller the body segment being studied (largest for right-
lung measures), in a similar way to IVC measures. It is thus preferable to measure larger 
variables in order to minimise measurement error. 
 
 
 
   111 
 
5.5.2   Repeated measures of physical biomeasures in response to ivF  
 
The patients studied were admitted with acute cardiogenic pulmonary oedema, and had to 
differing extents other signs and symptoms of decompensated HF. Interstitial space volume  
would thus be increased, while intravascular volume would be normal, reduced, or increased 
depending on baseline neurohormonal activation and haemodynamic variables [James et al., 
1996; Davidov et al., 1967; Henning et al., 1978]. This statement not only holds for patients 
who were studied on admission and those receiving their first few doses of ivF, but also for 
the patients who had received multiple previous doses of ivF, a large proportion of whom still 
had evidence of pulmonary oedema in the form of rales on lung auscultation on the day of the 
study despite being able to lie supine for the short duration of physical biomeasurements. 
Furthermore, these patients were still requiring ivF therapy on clinical grounds in view of 
their ongoing signs and symptoms of abnormal volume status.
 
 
 
As described in Chapter One, ivF administration in volume overloaded patients reduces 
cardiac preload secondary to almost immediate venodilatation followed by volume 
redistribution, natriuresis and diuresis within 30 minutes [Schaper et al., 1997].  The 
haemodynamic effects of ivF were still evident in a study by Ikram et al. by the end of a 4h-
monitoring period, where PCWP was still declining.  The net effect of ivF administration in 
my cohort of patients was therefore expected to be one of overall reduced ECW (likely to 
involve reduction in at least the interstitial space, and possibly in intravascular volume) 
secondary to venodilatation, diuresis and natriuresis, with possible temporary intravascular 
volume increase as a result of volume redistribution from the interstitial space. In an attempt 
to minimise the effects of variable baseline neurohormonal and haemodynamic status, I 
excluded any patients who were receiving more that their 10
th
 consecutive dose of ivF. In fact, 
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almost half of the patients were receiving their 1
st
-3
rd
 dose, and only three (9.7 %) patients 
were receiving more than their 7
th
 dose of ivF.  
 
Of the echocardiographic variables, statistically significant reductions were observed in 
vMVE, TVE, SIVCe, SIVCi, SIVCDe and SIVCDi, in addition to a statistically significant 
increase in MVDT, suggesting reduction in cardiac preload or intravascular volume following 
ivF. Maximal changes in tricuspid inflow indices occurred earlier than mitral inflow indices, 
suggesting that right heart measures may indeed change quicker in response to volume 
changes compared to left-sided measures due to the right heart being more distensible 
[Efthimiadis et al., 1999; Areias et al., 1998]. However, the maximal percentage change from 
baseline for each of these variables was small (Figure 5.1), particularly when the intra-
observer variability of each marker is taken into account. Considering the intra-observer 
variability values established prior to the study (Table 5.2), the maximal percentage change 
was only marginally above the intra-observer variability for the mitral and tricuspid inflow 
indices (e.g., for vMVE, the maximal percentage change from baseline was 8.8 % whereas the 
intra-observer variability was 7.1 %). This suggests that the maximal percentage change from 
baseline for these biomarkers is unlikely to be greater than their respective within-subject 
normal variance, which as discussed in Chapter Three, is determined by both the intra-
observer variability and within-subject biological variance.  
 
For the IVC indices, the maximal percentage change from baseline in response to ivF was in 
fact less than the respective intra-observer variability (e.g., for SIVCe, intra-observer 
variability was 6.7 % whereas maximal percentage change from baseline was 5.1 %), 
suggesting that the changes in IVC indices did not occur over and above their within-subject 
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normal variance. It is also unclear as to why there was a statistically significant reduction in 
vMVE and not MVE, as the strain phase of the Valsalva manoeuvre should in principle, 
attenuate the mitral inflow response to changes in volume status [Hamilton et al., 1994]. Thus, 
the statistically significant changes observed in biomarker levels in response to ivF in this 
cohort of patients are unlikely to represent biologically significant changes.  It is therefore 
reasonable to conclude that the repeated measures assessment of the above echocardiographic 
variables is unlikely to be clinically useful for tracking volume changes in the current study 
setting. 
 
On the other hand, the statistically significant reduction in dECW and statistically significant 
increase in some whole-body, trunk and right lung impedance values following ivF all 
occurred to a large extent above the respective values for intra-device variability.  For 
example, the maximal percentage reduction for dECW of 2.1 % was much larger than the 
intra-device variability of 0.22 %. This suggests that the changes in BIA measures might have 
occurred above their respective within-subject normal variance, although it is not possible to 
comment at this point on the magnitude of this within-subject normal variance. However, the 
observed BIA responses were small, as illustrated in Figure 5.5, with maximal changes from 
baseline of around 10 % at most. This suggests that these changes, despite being statistically 
significant, are unlikely to be biologically significant. Even if these changes in BIA measures 
were biologically significant, the small magnitude of change in the BIA measures would 
make their repeated measures assessment unsuitable for mapping changes in volume status in 
the current study setting. 
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 Furthermore, whereas the changes in whole-body BIA measures at least appear consistent 
with the expected reduction in overall ECW following ivF, with statistically significant 
reduction in dECW and statistically significant increase in Z at current frequencies of 5kHz, 
50kHz and 100 kHz (smaller frequency currents representing ECW), the statistically 
significant changes in only pZ50kHz and apZ50 kHz and apZ200kHz were less consistent.  
 
Thus, the potential clinical utility of BIA in monitoring patients receiving ivF for the 
treatment of acute pulmonary oedema demonstrated in a small number of studies which 
showed much larger percentage change from baseline was not replicated here. Noble et al. 
[2000] showed that compared to placebo in normal volunteers, ivF resulted in increased urine 
output, increased mean thoracic impedance by 13.6%, and increased lung impedance by 7.8%. 
Using a single frequency device, Coodley et al. [1994] showed that after 3 days of diuretic 
treatment (oral or intravenous), weight reduced by 4.1(0.6) Kg and resistance and reactance 
increased by 20.8(2.7)% and 22.7(6.1)% respectively.  Similarly, Soderberg et al. [2001], 
using a multi frequency device, showed a reduction of 2.9(1.7) Kg in body weight, of 3.2(2.4) 
L in TBW, of 2.7(1.6) L in ECW and 0.5(3.2) L in ICW over three days in 12 patients with 
acute congestion who were being treated with ivF.   
 
The lack of clinically significant response to ivF of the physical biomeasures studied may be 
explained firstly by a genuine lack of sensitivity of the bioamarkers at tracking volume status. 
The performance of the echocardiographic variables was severely limited by their large intra-
observer variability and small relative changes from baseline, whereas the changes in BIA 
variables were not as substantial as those seen in other studies. Secondly, the amplitude of 
overall volume depletion in this cohort in response to ivF may not have been large enough to 
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induce significant change in biomarkers levels. For example, the large percentage changes in 
BIA response observed due to reduction in volume status following diuretic treatment in the 
studies by Coodley et al. [1994] and Soderberg et al. [2001] were only achieved over three 
days. However, the potential utility of a suitably sensitive biomarker would have been 
strengthened by the fact that its levels changed significantly in response to smaller volume 
changes. 
 
Thirdly, the overall volume response to ivF in this heterogeneous cohort of patients may have 
been null as a result of differing volume response between the subjects studied. Despite small 
within-subject variability in furosemide responsiveness (unit sodium excreted per unit urinary 
furosemide), the between-subject patient response to ivF is highly variable [MacFadyen et al., 
2004; Cioffi et al., 2003].  Close inspection of the individual patient responses in Figures 5.1, 
5.3 and 5.5 confirms not only large variability in individual patient responses to ivF, but also 
large between-subject variance for individual baseline measures. This may be explained by 
widely different baseline neurohormonal, renal and haemodynamic status due to different 
aetiologies and stages of disease, concurrent cardiovascular medication, degree of renal 
dysfunction, prior dosing with ivF, and volume status, all these factors modulating subsequent 
response to ivF [Volpe et al., 1992; Anand et al., 1989]. Thus, while some patients may have 
had a priori expanded interstitial and intravascular volumes with reduction in both 
compartments and thus reduction in ECW overall following ivF, others may not have had 
much change in overall ECW due to redistribution of volume from an expanded interstial 
space into a hypovolaemic intravascular space. Furthermore, patients with renal dysfunction 
(39 % of the cohort) may exhibit diuretic resistance such that the doses of ivF being 
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administered during the study may not have been sufficient to have a net effect on overall 
volume status.  
 
5.6   Limitations  
There were a number of limitations to this study. The changes in biomarker levels following 
ivF were not compared to a gold standard such as blood volume analysis or haemodynamic 
measures. It is thus difficult to establish the exact volume status at baseline and the volume 
response to ivF. The use of gold standards would have clarified whether the lack of clinically 
significant change in biomeasures was due to lack of biomarker sensitivity or lack of 
significant volume change induced by ivF. Furthermore, surrogate measures of volume status 
such as urine output, blood pressure and body weight were not documented. These were not 
performed as the emphasis of this pilot study was to establish the feasibility and to gain 
familiarity with the set pattern of obtaining physical biomeasurements, such that measuring 
body weight, blood pressure and urine output may have jeopardised the achievement of these 
goals due to time constraints. 
 
As mentioned above, the baseline volume status and response to ivF was variable amongst 
this heterogeneous cohort due to a number of factors. Some of these factors could have been 
controlled either at the beginning or during the study in order to minimse this between-subject 
variance.  The aetiology of acute cardiogenic pulmonary oedema varied, as did the LVEF and 
renal function of the patients (29 % of patients had normal LVEF and 39 % of patients had 
renal impairment). Equally, subjects had variable concomitant medication, such as ACE 
inhibitors and oral nitrates, which may have compounded the overall fluid or venodilatory 
response to ivF. The oral fluid and salt intake of patients was also was not controlled. 
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Nevertheless, these factors are in common with routine clinical practice and this study was 
thus performed in a very realistic setting. 
 
The regression equations of commercial BIA devices providing estimates of body water 
composition are validated against radioisotope dilution techniques [Hannan et al., 1995].  
However, BIA regression equations are generally validated only in non-obese and euvolaemic 
population groups [De Lorenzo et al., 1994]. These will be less valid in patients with acute 
fluid and electrolyte shifts, such as in this study. Raw impedance values should thus be 
interpreted in preference to the estimates of body water composition. 
   
5.7   Summary 
 
Repeated measures assessment of BIA and echocardiographic variables were both feasible 
and well tolerated in a potentially unstable group of patients within the time constraints of the 
study.  Intra-observer variability for echocardiographic variables reduced following practice 
and increased familiarity with the set pattern of repeated measures of physical biomeasures, 
however, it remained large. The intra-device variability of BIA variables was much smaller 
compared to echocardiographic variables. No clinically significant change in the physical 
biomeasures was seen in response to ivF, indicating that their use would be limited as non-
invasive tests of volume change in this setting, which is very realistic of normal clinical 
practice involving a heterogeneous group of patients. However, because the findings may 
have been compounded by the heterogeneity of the cohort, further assessment of the 
performance of these biomarkers is warranted. 
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Chapter Six 
 
Studies in 1ormal Volunteers  
 
 
Establishing the 1ormal Variance of Blood and 
Physical Biomarkers in 1ormal Volunteers and their 
Differential Response to an Acute Load of Oral 
Water and Intravenous Saline 
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6.1   Introduction 
 
The acute ingestion of oral water in normal volunteers results in a transient reduction in 
plasma volume within a few minutes of the intervention followed by gradual increase back to 
baseline values within 30 minutes to an hour. This effect on plasma volume depends on study 
populations, the rate of water ingestion and the temperature of the water [Jordan et al., 2000; 
Callegaro et al., 2007; Endo et al., 2001], the mechanism for this response  possibly involving 
simultaneous activation of a pressor response and increased vagal tone. This results in an 
initial increase in mean arterial blood pressure, which then decreases, causing fluid shift 
between the intravascular and interstitial spaces.
 
 Thus, Endo et al. [2001] demonstrated that 
1L of tap water at 25°C ingested over 2 minutes resulted in a decrease in  plasma volume  
within 4 minutes of the start of drinking, followed by an increase in plasma volume to above 
baseline by 12-15 minutes, monitoring being discontinued after 50 minutes.   
 
 In contrast, the acute infusion of normal saline in normal volunteers  over approximately 30 
minutes increases plasma volume by 9% of volume infused, interstitial space volume by 13% 
of volume infused, and ECW by 23% of volume infused by the end of the infusion as 
evidenced by radioisotope studies [Ernest et al., 2001].  Lobo et al. [2009] have also shown 
that an intravenous normal saline infusion of 1L over 1h results in approximately 68% of the 
volume infused having moved from the intravascular space into the interstitial space (about 
200mL increase in blood volume and approximately 800mL increase in the interstitial space) 
within 1h of the start of the infusion.  Following the 1h measures, changes in blood volume 
plateaued, whereas interstitial volume reduced gradually to approximately –200mL by the end 
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of a 6h monitoring period, these changes were consistent with body weight returning to 
normal by the end of the experiment.  
 
Thus, acute oral water and intravenous saline loading constituted two different mechanisms 
by which controlled and consistent volume changes could be induced in normal volunteers.  
The response patterns of repeated measures of selected biomarkers to these two different 
interventions could thus be compared to their normal variance patterns, which in turn could be 
established by performing repeated measures without any intervention. The biomarkers whose 
response patterns deviate the most from their normal variance pattern would thus potentially 
be the most sensitive biomarkers to induced volume changes. 
 
6.2   Hypotheses (H1) 
 
I therefore hypothesised that: 
• Acute volume changes in normal volunteers following oral water and intravenous 
saline might induce changes in repeated measures of the selected panel of blood 
biomarkers and physical biomeasures. 
• These changes in repeated measures of biomarker levels might be detectable above the 
within-subject normal varianceof these biomarkers. 
• Normal volunteers will remain asymptomatic in response to the differential changes in 
volume status induced by acute volume loading. 
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6.3   Methods 
6.3.1   Study population 
 
30 normal volunteers were recruited from hospital staff and patients’ relatives at the Sandwell 
and West Birmingham Hospitals.  Posters were placed within the hospital compounds, and 
normal volunteers previously involved with studies at the Centre for Cardiovascular Sciences 
were also contacted.  The volunteers were asymptomatic with no significant past medical 
history, were on no medication likely to affect fluid homeostasis, and did not abuse alcohol or 
illicit substances.  They had a normal physical examination, including blood pressure, normal 
routine biochemical and haematological parameters (full blood count, urea and electrolytes, 
liver function and thyroid function tests, blood glucose and serum calcium).  They also had a 
normal screening echocardiogram (comprehensive study as per local hospital protocol), and 
negative urine dipstick (Bayer Multistix 10SG, MediSupplies, Dorset). 
 
6.3.2   Volume loading protocol 
 
Volunteers attended the research centre on 3 occasions, at least 5 days apart, at the same time 
on each occasion, to receive a different intervention each time. They fasted from 21:00 the 
previous day and abstained from alcohol, smoking and caffeine.  They were allowed normal 
fluid intake (they drank when they felt thirsty) in order to avoid baseline dehydration, and 
were asked to drink similar amounts prior to attending the study centre on each occasion. 
 
On each occasion, their body weight was recorded on arrival.  Their blood pressure and heart 
rate were measured in triplicate after they rested semi recumbent for 30 minutes.  They then 
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had baseline measurements of echocardiographic and BIA variables using the set pattern of 
measurement described in Chapter Five.  An intravenous cannula was then inserted and 
baseline blood samples were taken.  This was followed by bladder voiding and a urine 
collection.  They were given in random order, an oral water load (Oral Water, 1.5L of mineral 
water at room temperature, to drink in 20 minutes), an intravenous infusion of  normal saline 
(IV Saline, 1.5L at body temperature over 20 minutes), or no intervention (Control), as 
illustrated in Figure 6.1.  
 
Subsequent blood samples were withdrawn from the intravenous cannula after discarding an 
initial 5 mL of blood.  Blood samples were repeated at 0.5, 1, 2, 4, 6 and 8 h after the 
intervention and echocardiographic and BIA measures were repeated at 1, 2 and 4h 
respectively.  Urine volumes were collected throughout the 8-hour period to establish urine 
volume between 0-4h [Urine volume (4h)], urine volume between 4-8h [Urine volume (8h)], 
and total urine volume [Urine volume (total), calculated as Urine volume (4h) + Urine volume 
(8)].   
Figure 6. 1.  Volume loading protocol for normal volunteers. 
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Volunteers relaxed semi-recumbent in between measurements, were given lunch after the 4h 
measurements, and had a snack after the 6h measurements. Food and snacks were similar for 
all patients. They continued to abstain from caffeine, alcohol and smoking, and were allowed 
to ingest 1L of additional fluid at room temperature during the 8h monitoring protocol with 
meals in addition to their respective volume loading protocol. 
 
6.3.3   Blood biomarkers 
 
Blood samples were collected and stored for Hct, ANP and BNP analyses as described in 
Chapter Four. IMA and cTn were not studied as their levels in normal volunteers would in 
theory, be undetectable by available methods of analysis. 
 
6.3.3.1  Comparison of blood sampling from venesection and intravenous  
                       cannula 
 
In order to ensure that blood collection from the intravenous cannula did not impact on 
measured values compared to direct venesection, simultaneous blood collection from direct 
venepuncture and from the intravenous cannula following discarding of an initial 5mL of 
blood were compared using 4 normal volunteers at random (NV21, NV22, NV24 and NV27).  
Each sample was analysed three times and the mean value calculated for each normal 
volunteer (Table 6.1).  The mean values of samples collected by venesection and from the 
intravenous cannula were then compared using paired t-test. There was no significant 
difference between both groups, p= 0.771. This is in accordance with previous studies [Sliwa 
at al., 1997; Zlotowski et al., 2001]. 
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Table 6.1.  Simultaneous Haematocrit (Hct) values obtained by withdrawal of blood 
from intravenous cannula and direct venesection. 
Patient Analysis Hct from 
intravenous 
cannula (%) 
Mean Hct 
from 
intravenous 
cannula (%) 
Hct from 
Venepuncture 
(%) 
Mean Hct 
from 
Venepuncutre 
(%) 
NV 22 1 38.5  38.0  
 2 38.5  37.8  
 3 
 
38.4 38.5 37.8 37.9 
NV 23 1 30.8  31.9  
 2 30.8  31.0  
 3 
 
31.0 30.9 31.0 31.3 
NV 24 1 34.4  34.9  
 2 34.6  35.5  
 3 
 
34.7 34.6 35.6 35.3 
NV 27 1 39.2  38.7  
 2 39.2  39.2  
 
 
3 38.8 39.1 38.7 38.7 
      
 Combined means compared using paired t-test.  
 
 
6.3.4   Physical biomeasures 
 
Echocardiographic variables determined included mitral Doppler indices and IVC indices as 
described in Chapter Four. The tricuspid inflow traces were again noted to not be as well-
defined as the mitral inflow traces, similar to the situation in Chapter Five. As such, they were 
felt to be inappropriate biomarkers in the study setting as there would be considerable 
measurement error involved in analysising these traces. I thus chose not to include these in 
this part of the thesis.  BIA measures were determined with electrodes placed distally, 
proximally, and across the right -lung in the anterior-posterior and the sternum-rib positions. 
 
   125 
 
6.3.5   Statistical analysis 
 
 Within-subject normal variance was determined for each biomarker as described in Chapter 
Three over firstly, the 8h monitoring period on the Control day (within-day CVtws), and 
secondly, over the 3 attendances which were at least 5 days apart (between-day CVtws). 
Within-day within-subject normal variance was determined for blood biomarkers using the 7 
measurements at 0, 0.5, 1, 2, 4, 6 and 8h, and for physical biomeasures using the 4 
measurements at 0, 1, 2 and 4h obtained over the 8h monitoring period. Between-day within-
subject normal variance was calculated using the 3 baseline values on each attendance day 
(Time 0h). Within-day and between-day RCV for each biomarker were also calculated as 
described in Chapter Three. Furthermore, the patterns of biomarker levels on the Control day 
would constitute the mean within-subject normal variance for each biomarker against which 
biomarker responses to Oral Water and IV Saline would be compared. Between-subject 
normal variance for each biomarker was determined by using the baseline values from all 30 
normal volunteers on the Control day and dividing their cumulative standard deviation by 
their cumulative mean and multiplying by 100. Analytical variance (CVa) for blood 
biomarkers and intra-observer and intra-device variability (CVo) for physical biomeasures 
which were determined in Chapter Five were also tabulated to illustrate their relative 
contributions to overall variance of the biomarkers. 
 
General linear model repeated measures two-factor within-subject ANOVA was used to 
compare response patterns of each biomarker to each of the three interventions, and to 
establish the difference between the main interaction effect of intervention and time 
(intervention*time), so that for each response curve, measures at each time point, e.g., at 1h 
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on the Control day, were directly compared to measures at the same time point on the other 
intervention days. The main effect of time and the main effect of intervention alone were not 
documented.  If there was a significant main interaction effect between response patterns for a 
particular biomarker, Bonferroni post-hoc analysis was used to outline the interventions for 
which the response curves were significantly different.   The Bland-Altman method was used 
to assess the agreement between the long-axis and short-axis views for the measurement of 
IVC diameter.  All the biomarkers assessed in this study were normally distributed. 
 
Power calculations for the study were based on previous work by Lobo et al. [2010], 
Heringlake et al. [2004], and Singer et al. [1998]. A sample size of 30 volunteers would give a 
power of >85% for the detection of significant changes in ANP (116 %), BNP (130%), and 
Hct (4%) with an alpha value of 5%. No previous studies have investigated the effects of 
acute volume load on mitral Doppler indices, IVC indices and BIA in normal volunteers 
receiving acute volume loads, such that data for the latter variables is lacking to estimate 
power. 
 
6.4   Results 
 
Baseline demographic and clinical variables for the 30 normal volunteers are shown in Table 
6.2.  All normal volunteers remained haemodynamically stable throughout the study.  The 
mean age was 49 (9) years, and there were almost equal numbers of male and female 
volunteers. 
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Table 6.2.  Baseline demographic and clinical variables of 30 normal volunteers.  Mean 
(SD), n(%). 
Variable Value 
Male (%) 16 (53) 
Ethnicity (%)  
   Caucasian 
   Afro Caribbean 
   Asian 
   Mixed 
 
17 (57) 
7 (23) 
5 (17) 
1 (3) 
Age (years) 49 (9) 
Weight (Kg) 76.6 (12.4) 
Height (cm) 175.6 (10.0) 
Body surface area (m
2
) 1.92  (0.20) 
Body mass index (Kg/m
2
) 24.7 (2.9) 
Haemoglobin (g/dl) 13.8 (1.1) 
Haematocrit (%) 40.3 (2.9) 
Creatinine (mg/dL) 0.88 (0.15) 
Systolic BP (mmHg) 128 (10) 
Diastolic BP (mmHg) 78 (8) 
Heart rate (bpm) 73 (10) 
 
Table 6.3 illustrates the order of interventions as they were received by normal volunteers; 
there was no significant difference between the order of the interventions, p=0.136. 
 
Table 6.3.  Order of interventions for normal volunteers.  
 Control Oral Water IV saline 
First intervention 11 5 14 
Second intervention 9 14 7 
Third intervention 10 11 9 
Comparison using Chi-square. 
 
 
Normal volunteers drank comparable amounts of fluid (in addition to their Oral Water load on 
the day of this intervention) on all three occasions.  The mean oral intake was 983 (217) mL 
on the Control day, 940 (211) mL on the Oral Water day and 997 (167) mL on the IV Saline 
day, p=0.329. 
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6.4.1  Estimated blood volume 
 
There was a small but statistically significant increase in estimated blood volume on the 
Control day between the baseline value and all subsequent values, p<0.0001. Figure 6.2 
shows the estimated blood volume response to the three interventions. There was a significant 
main interaction effect (intervention*time) for the estimated blood volume curves in response 
to the three interventions. On post-hoc analysis for the effect of intervention, the estimated 
blood volume response to IV Saline increased significantly compared to normal variance and 
Oral Water. There was however, no significant difference in the reponse to Oral Water 
compared to the Control day. 
 
 
Figure 6.2.  Estimated blood volume response to Control, Oral Water and IV saline. 
 
   
Mean (SE). p value obtained from repeated measures two-factor within-subject ANOVA for main 
interaction effect of intervention and time. 
From Bonferroni post-hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
 
 
 
a, b 
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6.4.2  Blood biomarkers 
6.4.2.1  1ormal variance  
 
All blood biomarker levels at baseline were within normal limits as illustrated by the 0h 
measures on the Control, Oral Water and IV Saline days in Figure 6.3. Components of their 
variance are shown in Table 6.4.  Hct had the smallest, and BNP the largest between-subject 
and within-subject total variance. 
 
Table 6.4.  Within-day and between-day within-subject total variance (CVtws) and 
reference change values (RCV), analytical variation (CVa) and between-subject total 
variance (CVtbs) for blood biomarkers in normal volunteers. 
Biomarker Within-day 
CVtws (%) 
Within-day 
RCV (%)  
Between-day 
CVtws (%) 
Between-day  
RCV (%) 
CVa (%) 
 
CVtbs (%) 
n=30 
ANP  9.9 27.4 12.5 34.6 5.0 44.3 
BNP  43.9 121.7 68.4 189.6 11.6 89.1 
Hct 3.5 9.7 4.6 12.8 0.6 8.5 
ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; Hct: haematocrit 
 
On the Control day, a significant drop in Hct was observed between the 0h and all subsequent 
measures, p<0.0001.  The maximum change occurred at the 1h measurement, after which the 
Hct levels reached a plateau. Similarly, ANP values increased significantly over the 8h 
monitoring period, with all subsequent values being significantly higher than the baseline 
value, p<0.0001. The maximal increase occurred at the 6h measurement.  On the other hand, 
BNP levels were not significantly different from each other over the 8h monitoring period, 
p=0.356.  
 
6.4.2.2  Response patterns to differential volume loading protocols 
 
The response of blood biomarkers to the three different interventions is illustrated in Figure 
6.3.  There was a significant main interaction effect for the Hct and ANP response curves to 
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the three interventions. Thus, when compared to its normal variance pattern, the Hct response 
pattern decreased with IV Saline, but initially increased following Oral Water before 
eventually falling. Post-hoc analysis of intervention effect demonstrated that this differential 
Hct response was only significant between IV Saline and Oral Water (p=0.03); there was no 
significant difference between the response patterns to Oral Water or IV Saline compared to 
normal variance (p=0.716 and p=0.118 respectively). 
 
The ANP response pattern to IV Saline increased compared to its normal variance pattern, 
whereas that to Oral Water was similar to its normal variance pattern.  Post-hoc analysis of 
intervention effect revealed significant difference between the response to IV Saline 
compared to those to both Control and Oral Water (p<0.0001 respectively). However, there 
was no significant difference between the response to Oral Water compared to normal 
variance (p=0.250). 
 
There was no significant main interaction effect for the BNP response patterns to Control, 
Oral Water and IV Saline (p=0.084).  
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Figure 6.3.  Blood biomarker response to Control, Oral Water and IV Saline. 
 
 
 
ANP: Atrial natriuretic peptide; BNP: B-type natriuretic peptide. Mean (SE).  
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post-hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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6.4.3   Echocardiographic measures 
6.4.3.1  Mitral Doppler indices 
6.4.3.1.1  ormal variance  
Components of the variance of mitral Doppler indices are shown in Table 6.5; there were non-
significant trends in their within-subject total variance patterns on the Control day.   
 
Table 6.5. Within-day and between-day within-subject total variance (CVtws) and 
reference change values (RCV), intra-observer variability (CVo) and between-subject 
total variance (CVtbs) for mitral Doppler indices in normal volunteers. 
Biomarker Within-day 
CVtws (%) 
Within-day 
RCV (%) 
Between-day 
CVtws (%)  
Between-day 
RCV (%) 
CVo (%)  
 
CVtbs (%) 
n=30 
MVE  7.7 21.3 8.5 23.5 3.4 17.1 
vMVE  9.6 26.6 9.8 27.1 7.5 21.9 
MVDT  14.3 39.6 14.9 41.3 13.9 24.1 
vMVDT   17.1 49.0 17.6 48.8 5.87 26.0 
MVE/A 9.9 27.4 11.6 32.1 5.1 19.6 
vMVE/A 11.7 32.4 9.4 26.0 8.2 22.6 
E/Ea(l) 12.5 34.6 10.7 29.6 5.4 26.2 
E/Ea(s) 12.7 35.2 8.8 24.4 7.8 24.6 
MV: mitral inflow; TV: tricuspid inflow; DT: Deceleration time; E: early peak velocity; A: late peak velocity; v: 
Valsalva manoeuvre.Ea: tissue Doppler early diastolic mitral annulus velocity; l: lateral wall; s: septal wall. 
 
6.4.3.1.2  Response patterns to differential volume loading protocols 
 
Response patterns of mitral Doppler indices to the three interventions are shown in Figure 6.4. 
There was significant main interaction effect only for MVE, vMVE, MVE/A, and E/Ea(l) 
response curves. When compared to their respective within-subject normal variance patterns, 
response curves of these four biomarkers generally increased markedly following IV Saline, 
and to a lesser extent, following Oral Water, values peaking at the 1h measurement.  Post-hoc 
analysis of intervention effect revealed significant difference only between MVE and vMVE 
response to IV Saline compared to both Oral Water and Control (p<0.0001 respectively).  
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Figure 6.4.  Mitral inflow indices response to Control, Oral Water and IV Saline. 
 
 
                            
MV: mitral inflow; E: early peak velocity; A: mitral late peak velocity; DT: deceleration time; v: Valsalva 
manoeuvre; Ea: tissue Doppler early diastolic mitral annulus velocity; l: lateral wall; s: septal wall. Mean (SE). 
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post-hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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6.4.3.2  Inferior vena cava indices 
 
25 (83%) of normal volunteers had long-axis IVC diameter larger than 2cm, and 23 (77%) of 
normal volunteers had short-axis IVC diameter larger than 2 cm at baseline.  The bias (mean 
difference) between IVC diameters measured in the long-axis and short-axis views was 
relatively small and clinically acceptable at less than 0.10 cm, as shown in Figure 6.5.  The 
variability of measures using both methods appeared consistent regardless of the vessel 
diameter. 
 
Figure 6.5. Bland-Altman plot of long-axis and short-axis measures of IVC diameters. 
 L: long-axis; S: short-axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal 
inspiration; mean: mean difference between LIVC and SIVC measures; SD: standard deviation of the mean. 
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6.4.3.2.1  ormal variance  
 
The components of the variance of long-axis and short-axis IVC diameters are shown in Table 
6.6. There were non-significant trends in normal variance patterns for all IVC indices on the 
Control day. 
 
Table 6.6. Within-day and between-day within-subject total variance (CVtws) and reference 
change values (RCV), intra-observer variability (CVo) and between-subject total variance 
(CVtbs) for inferior vena cava indices in normal volunteers. 
Biomarker 
  
Within-day 
CVtws (%) 
Within-day 
RCV (%)  
Between-day 
CVtws (%) 
Between-day 
RCV (%) 
CVo ( %) 
 
CVtbs (%) 
n=30 
LIVCe  8.0 22.2 10.2 28.3 4.2 15.3 
LIVCi  9.8 27.1 10.9 31.2 7.8 18.7 
LIVCmi  12.3 34.1 13.8 38.2 13.8 23.8 
SIVCe  7.7 21.3 8.9 24.7 2.7 16.1 
SIVCi  11.2 31.0 11.3 31.3 7.3 17.8 
SIVCmi  11.7 32.4 14.6 40.4 5.7 22.8 
L: long axis; S: short axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal inspiration. 
 
6.4.3.2.2  Response patterns to differential volume loading protocols 
 
Response patterns of long-axis and short-axis IVC indices to the three interventions are 
shown in Figures 6.6 and 6.7 respectively. In general, the response curves for IVCdiameters 
(IVCe, IVCi, IVCmi and their respective indexed measures) increased following IV Saline 
when compared to the Control day. This response appeared more marked for short-axis 
measures compared to long-axis measures, with significant main interaction effect 
demonstrated for the SIVCe, SIVCmi, SIVCDe and SIVCDmi response patterns. Post-hoc 
analysis of intervention effect revealed significant difference between these biomarkers’ 
response patterns to IV Saline compared to only Oral Water [SIVCe: p=0.046; SIVCmi: 
p=0.028; SIVCDe: p=0.040; SIVCDmi: p=0.027).  There was also no significant main 
interaction effect for any of the IVCCI indices.  
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Figure 6.6.  Long-axis inferior vena cava indices response to Control, Oral Water and 
IV Saline. 
 
 
 
 
L: long axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal inspiration; IVCD: IVC 
corrected for body surface area; IVCCI: inferior vena cava collapse index. 
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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Figure 6.7.  Short-axis inferior vena cava indices response to Control, Oral Water and 
IV Saline. 
 
 
S: short axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal inspiration; IVCD: IVC 
corrected for body surface area; IVCCI: IVC collapsibility index. Mean (SE). 
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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6.4.4   Bioimpedance measures 
6.4.4.1   1ormal variance 
 
The components of the total variance of whole-body, trunk and right-lung BIA are shown in 
Table 6.7.  The variance of all BIA parameters was notably smaller when compared to those 
of blood biomarkers and echocardiographic measures, with variance increasing the smaller 
the body segment being studied. 
 
There was a general trend for all estimates of body water composition to reduce, and for all 
impedance values to increase over the monitoring period on the Control day.  These trends 
were statistically non-significant for BIA variables measured with electrodes placed distally.  
However, most of the trunk and right-lung parameters changed significantly over the 
monitoring period, most of the significant changes being between baseline values and all 
subsequent measures (p<0.005 for pTBW,  pECW,  pZ5kHz, pZ50kHz, pZ200kHz, apZ50kHz, 
apZ200kHz, rlZ5kHz, rlZ50kHz, rlZ100kHz, rlZ200kHz; p=NS for pZ100kHz, apZ5kHz, apZ100kHz).  
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Table 6.7. Within-day and between-day within-subject total variance (CVtws) and 
reference change values (RCV), intra-device variability (CVo) and between- subject 
total variance (CVtbs) for bioimpedance measures in normal volunteers. 
Biomarker Within-day 
CVtws (%) 
Within-day 
RCV (%)  
Betwen-day 
CVtws (%) 
Betwen-day 
RCV (%) 
CVo (%) 
 
CVtbs (%) 
n=30 
dTBW 0.9 2.5 2.4 6.6 0.22 10.4 
dECW  0.7 1.9 2.2 6.1 0.22 7.8 
dICW  0.9 2.5 1.8 5.0 0.36 11.2 
dZ5kHz  1.2 3.3 2.8 7.8 0.22 14.6 
dZ50kHz  1.1 3.0 2.6 7.2 0.35 15.5 
dZ100kHz  1.2 3.3 2.6 7.2 0.51 15.8 
dZ200kHz  
 
1.3 3.6 2.6 18.7 0.54 16.0 
pTBW  1.2 3.3 4.8 13.3 0.63 15.0 
pECW  1.7 4.7 4.5 12.5 0.43 12.8 
pICW  1.6 7.1 5.1 14.1 0.34 17.8 
pZ5kHz  3.2 8.9 2.7 7.5 0.74 8.6 
pZ50kHz  2.9 8.0 2.8 7.8 0.47 9.4 
pZ100kHz  2.9 8.0 3.0 8.3 0.50 9.9 
pZ200kHz 
 
2.0 5.5 3.1 8.6 0.50 10.7 
apZ5kHz 4.6 12.7 6.3 17.5 2.62 18.4 
apZ50kHz  5.0 13.9 7.2 19.9 2.1 19.6 
apZ100kHz  5.6 15.5 7.5 20.8 2.4 20.4 
apZ200kHz  
 
6.2 17.2 7.4 20.5 2.85 21.4 
srZ5kHz  6.3 17.5 6.3 17.5 0.82 18.2 
srZ50kHz  5.6 15.5 6.5 18.0 0.95 19.7 
srZ100kHz  7.2 19.9 6.6 18.3 1.69 20.9 
srZ200kHz  7.2 19.9 7.0 19.4 1.10 22.5 
d: whole-body; p: trunk; ap: antero-posterior electrode position for right-lung BIA; sr: sternum-rib electrode 
position for right-lung BIA; TBW: total body water; ECW: extracellular water; ICW: intracellular water; Z: 
impedance; 5-200kHz: current frequency. 
 
 
6.4.4.2  Response patterns to differential volume loading protocols 
 
Response of whole-body, trunk, and right-lung BIA measuress are illustrated in Figures 6.8, 
6.9 and 6.10 respectively.  All response patterns for estimates of body water composition 
determined both distally and proximally increased markedly following IV Saline, compared to 
the normal variance and Oral Water curves. Response of all distal and proximal impedance 
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values determined at all four current frequencies reduced markedly following IV Saline 
compared to normal variance and following Oral Water, with values still much lower than the 
normal variance curves by the end of the 4h monitoring period.  
 
There was a significant main interaction effect for all whole-body and trunk BIA response 
patterns. Post-hoc analysis for the effect of intervention showed significant difference mainly 
between the IV Saline response curves and both the Oral Water and Control curves 
(p<0.0001). There was no significant difference between the Oral Water response patterns 
compared to normal variance (p=0.141). 
 
Response curves for right-lung impedance values determined with both the anterior-posterior 
and sternum-rib electrode placements at all four current frequencies appeared less sensitive as 
markers of differential response to Oral Water and IV Saline compared to normal variance. 
Significant main interaction effect was only found for apZ5kHz and srZ50kHz response patterns 
on the three separate days, with significant difference between responses to IV Saline 
compared to Control and following Oral Water on post-hoc analysis.   
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Figure 6.8.  Whole body bioimpedance response to Control, Oral Water and IV Saline. 
 
 
 
d: whole-body; TBW: total body water; ECW: extracellular water; ICW: intracellular water; Z: impedance; 5-
200kHz: current frequency. Mean (SE). 
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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Figure 6.9.  Trunk (proximal) bioimpedance response to Control, Oral Water and IV saline. 
 
 
p: trunk; TBW: total body water; ECW: extracellular water; ICW: intracellular water; Z: impedance; 5-200kHz: 
current frequency. Mean (SE). 
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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Figure 6.10.  Right-lung impedance response (with anterior-posterior and sternum-rib 
electrode placements) to Control, Oral Water and IV Saline. 
 
  
Z: impedance; 5-200kHz: current frequency; ap: anterior-posterior electrode position;sr: sternum-rib electrode 
position. Mean (SE). 
p value obtained from repeated measures two-factor within subject ANOVA for main interaction effect of 
intervention and time. 
From Bonferroni post hoc analysis, significant effect of intervention (p<0.05) between: 
a
 IV Saline and Control            
b
 IV saline and Oral Water       
c
 Control and Oral Water 
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6.4.5   Urine volume response to differential volume loading protocols 
 
 
 
Total urine volume rose significantly following both Oral Water and IV Saline compared to 
the Control day as shown in Table 6.8. An interesting observation was the larger relative 
increase following Oral Water compared to IV Saline at the 4h measurement. 
 
Table 6.8.  Urine volume response to Control, Oral Water and IV Saline. 
Urine volume 
(mL) 
Control Oral Water IV saline p 
4h 528 (241)
 a,c 
 1643 (437) 
b,c 
 934 (363)
 a,b
  <0.0001 
8h 298 (141)
 a,c
 430 (215)
 c
 476 (186)
 a
 <0.0001 
Total 826 (282) 
a,c
 2073 (454) 
b,c
 1409 (443) 
a 
 <0.0001 
p value obtained from repeated measures one-factor within-subject ANOVA 
Significant difference on Bonferroni post-hoc analysis between: 
a
 IV Saline and Control    
b
 IV saline and Oral Water     
c
 Control and Oral Water 
 
6.5   Discussion 
6.5.1   1ormal variance 
 
Within-subject and between-subject total variance for a number of biomarkers relevant to the 
pathophysiology of abnormal volume status in LVSD were established in normal volunteers 
in this Chapter.  Within-subject variance was observed to be higher the longer the time period 
over which sampling was performed (between-day CVtws larger than within-day CVtws), and 
the more times it was measured over a specific period of time. For example, for blood 
biomarkers over the 8h monitoring period on the Control day, within-subject variance was 
higher when calculated using 7 measures (at 0, 0.5, 1, 2, 4, 6 and 8h) compared to just using 5 
measures (at 0, 2, 4, 6 and 8h).  Within-subject variance was smaller compared to between-
subject variance, as is the case with most biomarkers.
 
The largest variance (both between-
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subject and within-subject) was observed for BNP, and the smallest variance was observed for 
BIA measures. 
Knowledge of the different components of variance of a biomarker enables the clinician to 
interpret a measured level of the biomarker appropriately in the relevant clinical context. For 
example, the highest ANP value measured in this group of normal volunteers was 69 pg/mL 
on the Control day.  The between-day within-subject variance of ANP (calculated as 12.5%) 
implies that ANP levels of up to 78 pg/mL would still be within normal limits for this 
individual, and if the principle of RCV were applied to this individual (between-day RCV 
34.6%), his ANP level would have to be higher than 92 pg/mL before this implies a 
significant change in clinical status, such as the possible diagnosis of HF, or significant 
increase in volume status. Both these values are however above the manufacturer-
recommended population cut-off value of 70 pg/mL, but are clearly occurring in a healthy, 
asymptomatic individual, supported by a completely normal physical and echocardiographic 
examination.  
 
Furthermore, some biomarker levels changed statistically significantly with time on the 
Control day, such as Hct, ANP, estimated blood volume and right lung impedance. Being 
aware of this trend in normal variance for these particular biomarkers is important for future 
studies, where an intervention may be applied which does not have significant biological 
effect, but where these statistically significant trends in normal variance may erroneously be 
attributed to that particular intervention.  
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6.5.1.1  Blood biomarkers 
 
The normal variance of Hct and ANP followed a similar pattern, with an initial significant 
drop for Hct and increase for ANP following the baseline measures compared to all 
subsequent measures, which eventually plateaued. These patterns have been previously 
documented. Renbourn [1947] demonstrated a significant drop in Hct levels between 07:00 
and subsequent measures up to 02:30, and showed that this variance could be affected by, but 
not due to, posture, sleep, exertion or food intake. Furthermore, the variance pattern of Hct 
was similar whether in normal volunteers or in ill-health. Although there are no studies 
directly involving the normal variance of ANP, Heringlake et al. [2004] showed that 
NTproANP levels increased significantly from baseline level measured at 09:00 to subsequent 
values measured over a 10h monitoring period.  
 
Similarly, estimated blood volume, based on changes in Hct values, increased significantly 
from the baseline value to all other subsequent values, this observation not having been 
previously documented. In my study, these changes cannot be attributed to postural changes 
as patients were semi-recumbent throughout the study with the exception of standing to void 
for urine collections. Furthermore, the collection of blood from the intravenous cannula was 
shown to produce comparable biomarker values to venesection and thus they cannot be 
attributed to dilutional changes during blood sampling from the cannula. Overall, this normal 
variance could be attributed to the diurnal secretion of ANP, modulating changes downstream 
with subsequent increase in blood volume and thus reduction in Hct. However, it may also 
involve variations in neurogenic tone. A study by Bau et al. [2008] demonstrated brachial 
artery diameter at 07:00 to be smaller compared to 17:00 and 22:00, suggesting that 
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vasodilatation occurs subsequently from 07:00. Blood volume may increase as a result of net 
movement of volume from the interstial space into the intravascular compartment in response 
to this vasodilatation.  
 
Despite these initial significant changes in Hct and ANP, their normal variance was relatively 
small. The within-subject variance of Hct was the smallest of the blood biomarkers, being 
comparable to that of the BIA variables.  This was also consistent with the findings of Thirup 
et al. [2003] who documented a within-subject variance of 3 % in healthy individuals over a 
period ranging from 1 day to 2 months. 
 
The observed within-day within-subject variance for ANP of 9.9 % was markedly lower 
compared to that of 65 % observed by McDowell et al. [2002] in normal volunteers.  ANP has 
a short half-life of 2-5 minutes, and is secreted in bursts, thus potentially explaining the large 
variability in McDowell’s study [Pedersen et al., 1999].   McDowell’s observations were also 
based on samples measured every two minutes over a 90-minute observation period in the 
morning.  As previously discussed, ANP levels in my study increased significantly between 
the baseline value and all subsequent values, which in turn were not significantly different 
from each other.  Thus, McDowell et al. may have been measuring this increased short-lived 
variability in the morning. Furthermore, the larger number of repeated measures used to 
calculate within-subject normal variance (45 measures in total) would also have contributed to 
their higher estimation of this variance. The variance data generated from this Chapter is, 
however, more clinically useful as patients will routinely attend for investigations at any time 
of the day rather than only in the morning.  
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The observed within-subject variance for BNP in this study was similar to that measured by 
Wu et al. [2003] in normal volunteers, who published values for within-day within-subject 
biological variance of 43.6% which they calculated from 4 samples measured on the same 
day. The calculated within-day within-subject biological variance for my cohort of normal 
volunteers was 42.7% (calculated as described in Chapter Three).  
 
6.5.1.2  Physical biomeasures 
 
Data on intra- and inter-observer variability is available for a number of echocardiographic 
variables [Khan et al., 2004; Rijsterborgh et al., 1990], as are data on between-subject 
variance, mainly generated to establish population reference values. However, data on the 
variation of echocardiographic measures within a subject over a specified period of time is 
surprisingly non-existent. This is thus the first study to establish the within-subject total 
variance of the echocardiographic measures studied here.  
 
The small within-subject total variance demonstrated for all BIA measures in my study was 
consistent with findings from a study in paediatric patients which demonstrated the within-
subject variance of body water composition and resistance values using a non-invasive BIA 
device [Andersen et al., 2010]. The within-day within-subject variance was 1.1-2.8%, and the 
between-day within-subject variance was 2.4-5.7%, variance increasing with reducing age.  
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6.5.2   Changes in estimated blood volume to differential volume loading 
 
The significant overall increase in estimated blood volume observed following IV Saline, 
with intravascular volume still expanded at the end of the 8h monitoring period is consistent 
with findings from previous studies, which have in addition demonstrated that the interstitial 
space had re-equilibrated, and that a proportion of the fluid infused had still not been excreted 
by the end of similar monitoring periods.  [Ernest et al., 2001; Lobo et al., 2009 ; Reid et al., 
2003; Lobo et al., 2001].   
 
The absence of any significant change in estimated blood volume observed following Oral 
Water loading compared to normal variance was in contrast to the initial significant reduction 
in plasma volume observed by some authors which occurred within minutes of the 
intervention [Callegaro et al., 2007;  Endo et al., 2001]. However, these acute changes in 
plasma volume were short-lived, normalising within 15-30 minutes. My first biomarker 
measurements were made 0.5h after the start of Oral Water drinking, it is therefore likely that 
these initial changes were not recorded in my experiments.  
 
Furthermore, the rate of ingestion of Oral Water in the present study was slower compared to 
previous studies. Callegaro et al. [2007] instructed their normal volunteers to drink 500mL of 
mineral water at 22°C in less than 5 minutes; Endo et al. [2001] instructed their volunteers to 
ingest 1L of tap water at 25°C over 2 minutes, the latter reporting that the same experiment 
using 500mL of water ingested over the same time period had caused a similar pattern of 
response but of lesser magnitude.  
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The mechanisms for the transient activation of the SNS and simultaneous vagal response that 
result in increased systemic blood pressure and extravasation of fluid into the interstitial space 
and thus of reduction of plasma volume following the acute ingestion of oral water are still 
not well understood, but may involve autonomic response to activation of osmoreceptors 
within the orophaynx, gut or portal system [Andersen et al., 2000].  The afferent response 
may involve the hypoosmotic property of oral water, as drinking normal saline does not result 
in similar SNS activation and increased vagal tone compared to oral water ingestion [Brown 
et al., 2005].
 
 The study by Akasihi et al. [1989] may explain the significantly higher urine 
volume at 4h observed in my study following Oral Water compared to both Control and IV 
Saline (Table 6.8). They demonstrated that normal volunteers who drank minimal amounts of 
water (enough to keep the pharynx moist) over 20 minutes experienced a hypotonic diuresis, 
whereas those who drank the same amount within seconds did not.  Unfortunately, urine 
osmolality was not measured in my study to explore this.  
 
6.5.3   Changes in blood biomarkers to differential volume loading 
  
As potential biomarkers of intravascular volume, the response pattern of the blood biomarkers 
studied would be expected to change according to estimated blood volume changes in 
response to IV Saline and Oral Water. Thus, ANP and BNP response, if suitably sensitive, 
would be expected to rise, and Hct response to reduce significantly following IV Saline 
compared to normal variance.  While no significant changes were observed between the 
responses to Oral Water and normal variance as expected [Yamasaki et al., 1998], Hct levels 
following IV Saline, although showing an overall reduction, did not differ statistically to the 
normal variance curve. The ANP response curve to IV Saline (Figure 6.3), although showing 
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a statistically significant difference to both Oral Water and normal variance, does not appear 
to show changes of different magnitude to the normal variance pattern, the only difference 
between the two curves being a higher starting point at baseline on the IV Saline day. The 
lack of significant change of the BNP curve following IV Saline compared to normal variance 
was expected from previous documented lack to senisitivities to acute volume loading [Lang 
et al., 1993, Larsen et al., 2006; James et al., 2005, Heringlake et al., 2004]. Thus, none of the 
three blood biomarkers studied appear to be sensitive enough to map the acute changes in 
volume status induced in the study setting, and would not be clinically useful for monitoring 
volume status. 
 
6.5.4   Changes in echocardiographic variables to differential volume loading 
 
6.5.4.1  Mitral Doppler indices 
 
The only mitral inflow indices that appeared sensitive to changes in volume status were MVE 
and vMVE. As potential markers of cardiac preload and thus of intravascular volume, their 
responses to both Oral Water and IV Saline mirrored the changes in estimated blood volume, 
with levels still elevated by the end of the 4h monitoring period following IV Saline. 
Furthermore, the magnitude of the maximal percentage change from the corresponding 
measure on the control day was of the order of 18-19 %, which was larger than the maximal 
percentage change observed for BIA measures following IV Saline compared to normal 
variance, of the order of 8-10 %.The fact that MVE still changed significantly with the 
Valsalva manoeuvre, which should attenuate its sensitivity, further supports its potential for 
tracking volume changes of the magnitude observed in this study. However, the fact that the 
maximal percentage change from baseline of MVE and vMVE, despite occurring above their 
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respective within-subject total variance, was less than their respective within-subject RCV 
suggests that these results need to be interpreted with caution, and their potential clinical 
application for monitoring of volume status needs further clarification. This is particularly 
true in the context of the routine care of LVSD patients, in whom much less acute and large 
changes in volume status might be expected to take place during decompensation. 
 
Although there was a statistically significant main interaction effect for the MVE/A and 
E/Ea(l) curves, post hoc analysis for the effect of intervention did not show any statistically 
significant effect of either Oral Water or IV Saline compared to normal variance, suggesting 
that these markers would not be sensitive enough to track the changes in estimated blood 
volume induced in my normal volunteers despite their previously good correlations 
demonstrated with spot measurements of LV filling pressures [Rivas-Gotz et al., 2003].  The 
lack of sensitivity of MVDTmay be secondary to the large intra-observer variability and 
within-subject total variance of its measurement. 
 
6.5.4.2  Inferior vena cava indices 
 
While several studies have demonstrated fair to good correlation between IVC indices and 
right atrial pressure or PCWP in various settings, no study so far has evaluated their potential 
utility at tracking changes in volume status. Despite the apparently higher sensitivity to 
volume changes of SIVC indices compared to LIVC indices, with statistically significant 
main interaction effect demonstrated for SIVCe, SIVCmi, SIVCDe and SIVCDmi, there was 
significant intervention effect only between the Oral Water and IV Saline response curves, 
and no significant difference of IV Saline response compared to normal variance. This implies 
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that changes in SIVC indices were of too little magnitude in response to the significant rise in 
intravascular volume following IV Saline. This could be explained by the lack of capacity of 
the IVC in my volunteers to distend to a much larger extent as the majority of the volulnteers 
had IVC diameters on expiration of >2cm at baseline with the IVCCI indices being all <50 %, 
which in turn could be due to the normal volunteers being well hydrated at baseline.  
Furthermore, in agreement with Brennan’s study [2007], indexing the IVC for body surface 
area did not statistically improve the predictive accuracy of this marker for mapping volume 
changes in response to differential volume loading.  
 
The changes in IVCCI indices did not appear consistent with the observed changes in 
estimated blood volume. Thus despite the good correlation between IVCCI indices and 
invasive haemodynamic indices demonstrated in previous studies [Cheriex et al., 1989], 
IVCCI indices are not sensitive enough for tracking acute volume changes in the current 
setting. 
 
6.5.5   Changes in bioimepedance measures to differential volume                  
  loading  
 
The largest and most consistent changes in biomarkers in response to acute volume loading 
were observed with the BIA variables following IV saline, in particular all whole-body 
measures, and impedance values using trunk measures, with significant difference between IV 
Saline and both the normal variance and Oral Water response curves.  In addition, the 
maximal percentage change in these markers occurred over and above both their respective 
within-subject total variance and within-subject RCV. This comparably larger change in BIA 
response compared to the other biomarkers studied in this section may be explained by the 
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fact that BIA is indeed measuring ECW. As previously discussed, the infusion of IV Saline 
results in an increase not only in blood volume, but also in a comparatively larger initial 
increase in interstitial space, such that BIA would reflect the overall increase in both 
compartments following IV Saline. This would also be consistent  with the larger relative 
increase in ECW compared to ICW.The significant concurrent changes  observed in ICW may 
occur as a result of osmostic processes.  
 
Right-lung measures did not seem particularly sensitive at tracking volume changes to 
differential volume loading in this cohort. Thus, although redistribution of volume from the 
intravascular space into the interstitial space does occur following IV Saline, this may not 
occur significantly within the lungs. It is however, more likely that right-lung BIA measures 
are not as sensitive as whole body measures at tracking volume changes, given their relatively 
larger within-subject variance. 
 
6.5.6   Differential urine volume response 
 
The more marked urine volume response with Oral Water compared to IV Saline was an 
interesting observation, and is not well documented in the literature.  An increase in ANP 
secondary to atrial stretch [Anderson et al., 1986], and a reduction in renin, aldosterone and 
angiotensin II levels in response to IV Saline would both mediate diuresis and natriuresis, 
resulting in increased urinary volume [Singer et al., 1998].  However, plasma osmolality does 
not change significantly following IV saline and studies have failed to demonstrate a rise in 
ADH within 30 minutes of IV saline infusion. This thus results in the increased excretion of 
iso-osmotic urine with normal sodium content [Lobo et al., 2001]. As previously discussed, a 
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proportion of the infused volume is still not excreted by the end of similar monitoring periods 
to that used in this study, such that blood volume is still expanded. Only 1409 (443) mL had 
been excreted at the end of the 8h monitoring period compared to the total volume input of 
2.5 L (initial 1.5L IV Saline and 1L oral fluids throughout the study).   
 
Oral water drinking, on the other hand,  produces rapid reductions in plasma osmolality and 
plasma sodium, which gradually return back to normal [Kimura et al., 1997]. This in turn 
reduces ADH levels, resulting in increased diuresis of lower osmolality urine with no 
significant change in blood volume as demonstrated ealier in my study. Intravenous infusion 
of 5% dextrose compared to normal saline in normal volunteers results in a 3-fold increase in 
urine output of much lower osmolality, thus further supporting the hypoosmolar mechanism 
of diuresis observed [Lobo et al., 2001].  Simultaneous serum and plasma osmolalities as well 
as urinary sodium would be required to clarify the differential neuroendocrine mechanisms. 
 
6.6  Limitations  
 
The volume loading protocols used in this study are based on previously documented volume 
changes following acute oral water and IV Saline in normal volunteers. Thus, utility of the 
blood biomarkers and physical biomeasures studied here are defined on the basis of a 
presumed acute and sustained extracellular volume expansion following IV Saline and no 
change in intravascular volume following Oral Water at the time points when biomarkers 
were measured, mapped with some degree of accuracy by the calculated estimated blood 
volume. For the relative sensitivities of the biomarkers studied to volume changes to be more 
robust, gold standards such as blood volume analysis or invasive haemodynamic measures 
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would be required. I also did not perform repeated measures of body weight which would 
have consisted of a simple means of shedding further light on the changes in volume status 
observed in this study. Furthermore, repeated measures of blood pressure may have helped to 
clarify the observed significant changes in the normal variance of ANP and Hct. Simultaneous 
plasma and urine osmolalities would have contributed to further understanding of the 
differential urine volume response to IV Saline and Oral Water. 
 
Establishing differential response of physical biomeasures over a longer period (8h) may have 
been more informative as some markers had not reduced to baseline by 4h. Thus, whereas 
relative sensitivities have been established to increases in volume status, it is not possible to 
extrapolate these findings to subsequent reductions in some compartments of volume status. 
 
A large number of biomarkers were studied, which may explain the large proportion of 
statistically significant results with perhaps not much evidence for biological significance for 
some biomarker responses. Great care was thus taken in interpreting these results in the light 
of the potential clinical application of the biomarkers studied for monitoring volume status. 
Furthermore, the aim of the study was to identify the most potentially useful markers, such 
that it was important to study a large number of markers in order to maximise the possibility 
of identifying the most sensitive markers, and thus to optimise the use of the interventions 
applied. 
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6.7   Summary 
 
In this series of observations, the normal variance of a panel of blood biomarkers and physical 
biomeasures of relevance to volume status in LVSD was established in normal volunteers.  
The response pattern of these biomarkers to Oral Water and IV Saline as a deviation from 
their normal variance was demonstrated, and is a particular strength of this study, with each 
volunteer acting as his/her own control. Overall, changes in the levels of the blood biomarkers 
and echocardiographic measures, with the possible exception of MVE and vMVE, did not 
appear to be sensitive enough to have clinical utility for monitoring acute volume changes. 
The most potentially useful markers in this respect were all whole-body BIA measures and 
trunk impedance measures, whose levels changed consistenly not only over and above their 
normal variance, but also their respective RCV. These sensitivities need to be tested further in 
the LVSD population.  
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Chapter Seven 
 
Studies in Stable Patients with LVSD 
 
Blood and Urine Biomarkers, and Physical 
Biomeasures of Response to Diuretic-induced 
Volume Changes in Left Ventricular Systolic 
Dysfunction 
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7.1   Introduction: Volume changes in response to diuretic  
                     manipulation 
 
Temporary withdrawal of diuretics in selected LVSD patients is well tolerated, and permanent 
withdrawal is possible in a small proportion of these patients, higher LVEF and lower 
baseline dose of diuretics being positive predictive factors [Grinstead et al., 1994]. 
 
Using an 
implantable haemodynamic monitor, Braunschweig and colleagues [2002] demonstrated that 
a temporary 50% reduction of chronic diuretic dose for a week, followed by complete 
withdrawal of diuretic for another week in 4 stable LVSD patients resulted in increased 
haemodynamic measures of LV filling pressure.  The trend towards increasing cardiac 
pressures was apparent from the start of diuretic dose reduction, but was more marked after 
the complete withdrawal of diuretic.  Using a combination of blood biomarker (BNP, 
sCreatinine), haemodynamic and functional (NYHA class, 6-minute walk test) measures, the 
optimal oral dose of diuretic was determined for each patient. Pressure levels normalised to 
the initial values within a few days after reinitiation of the optimised oral diuretic dose.  
Although some patients developed worsening symptoms and signs during the study protocol, 
none of them needed their diuretic to be reinitiated earlier than planned. 
 
In this third and last series of investigations, careful manipulation of diuretics constituted a 
means of inducing controlled volume changes in stable LVSD patients on small doses of 
chronic oral diuretic treatment (up to 80 mg of furosemide daily). Unlike Braunschweig’s 
study, where diuretics were withdrawn for weeks, resulting in the onset of symptoms and 
signs of volume overload in some patients towards the end of the study period, the temporary 
withdrawal of diuretics for a few days in stable LVSD patients would provide a means of 
controlled volume expansion with little likelihood of decompensation.  This would be similar 
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to the common occurrence of patients being variably non-compliant with their diuretic 
treatment [MacFadyen et al., 2004].  The administration of ivF after this short phase of 
diuretic withdrawal, followed by reinitiation of chronic oral diuretic treatment would, in 
theory,  restore volume balance after a few days in these patients who would in principle, 
remain asymptomatic.  
 
7.2   Hypotheses (H1)     
 
 
 I therefore hypothesised that: 
• The temporary withdrawal of chronic oral diuretic dosing over a three-day period will 
produce an asymptomatic increase in intravascular volume and LV filling pressure in 
stable LVSD patients.  Interstitial space volume is also likely to increase. 
• ivF and reinstatement of chronic dose of oral diuretics following this diuretic 
withdrawal phase will result in an asymptomatic decrease and re-equilibration of 
intravascular volume, LV filling pressure and interstitial volume. 
• These asymptomatic diuretic-induced volume changes will be reliably mapped by 
repeated measures of a panel of blood and urine biomarkers, and physical biomeasures 
of volume status. 
• Asymptomatic volume expansion in stable patients with LVSD secondary to diuretic 
withdrawal may give rise to a degree of subclinical myocardial ischaemia as part of 
the process of cardiac remodelling; this might be reflected by changes in biomarkers 
of ischaemia. 
• A proportion of patients in this cohort of clinically euvolaemic and stable LVSD 
patients may be intravascularly dehydrated, and diuretic withdrawal may result in 
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improvement in markers of renal tubular function. Alternatively, diuretic withdrawal 
may result in increased markers of renal tubular function by an increase in renal 
venous congestion. 
 
7.3   Methods 
7.3.1  Study populatiom 
 
Stable LVSD patients with an LVEF of <40% (by MUGA or Simpson’s rule on 
echocardiography in the last 6 months) and who were on chronic furosemide dosing (40-
80mg daily) were recruited. Patients also had to be on clinically optimised LVSD therapy 
including RAAS blockade, beta-blockers, and spironolactone if indicated.  Exclusion criteria 
included recent hospitalisation for any major illness 3 months prior to enrolment into the 
study, poor treatment compliance, uncontrolled hypertension or diabetes, clinically significant 
other illness such as malignancy, unstable stroke disease or neurodegenerative illness, history 
of ongoing alcohol or substance abuse, and any patient in whom planned diuretic withdrawal 
would be likely to cause symptomatic decompensation. 
 
Patients were recruited from the HF Services at City and Sandwell Hospitals.  The HF 
services database at Sandwell Hospital was systematically screened for patients enrolled with 
the services with documented LVEF<40% who were on 40-80mg of furosemide daily. These 
patients’ notes were then assessed to determine whether they would fit the criteria for the 
study.  Unlike at Sandwell Hospital, no such database was available at City Hospital.  Thus, 
all notes held in the HF Services at City Hospital had to be assessed for patients’ suitability. 
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Potential candidates thus identified were then discussed with their respective HF nurse to 
assess their general suitability further. Selected patients were then contacted and invited to 
take part in the study.  Patients who were interested underwent a (one-hour) screening visit, 
which constituted of the following: 
• Thorough cardiovascular, past medical and drugs history. 
• Thorough assessment of HF symptoms. 
• Clinical examination to ensure absence of signs of abnormal volume status and 
clinical instability and to ascertain baseline clinical status, such as blood pressure and 
heart rate, and the presence of signs such as the longstanding presence of lung crackles 
not attributed to abnormal volume status in a patient with pulmonary fibrosis.   
• Suitability for intravenous cannulation.  
• Screening echocardiogram to assess echocardiographic windows and to confirm LVEF 
by Simpson’s biplane formula.  
• Screening blood tests including full blood count, urea and electrolytes, eGFR and liver 
function tests. 
• Medication could be adjusted at this stage to optimise LVSD treatment, but was not 
needed for any of the patients eventually enrolled in the study.  If medication had been 
altered, a further appointment to assess adequate response was planned. 
• Explanation of the LVSD protocol and explanation of plan of action in case of 
decompensation during the protocol.  Information leaflets and contact details were 
provided, including a 24-h mobile phone number to contact me during the 7-day 
protocol in case of emergencies. All patients’ questions and concerns were addressed. 
• Gaining written informed consent to participating in the study. 
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• Booking of week for LVSD protocol for each patient, and transport arrangements 
made. 
 
7.3.2             Study design  
 
Patients took part in a 7-day diuretic manipulation protocol, as shown in Figure 7.1.  On Day 
1 they received their usual chronic diuretic dose at 0h (Baseline).  They then omitted their oral 
diuretic on Days 2, 3 and 4 (diuretic withdrawal phase), presumed maximal volume expansion 
during the protocol being achieved at 0h on Day 4. Following the 0h measure on Day 4, they 
were given a standard bolus dose of ivF (50mg) in order to start the re-equilibration phase of 
volume manipulation; this was then followed by reinstatement of their usual diuretic dose 
from Day 5 onwards to Day 7 (diuretic resumption phase). Re-equilibrium of volume status 
was presumed to be achieved at 0h on Day 7. 
 
Patients attended the study centre on Days 1, 2, 3, 4 and 7 at the same time on each occasion 
(between 07:30 and 08:30) in small groups, with attendances between patients staggered by 
30 minutes to enable me to perform timed repeated measures in each individual patient. Blood 
and urine biomarkers and physical biomeasures were performed at the same time for each 
individual patient on each day of attendance (0h measures).  After the 0h measures, usual oral 
diuretic was given on Day 1, and a bolus dose of ivF (50 mg) was given on Day 4.  Thus, on 
Days 1 and 4, patients were in addition, monitored over an 8h period with repeated measures 
of biomarkers at 0.5, 1, 2, 4, 6 and 8h for blood biomarkers, at  1, 2 and 4h for physical 
biomeasures, and at 4 and 8h for urine biomarkers and urine volume, in a similar procotol to 
the normal volunteers study.   
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Figure 7.1.  7-day diuretic manipulation protocol and study design. 
 Baseline Diuretic withdrawal Diuretic resumption 
Day 1 
Tue 
Baseline 
at 0h 
2 
Wed 
3 
Thurs 
4 
Fri 
Presumed 
maximal 
volume 
expansion 
at 0h  
5 
Sat 
6 
Sun 
7 
Mon 
Presumed 
volume re-
equilibrium 
at 0h 
Usual dose 
of oral 
furosemide 
√ × × × 
ivF 
following 
0h 
measures 
√ √ √ 
Attendance 
to study 
centre 
√ √ √ √ × × √ 
8-h 
monitoring* 
√ × × √ × × × 
Blood 
biomarker 
√ √ √ √ × × √ 
Echo √ √ √ √ × × √ 
BIA √ √ √ √ × × √ 
Urine  √ √ √ √ × × √ 
Body 
weight 
√ √ √ √ × × √ 
VAS √ √ √ √ √ √ √ 
*8-h monitoring: Blood biomarkers measured at 0, 0.5, 1, 2, 4, 6 and 8h; urine biomarkers at 0, 4 and 8h; 
bioimpedance and echocardiographic measures at 0, 1, 2, 4h; lunch after the 4h measures, snack after the 6h 
measures. Usual oral furosemide on Day 1 after 0h measures, ivF on Day 4 after 0h measures. 
Echo: echocardiographic variable; BIA: bioimepedance analysis; VAS: visual analogue score; ivF: intravenous 
furosemide 50 mg; √: attended/given/measured; ×: not attended/given/measured. 
 
 
While mainly interested in the longitudinal effect of diuretic withdrawal followed by 
resumption provided by the 0h measures on Days 1, 2, 3, 4 and 7, the study also provided two 
further cross-sectional settings for the study of volume status in the form of the 8h monitoring 
periods on Days 1 and 4. The 8h monitoring period on Day 1 would enable me to establish the 
within-subject normal variance of the panel of biomarkers, whereas the 8h monitoring period 
on Day 4 would provide insight into the volume depletion stimulus provided by ivF.  Thus, 
the results will be reported as:  
1. Normal variance (8h monitoring on Day 1). 
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The 8h monitoring period on Day 1 would enable the calculation of within-day within-
subject variance for all biomarkers in stable LVSD patients on optimised medical 
treatment, including their chronic oral diuretic, using the 0, 0.5, 1, 2, 4, 6 and 8h 
measures for blood biomarkers, the 0, 1, 2 and 4h measures for physical biomeasures, 
and the 0, 4 and 8h measures for urine biomarkers. 
2. Longitudinal response pattern of repeated measures of each biomarker to diuretic-
induced volume manipulation over the 7-day protocol. 
This would be defined from the analysis of the five 0h biomarker measures on Days 1, 
2, 3, 4 and 7, with the Day 1 measure as baseline biomarker measure on optimised 
LVSD treatment, the Day 2, 3 and 4 measures as measures of volume status during the 
diuretic withdrawal phase (Day 4 0h measure being the measure of presumed 
maximal volume expansion during the protocol), and the Day 7 measure reflecting 
presumed re-equilibrium of volume status. 
3. Response pattern of repeated measures of biomarkers to ivF at presumed maximal 
volume expansion (8h monitoring Day 4). 
 This would be outlined by the 0, 0.5, 1, 2, 4, 6 and 8h measures for blood biomarkers, 
the 0, 1, 2 and 4h measures for physical biomeasures, and the 0, 4 and 8h measures for 
urine biomarkers, ivF being given after the 0h measures.  This 8h monitoring period 
was primarily performed to ensure there were no complications from the bolus dose of 
ivF. This response pattern could not be compared directly to the normal variance 
pattern on Day 1 in a similar manner to the normal volunteers study, where biomarker 
responses to different interventions were directly compared to normal variance. 
Firstly, the 0h biomarker values on Days 1 and 4 in the LVSD cohort were different, 
the former occurring during a presumed euvolaemic state, the latter occurring at 
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presumed maximal volume expansion. Secondly, the dosing and means of 
administration of furosemide were different, and I did not have anticipated furosemide 
responsiveness data to enable me to correct for this. This acute response would 
therefore be interpreted in the context of maximal changes from baseline measures, 
taking into account their respective normal variance. 
 
Patients starved from 21:00 the prior evening, refrained from alcohol, caffeine and smoking.  
However, they were allowed normal fluid intake (drank when they were thirsty) to avoid 
dehydration.  On arrival to the study centre on each occasion, their body weight and height 
were measured. They rested supine for 30 minutes, following which their blood pressure and 
heart rates were measured in triplicate. This was then followed by bladder voiding, urine 
collection and the insertion of an intravenous cannula with blood sampling for blood 
biomarker analyses. BIA and echocardiographic measurements were then performed using a 
similar pattern to Chapters Five and Six.  
 
On each day of the protocol, in addition to being asked to document specifically symptoms of 
decompensation (dyspnoea, oedema, chest pain, orthopnoea, paroxysmal nocturnal dyspnoea 
and perceived reduction in exercise capacity), patients were also asked to rate their sense of 
general well being on a non-graduated visual analogue score on a scale of 0 to 10 [Sneed et 
al., 2001].    
 
Patients were reviewed on a daily basis during the diuretic withdrawal phase.  They were 
examined on each occasion for any signs of acute decompensation. To ensure further patient 
safety, I was available by telephone 24h a day for any emergencies.  In case of 
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decompensation, admission to the acute Cardiology ward was pre-planned for observation 
and/or treatment. 
 
 7.3.3   Blood biomarkers 
 
As outlined in Chapter Four, Hct was measured as a potential biomarker of 
haemoconcentration or haemodilution; ANP and BNP were measured as the most obvious 
biomarkers of cardiac stretch or LV filling pressure.  Although BNP levels were not expected 
to change significantly during the 8h monitoring period following either chronic oral or acute 
intravenous diuresis, 
 
significant changes in baseline BNP measures over the 7-day protocol 
might occur [Braunschweig et al., 2002; Salvatore et al., 2005].  IMA and cTnI were also 
measured as potential sensitive markers of subclinical myocardial ischaemia which could 
result from abnormal volume status as part of the remodelling process [Braunwald et al., 
2008].
 
Although cTnT is more specific for myocardial ischaemia compared to cTnI, cTnT 
levels were undetectable by our assay in 100 samples selected randomly as discussed in 
Chapter Four.  cTnT was therefore not further studied. 
 
7.3.4  Markers of renal tubular function 
 
As outlined in Chapter Four, the renal tubular markers uKIM -1, uNAG, uNGAL and sNGAL 
were determined as potential measures of subclinical acute renal injury [Vaidya et al., 2008].  
All urinary biomarker levels were divided by respective uCreatinine in order to correct for 
urinary concentration which would undoubtedly be affected by varying furosemide treatment 
during the study protocol. 
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7.3.5    Physical biomeasures 
 
Echocardiographic measures obtained included mitral inflow indices and IVC indices as 
outlined in Chapter Four. BIA measures were obtained with electrodes placed distally, 
proximally and across the right lung (anterior-posterior and sternum-rib positions).  
 
7.3.6   Statistical analysis 
 
Within-day within-subject variance for each biomarker was determined using measurements 
over the 8h monitoring period on Day 1, as outlined in Chapter Three. For blood biomarkers, 
7 measurements (time points 0, 0.5, 1, 2, 4, 6 and 8h) were used, for urinary tubular markers, 
3 measurements (time points 0, 4, 8h) were used, and for physical biomeasures, 4 
measurements (0, 1, 2, 4h) were used. Within-day RCV for each biomarker was also 
calculated as described in Chapter Three. Furthermore, between-subject variance for each 
biomarker was determined by using the baseline values from all 30 LVSD patients on Day 1 
and dividing their cumulative standard deviation by their cumulative mean and multiplying by 
100. Analytical variance (CVa) for blood and urine biomarkers, and intra-observer or intra-
device variability (CVo) for physical biomeasures calculated in Chapter Five are also 
documented to illustrate their relative contributions to total variance. 
 
General linear model repeated measures one-factor within-subject ANOVA was used to 
establish the longitudinal response of parameters to diuretic manipulation over the 7-day 
protocol using the five 0h measures on Days 1, 2, 3, 4 and 7.  Bonferroni post-hoc analysis 
was performed to outline significant differences in values measured at different time points. 
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Similar analyses were performed to describe the within-subject normal variance pattern of 
biomarkers in LVSD patients on Day 1, and their response patterns to acute ivF on Day 4 both 
over the 8h monitoring period.  For illustration purposes, both normal variance curves (Day 1) 
and response to ivF curves (Day 4) are shown on the same graph. ANP, BNP, cTnI, 
sCreatinine, uCreatinine, uKIM-1, uNGAL and uNAG were non-normally distributed. Non-
normally distributed data was log10-transformed prior to repeated measures ANOVA.  The 
Bland-Altman method was used to assess the agreement between the long-axis and short-axis 
views for the measurement of IVC diameters. 
 
Power calculations for the study were based on previous work by Braunschweig et al. [2002] 
and Galve et al. [2005]. A sample size of 30 patients would give a power of > 85 % to detect 
significant changes in ANP (46 %), BNP (145%), and mitral valve inflow indices (14%) with 
an alpha value of 5 %. No previous studies have involved studying the effect of chronic 
diuretic manipulation in LVSD on E/Ea indices, IVC indices, Hct, renal tubular markers, and 
BIA variables, such that data for the latter variables is lacking to estimate power. 
  
  7.4   Results 
 
Baseline demographic and clinical variables of the 30 recruited patients are shown in Tables 
7.1 and 7.2 respectively. Patients were mostly male (87%), with mean LVEF of 25(8)%. Two-
thirds of patients had ischaemic cardiomyopathy, with the majority being in NYHA Class II. 
They were all on RAAS blockade.  Two-thirds of patients were on 40mg of furosemide daily, 
the rest were on 80mg of furosemide daily.   
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All patients remained haemodynamically stable without signs of acute decompensation 
throughout the 7-day diuretic manipulation protocol.  Thus all patients completed the study in 
accordance with the protocol; no emergency calls were made, and no hospital admissions for 
acute decompensation were required.  
 
Table 7.1.  Baseline demographic variables of LVSD patients. Mean (SD), n (%). 
Characteristic Value 
Male, n(%) 26 (87) 
Age (years) 70 (7) 
Height (m) 1.74 (0.09) 
Weight (Kg) 80.2 (19.4) 
BMI (Kg/m
2
) 26.3 (5.5) 
Ethnicity, n(%) 
   Caucasian  
   Afro Caribbean  
   Asian 
 
23 (77) 
3 (10) 
4 (13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   171 
 
Table 7.2.  Baseline clinical variables of cohort of 30 LVSD patients. Mean (SD), Median 
(IQ range), n (%). 
Characteristic Value 
Haemoglobin (g/dL) 13.8 (1.8) 
Haematocrit (%) 42.3 (4.7) 
Sodium (mmol/L) 139 (3) 
Urea (mmol/L) 9.5 (4.8) 
Serum Creatinine (mg/dL) 1.66 (1.29-2.32) 
Estimated glomerular filtration rate (mL/min/1.73 m
2
) 55 (16) 
Albumin (g/L) 45 (3) 
Systolic blood pressure (mmHg) 134 (21) 
Diastolic blood pressure (mmHg) 76 (11) 
Mean blood pressure (mmHg) 105 (14) 
Mean heart rate 64 (14) 
Left ventricular ejection fraction (%) 25 (8) 
Aetiology of LVSD, n(%) 
     Ischaemia 
     Hypertension 
     Idiopathic dilated cardiomyopathy 
     Others 
 
20 (67) 
1 (3) 
5 (17) 
4 (13) 
Heart Rhythm, n(%) 
     Sinus rhythm  
     Atrial fibrillation/flutter 
 
19 (63) 
11 (37) 
NHYA class, n(%) 
     I   
     II  
     III 
 
1 (3) 
26 (87) 
3 (10) 
Comorbidities, n(%) 
     Diabetes 
     Hypertension 
     Hypercholesterolaemia 
     Coronary artery disease 
     Cerebrovascular/peripheral vascular disease 
     Lung disease 
     Smoker 
 
10 (33) 
14 (47) 
5 (17) 
20 (67) 
3 (3) 
6 (20) 
7 (23) 
Medication, n(%) 
     Beta blockers  
     ACE inhibitors  
     Angiotensin II receptor blockers  
     Aspirin 
     Warfarin  
     Lipid lowering        
     Vasodilators   
 
23 (77) 
20 (67) 
10 (33) 
17 (57) 
12 (40) 
22 (73) 
9 (30) 
Dose of daily diuretic 
     Furosemide 40 mg  
        Spironolactone 25 mg 
        Spironolactone 50 mg 
     Furosemide 80 mg 
        Spironolactone 25 mg 
        Spironolactone 50 mg 
 
20 (67) 
  5 
  1 
10 (33) 
  3 
  1 
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7.4.1   1on-graduated visual analogue scores and body weight 
 
Despite all patients remaining asymptomatic on direct questioning during the 7 days, their 
visual analogue scores showed a non-significant decrease from Day 1 to Day 6, and an 
increase on Day 7, as shown in Table 7.3. Body weight showed a non-significant increase 
from Day 1 to Day 4 before reducing on Day 7. 
 
Table 7.3.  Visual analogue scores and body weight of patients throughout 7-day 
protocol. Mean (SD). 
Day 1 2 3 4 5 6 7 p 
Visual 
analogue 
score 
7.43 
(1.50) 
 
7.33 
(1.86) 
7.21 
(1.92) 
7.07 
(1.83) 
6.65 
(2.23) 
6.49 
(2.35) 
7.17 
(1.69) 
0.127 
Body 
weight 
(Kg) 
80.2 
(19.3) 
80.8 
(19.2) 
81.5 
(19.2) 
81.8 
(19.3) 
 
- - 81.3 
(19.4) 
0.149 
Visual analogue score=0: Unwell; visual analogue score=10: Well.  
 
7.4.2   Blood biomarkers 
 
At baseline, all patients had elevated ANP levels. However, BNP levels were not particularly 
elevated in this cohort of patients; only 5(17%) patients had BNP levels >400pg/mL.  The 
majority of patients [18(60%)] had BNP levels 100-400 pg/mL, and 7(23%) had BNP levels 
<100pg/mL.  The majority of patients had elevated cTnI levels [26(87%)], and elevated IMA 
levels [29(97%)]. Only 1 patient had a Hct <35%. 
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7.4.2.1  ormal Variance (0, 0.5, 1, 2, 4, 6 and 8h measures on Day 1) 
 
The components of the variance of blood biomarkers are shown in Table 7.4. Overall, 
variance was small for Hct and IMA, moderate for ANP and BNP, and large for cTnI. 
 
Table 7.4.  Within-day within subject total variance (CVtws) and reference change values 
(RCV), analytical coefficient of variation (CVa) and between-subject variance (CVtbs) of 
blood biomarkers. 
 
The mean within-day within-subject variance of each cardiovascular blood biomarker is 
illustrated in Figure 7.2 as the curve on Day 1.  Hct levels showed a small but statistically 
significant drop from 0h compared to all subsequent values, p<0.0001.  For ANP and IMA, 
there was a small but significant trend towards increasing values with time (both p<0.0001). 
There were non-significant changes in BNP (p=0.183) and TnI (p=0.397) values with time. 
 
 
Biomarker Normal 
range 
Baseline 
Mean (SD)/  
 Median (IQR) 
CVtws 
(%) 
RCV (%) CVa (%) CVtbs (%) 
ANP (pg/mL) 
 
<70 794 
(264 – 2543) 
 
10.2 28.3 5.0 185.9 
BNP (pg/mL) 
 
<100 155  
(96-295) 
 
16.9 46.8 11.6 116.2 
cTnI (ng/mL) 
 
<0.004 0.019  
(0.009-0.019) 
 
46.6 129.1 3.3 134.5 
IMA (KU/L) 
 
<85 126  (28) 
 
5.4 15.0 2.2 22.2 
Hct (%) > 35 
 
42.3  (4.7) 3.3 9.1 0.6 11.1 
Hct: haematocrit; ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; IMA: ischaemia 
modified albumin; cTnI: cardiac troponin I. 
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Figure 7.2.   1ormal variance of blood biomarkers over 8 hours on chronic oral diuresis 
(Day 1), and response to acute intravenous diuresis following maximal volume expansion 
(Day 4). 
 
  
 
 
Hct: haematocrit; ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; IMA: ischemia modified 
albumin; cTnI: cardiac troponin I. Mean (SE) for Hct and IMA; median (IQR) for ANP, BNP and TnI. 
Oral furosemide given following 0h measures on Day 1; ivF given following 0h measures on Day 4. 
 Day 4: ∆: maximal percentage change from 0h measure, ∗: time of maximal change from 0h measure. p value 
obtained from repeated measures one-factor within subject ANOVA. 
 
∗ 
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7.4.2.2  Longitudinal response to diuretic manipulation over 7-day protocol  
                      (0h measures on Days 1, 2, 3, 4 and 7) 
 
The longitudinal response of blood biomarkers to diuretic withdrawal followed by 
reinstitution of diuretic treatment is shown in Table 7.5, and blood biomarker responses in 
individual patients to volume manipulation are illustrated in Figures 7.3 and 7.4.  Hct values 
showed a significant decrease following diuretic withdrawal. However, Hct levels continued 
to reduce and failed to re-equilibrate to baseline values following diuretic reinstatement, with 
Hct levels at their lowest on Day 7. Similar significant trends were observed for the ANP and 
IMA responses, whereby levels showed statistically significant increases following diuretic 
withdrawal, but levels continued to increase following diuretic reinstatement. BNP levels 
showed statistically significant increase to a maximum on Day 4 following diuretic 
withdrawal and reduced to baseline values on Day 7 after diuretic resumption. cTnI levels did 
not change significantly over the 7-day protocol.  
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Table 7.5.  Longitudinal response of blood biomarkers to 7-day diuretic-induced volume 
manipulation protocol.  Mean (SD), median (IQR). 
Variable Baseline 
Day 1(0h) 
 Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4 (0h) 
Hct (%) 42.3  
(4.7)
2,3,4,7 
 
41.1  
(4.9)
1,3,4,7
 
40.1  
(4.9)
1,2
 
40.0  
(4.8)
1,2
 
39.7  
(4.7)
1,2
 
<0.0001 
ANP  
(pg/mL) 
794 
(264-2543)
2,3,4,7
 
937 
(347-2748)
1 
 
879 
(384-2845)
1
 
880 
(343-2704)
1
 
1183 
(421-2794)
1
 
0.011
#
 
BNP  
(pg/mL) 
 
155  
(96-295)
2
 
142  
(63-239)
1,3,4
 
150  
(92-294)
2
 
219  
(98-354)
2
 
148  
(72-365) 
0.001
#
 
IMA  
(KU/L) 
126  
(28)
2,3,4,7 
 
136  
(30)
1
 
139  
(30)
1
 
139  
(32)
1
 
138  
(31)
1
 
<0.0001 
cTnI  
(ng/mL) 
0.019 
(0.009-0.032) 
0.020 
(0.010-0.039) 
0.017 
(0.007-0.027) 
0.024 
(0.010-0.029) 
0.021 
(0.008-0.031) 
0.323
#
 
Hct: haematocrit; ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; IMA: ischaemia modified 
albumin; cTnI: cardiac troponin I. 
p values obtained from repeated measures one-factor within-subject ANOVA 
#: p values obtained after repeated measures ANOVA of log10-transformed values 
Significant difference on Bonferroni post hoc analysis between:  
1
: Day 1 and other day       
2
: Day 2 and other day           
3
: Day 3 and other day   
4
: Day 4 and other day       
7
: Day 7 and other day 
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Figure 7.3.  Haematocrit and atrial natriuretic peptide response over 7-day diuretic 
manipulation protocol (0h measures on Days 1, 2, 3, 4 and 7). 
 
Hct: haematocrit; ANP: atrial natriuretic peptide. Baseline: 0h on Day 1; IV furosemide: 50 mg bolus given after 
Day 4 0h measures. 
Red line joins mean (Hct) and median (ANP) values. 
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Figure 7.4.  B-type natriuretic peptide and ischaemia modified albumin response over 7-
day diuretic manipulation protocol (0h measures on Days 1, 2, 3, 4 and 7). 
 
 
BNP: B-type natiuretic peptide; IMA: ischaemia modified albumin. 
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus given after Day 4 0h measures. 
Red line joins mean (IMA) and median (BNP) values. 
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7.4.2.3   Response to acute intravenous diuresis following presumed maximal volume  
                        expansion (0, 0.5, 1, 2, 4, 6 and 8h measures on Day 4) 
 
The response curves of cardiovascular blood biomarkers to ivF on Day 4 at presumed 
maximal volume expansion are shown as the Day 4 curves in Figure 7.2. Time points of 
maximal biomarker change from 0h measures are highlighted, and maximal percentage 
change from 0h is shown for each biomarker.   All maximal changes from 0h occurred at, or 
after 6h; the maximal percentage changes not exceeding within-subject variance for some 
biomarkers, or not being markedly higher than the within-subject variance for others. 
Furthermore ANP, IMA, BNP and TnI levels did not change significantly from baseline in 
response to ivF.   
 
7.4.3         Markers of renal tubular function 
 
Mean eGFR was reduced [55(16) mL/min/1.73 m
2
], with all patients having an eGFR below 
the normal range of >90 mL/min/1.73 m
2
.  2(7%) patients had an eGFR <30 mL/min/1.73 m
2
, 
18(60%) patients had an eGFR 30-60 mL/min/1.73 m
2
; 10(33%) patients had eGFR 60-90 
mL/min/1.73 m
2
. Baseline median sCreatinine was also raised at 1.66 (1.29- 2.32)mg/dL, with 
24(80%) patients having a sCreatinine above the normal range of 1.20 mg/dL. Baseline 
median uKIM-1 levels were elevated at 562(132-1357)ng/gCr, with 22(73%) patients having 
uKIM-1 levels above the normal range of >200ng/gCr.   Median uNAG levels were 8.5(5.8 – 
13.4)U/gCr (normal value <3U/gCr), with 27(90%) patients having uNAG levels >3U/gCr.  
Median sNGAL levels were also increased at 470(333-601)ng/mL, with all patients having a 
sNGAL level above the normal range (<20ng/mL). Median uNGAL levels measured 1.4(0.5-
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26)µg/gCr (normal <60µg/gCr) were not elevated in the overall study population, with only 3 
patients (10%) having elevated baseline levels. 
 
7.4.3.1  ormal variance (0, 4, and 8h measures on Day 1) 
 
The components of the variance of markers of renal tubular function are shown in Table 7.6. 
The variance of the urine biomarkers was large in general. 
Table 7.6.  Within-day within-subject total variance (CVtws) and reference change values 
(RCV), analytical coefficient of variation (CVa) and between-subject variance (CVtbs) of 
markers of renal tubular function. 
Biomarker Baseline 
Mean (SD)/ 
median (IQR) 
CVtws(%) RCV (%) CVa (%) CVtbs (%) 
sCreatinine (mg/dL) 
 
1.66 (1.29-2.32) 24.7 68.5 NA 45.1 
uCreatinine (mg/dL) 
 
81.7 (42.0-115.4) 57.8 160.1 <20 56.1 
uKIM-1/Cr (ng/gCr) 
 
562 (99-1379) 76.1 210.9 <20 94.3 
uNGAL/Cr (µg/gCr) 
 
1.4 (0.5-26.2) 88.8 246.1 <20 235.7 
sNGAL (ng/mL) 477  (176) 
 
12.6 34.9 <20 37.0 
uNAG/Cr (U/gCr) 8.5 (5.7-14.0) 33.2 92.0 <20 70.2 
u: urinary; s: serum; KIM-1: kidney injury molecule-1; NGAL: N-acetyl beta-d-glucosaminidase; NAG: 
neutrophil gelatinase associated lipocalin; /Cr: corrected for urinary creatinine concentration.NA: not available. 
 
The mean within-day within-subject normal variance for each renal tubular biomarker is 
illustrated in Figure 7.5 as the curve on Day 1.  There were statistically significant trends 
towards a reduction in all four urinary renal tubular markers at the 4h measurement, followed 
by an increase in levels at the 8h measurement (uKIM-1: p=0.001; uNGAL: p=0.033; uNAG: 
p=0.002; uCreatinine: p<0.0001).  There were no significant changes in sNGAL levels 
(p=0.163). 
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Figure 7.5.  1ormal variance of renal tubular biomarkers on chronic oral diuresis over 
8h (Day 1) and response to acute intravenous diuresis following maximal volume 
expansion (Day 4). 
 
 
 
KIM-1: kidney injury molecule-1; NGAL: N-acetyl beta-d-glucosaminidase; NAG: neutrophil gelatinase 
associated lipocalin; s: serum; u: urinary. Mean (SE) for sNGAL; median (IQR) for uKIM-1, uNGAL, uNAG, 
uCreatinine. 
Oral furosemide given following 0h measures on Day 1; ivF given following 0h measures on Day 4. 
Day 4: ∆: maximal percentage change from 0h measure, ∗: time of maximal change from 0h measure. p value 
obtained from repeated measures one-factor within-subject ANOVA. 
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7.4.3.2  Longitudinal response to diuretic manipulation over 7-day protocol  
                      (0h measures on Days 1, 2, 3, 4 and 7) 
 
The longitudinal response of renal tubular biomarkers to diuretic withdrawal followed by 
diuretic resumption is shown in Table 7.7 and Figures 7.6 and 7.7.  As a positive control for 
diuretic manipulation, uCreatinine increased during diuretic withdrawal and reduced to near-
baseline values on Day 7. uKIM-1 and uNAG levels showed statistically significant changes 
during the protocol, with levels increasing during diuretic withdrawal, and reducing to 
baseline on Day 7 following diuretic resumption.  However, post-hoc analysis revealed 
significant difference for uNAG only between Days 2 and 3. sCreatinine, sNGAL and 
uNGAL levels showed no significant changes during the protocol. 
 Table 7. 7 Response of renal tubular markers to 7-day diuretic-induced volume 
manipulation protocol. Mean (SD), median (IQR). 
Variable Baseline 
Day 1(0h) 
 Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4 (0h) 
uKIM-1/Cr 
(ng/gCr) 
562  
(99-1379)
2,3,4 
 
1025  
(587-1944)
1,7 
1115  
(579-1732)
1,7 
995  
(401-1545)
1 
506  
(189-1641)
2,3 
<0.0001
#
 
uNGAL/Cr 
(ug/gCr) 
1.4  
(0.5-26.2) 
 
2.7  
(0.5-33.3) 
1.6  
(0.3-32.4) 
3.1  
(0.5-24.3) 
2.5 
(0.5-24.9) 
0.723
#
 
uNAG/Cr 
(U/gCr) 
8.3  
(5.7-14.0) 
 
7.7  
(5.6-13.2)
3 
9.9  
(6.3-15.2)
2 
9.6  
(4.8-15.7) 
8.6  
(5.4-15.1) 
0.044
#
 
sNGAL 
(ng/mL) 
 
477 (176) 505 (200) 469 (157) 489 (173) 501 (212) 0.459 
uCreatinine 
(mg/dL) 
81.7  
(42.0-
115.4)
2,3,4 
189.1  
(149.9-
225.2)
1,7 
 
181.1  
(118.8-
227.0)
1,7 
167.9  
(102.7-
205.8)
1,7 
84.1  
(54.6-
109.4)
2,3,4 
<0.0001
#
 
sCreatinine 
(mg/dL) 
1.66  
(1.29-2.32) 
1.70  
(1.31-2.18) 
1.52  
(1.29-2.13) 
1.66  
(1.40-2.21) 
1.64  
(1.31-2.21) 
0.994
#
 
u: urinary; s: serum; KIM-1: kidney injury molecule-1; NGAL: N-acetyl beta-d-glucosaminidase; NAG: 
neutrophil gelatinase associated lipocalin;  /Cr: normalised for urinary creatinine. 
p values obtained from repeated measures one-factor within subject ANOVA. 
#: p values obtained after repeated measures ANOVA of log10 transformed values. 
Significant difference on Bonferroni post hoc analysis between:  
1
: Day 1 and other day       
2
: Day 2 and other day         
3
: Day 2 and other day 
4
: Day 2 and other day       
7
: Day 2 and other day  
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Figure 7.6.  Response of uKIM-1 and u1GAL to 7-day diuretic manipulation protocol                       
(0h measures on Days 1, 2, 3, 4 and 7) 
 
 
u: urinary; s: serum; KIM-1: kidney injury molecule-1; NGAL: N-acetyl beta-d-glucosaminidase.  
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus of furosemide given after Day 4 0h measures. 
Red line joins median biomarker values. 
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Figure 7.7.  Response of u1AG and uCreatinine to 7-day diuretic manipulation protocol 
(0h measures on Days 1, 2, 3, 4 and 7). 
.  
 
 
u: urinary; NAG: neutrophil gelatinase associated lipocalin.   
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus of furosemide given after Day 4 0h measures. 
Red line joins median biomarker values. 
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7.4.3.3  Response to acute intravenous diuresis following presumed maximal  
                       volume expansion (0, 4 and 8h measures on Day 4) 
 
The response curves of renal tubular biomarkers to ivF on Day 4 are shown as the Day 4 
curves in Figure 7.5. Time points of maximal biomarker change from 0h measures are 
highlighted, and maximal percentage change from 0h is shown for each biomarker. 
uCreatinine reduced significantly 4h after ivF, and increased by 8h. All urinary renal tubular 
markers levels showed a significant trend to a marked reduction in levels at 4h (8h for 
uNAG), followed by a subsequent increase at 8h.  However, the maximal percentage change 
in these biomarker levels was either marginally above their within-subject normal variance or 
lower than their respective within-subject normal variance. sNGAL did not change 
significantly in response to ivF.  
 
7.4.4  Echocardiographic variables 
7.4.4.1  Mitral Doppler indices 
7.4.4.1.1  Normal variance (0, 1, 2 and 4h measures on Day 1) 
 
The components of the variance of mitral Doppler indices are shown in Table 7.8. The 
variance of these measures overall was moderate, with significant contribution from the intra-
observer variability, e.g., for MVDT, CVtws was 15.3 %, whereas CVo was 13.9 %.  
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Table 7.8.  Within-day within-subject total variance (CVtws) and reference change values 
(RCV), intra-observer variability (CVo) and between-subject variance (CVtbs) of mitral 
Doppler indices. 
Biomarker Baseline  
Mean (SD) 
/median (IQR) 
CVtws 
(%) 
RCV (%) CVo (%) CVtbs 
(%) 
MVE (m/s)  0.84  (0.24) 10.0 27.7 3.4 28.2 
vMVE (m/s) 0.76 (0.21) 11.9 33.0 7.54 27.6 
MVDT (ms) 268 (85) 15.3 42.4 13.9 31.6 
vMVDT (ms) 266 (78) 17.4 48.2 5.9 29.3 
MVE/A 0.85 (0.78-1.65) 12.1 33.5 5.1 77.4 
vMVE/A 0.84 (0.77-0.92) 16.9 46.8 8.2 74.4 
E/Ea(l) 9.8 (3.6) 14.2 39.3 5.4 37.1 
E/Ea(s) 13.7 (5.4) 13.4 37.1 7.8 39.5 
MV: mitral valve; E: early peak velocity, v: Valsalva manoeuvre; DT: early deceleration time; A: late peak 
velocity; Ea: tissue Doppler early diastolic mitral annulus velocity; l: lateral wall; s: septal wall. 
 
 
The mean within-day within-subject variance for mitral Doppler indices is shown in Figure 
7.8 as the curves on Day 1.   There were significant trends towards a reduction in MVE and 
vMVE after the 0h measures over 4h (p<0.0001 respectively).  MVDT, vMVDT, MVE/A, 
vMVE/A, E/Ea(l) and E/Ea(s) values did not change significantly with time on Day 1. 
 
 
 
 
 
 
 
 
 
 
 
   187 
 
Figure 7.8.  1ormal variance of mitral Doppler indices on chronic oral diuresis (Day 1) and response to 
acute intravenous diuresis following maximal volume expansion (Day 4). 
 
 
 
 
MV: mitral valve; E: early peak velocity, v: Valsalva manoeuvre; DT: early deceleration time; A: late peak 
velocity; Ea: tissue Doppler early diastolic mitral annulus velocity; l: lateral wall; s: septal wall. Mean (SE).  
Oral furosemide given following 0h measures on Day 1; ivF given following 0h measures on Day 4. 
Day 4: ∆: maximal percentage change from 0h measure, ∗: time of maximal change from 0h mesure. p value 
obtained from repeated measures one-factor within-subject ANOVA. 
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7.4.4.1.2  Longitudinal response to diuretic manipulation over 7-day protocol (0h  
                        measures on Days 1, 2, 3, 4 and 7) 
 
The responses of mitral Doppler indices to diuretic withdrawal followed by diuretic 
resumption are shown in Table 7.9 and Figure 7.9.  MVE, vMVE and MVE/A showed 
statistically significant increase from baseline to Day 4 following diuretic withdrawal.  These 
biomarker levels then reduced back to baseline values as a result of diuretic resumption. 
Although E/Ea indices increased from baseline to Day 4 and reduced on diuretic resumption, 
these changes were statistically non-significant. 
 
Table 7.9.  Changes in mitral inflow indices in response to 7-day diuretic manipulation.  
Mean (SD), median (IQR). 
Variable Baseline 
Day 1(0h) 
Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4(0h) 
MVE (m/s) 
 
0.84 (0.24)
4
 0.82 (0.24)
4
 0.86 (0.21) 0.90 (0.22)
1,2
 0.84  (0.24) 0.008 
vMVE (m/s) 
 
0.76 (0.21) 0.78 (0.27) 0.76 (0.22) 0.82 (0.24)
7 
0.75 (0.22)
4 
0.010 
MVDT (ms)  
 
268 (85) 259 (59) 271 (80) 268 (66) 249 (46) 0.454 
vMVDT (ms) 
 
266 (78) 249 (67) 269 (69) 255 (67) 239 (57) 0.133 
MVE/A 
 
 
0.85 
(0.78-1.65) 
0.78 
(0.69-0.96)
4 
0.89 
(0.74-0.98) 
0.95 
(0.79-1.28)
2 
0.85 
(0.75-0.94) 
0.040
#
 
vMVE/A 
 
 
0.84 
(0.77-0.92) 
0.81 
(0.67-0.95) 
0.83 
(0.72-0.98) 
0.92 
(0.70-1.2) 
0.77 
(0.64-0.97) 
0.425
#
 
E/Ea(l) 
 
9.8 (3.6) 10.0 (4.3) 9.6 (3.1) 10.2 (3.3) 9.8 (3.4) 0.741 
E/Ea(s) 
 
13.7 (5.4) 13.3 (4.9) 15.3 (9.3) 15.5 (5.8) 14.3 (5.5) 0.232 
MV: mitral valve; E: early peak velocity, v: Valsalva manoeuvre; DT: early deceleration time; A: late peak 
velocity; Ea: tissue Doppler early diastolic mitral annulus velocity; l: lateral wall; s: septal wall. 
p values obtained from repeated measures one-factor within-subject ANOVA. 
#: p values obtained after repeated measures ANOVA of log10-transformed values. 
Significant difference on Bonferroni post-hoc analysis between:  
1
: Day 1 and other day        
2
: Day 2 and other day        
3
: Day 3 and other day    
4
: Day 4 and other day        
7
: Day 7 and other day 
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Figure 7. 9.  Response of MVE and MVE/A to diuretic-induced volume changes over 7-
day protocol (0h measures on Days 1, 2, 3, 4 and 7). 
 
 
MV: mitral valve; E: early peak velocity; A: late peak velocity. 
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus of furosemide given after Day 4 0h measures. 
Red line joins mean (MVE) and median (MVE/A) values. 
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7.4.4.1.3  Response to acute intravenous diuresis following presumed maximal  
                        volume expansion (0, 1, 2 and 4h measures on Day 4) 
 
The response curves of mitral Doppler indices to ivF on Day 4 are illustrated as the Day 4 
curves in Figure 7.8. Time points of maximal biomarker change from 0h measures are 
highlighted, and maximal percentage change from 0h is shown for each biomarker.   MVE, 
vMVE, MVE/A, vMVE/A, E/Ea(l) and E/Ea(s) showed statistically significant reduction 
following intravenous diuresis. However, the maximal percentage changes in biomarker 
levels were either smaller than the respective within-subject variance or not markedly larger 
than the within-subject variance in other cases. 
 
7.4.4.2  Inferior vena cava indices 
 
IVC views were obtained easily and consistently in all patients in this study.  15 (50 %) of 
patients had long-axis IVC diameter on expiration larger than 2 cm, and 18 (60 %) of patients 
had short-axis IVC diameter on expiration larger than 2 cm. Bland-Altman plots of the 
agreement between the long-axis and short-axis views for the measurement of IVC diameters 
are shown in Figure 7.10. The bias (mean difference) between the two methods was small (< 
0.10 cm for IVCe and IVCi). The variability of measures using both methods appeared 
consistent regardless of the vessel diameter. 
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Figure 7.10. Bland-Altman plots of agreement between long-axis and short-axis 
measurement of IVC diameters 
 
L: long-axis; S: short-axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal 
inspiration; mean: mean difference; SD: standard deviation. 
 
7.4.4.2.1  Normal variance (0, 1, 2 and 4h measures on Day 1) 
 
The components of the variance of IVC indices are shown in Table 7.10. These were similar 
to the variance of mitral inflow indices. 
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Table 7.10.  Within-day within-subject total variance (CVtws) and reference change 
values (RCV), intra-observer variability (CVo) and between-subject variance (CVtbs) of 
inferior vena cava indices. 
Biomarker Baseline CVtws (%) RCV (%) CVo (%) CVtbs (%) 
LIVCe (cm)  2.18 (0.52) 9.7 26.9 4.2 24.1 
LIVCi (cm) 1.72 (0.49) 11.6 32.1 7.8 28.4 
LIVCmi (cm) 
 
1.38 (0.43) 13.8 38.2 13.8 31.6 
SIVCe (cm) 2.23 (0.46) 9.5 26.3 2.7 20.5 
SIVCi (cm) 1.78 (0.44) 13.1 36.3 7.3 24.7 
SIVCmi (cm) 1.51 (0.40) 15.0 41.6 5.7 26.8 
L: long axis; S: short-axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal 
inspiration. 
 
 
The mean within-day within-subject variance for selected IVC indices is illustrated in Figure 
7.11 as the curves on Day 1.  There was general trend towards a reduction in all IVC indices 
over the 4h monitoring period.  This trend was significant for LIVCe (p=0.013), LIVCDe 
(p=0.006), SIVCe (p=0.012), SIVCi (p=0.002) and SIVCDe (p=0.010).   
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Figure 7.11.  1ormal variance of selected IVC indices on chronic oral diuresies (Day 1) and response to 
acute intravenous diuresis following maximal volume expansion (Day 4). 
 
 
 
 
 
L: long axis; S: short-axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal 
inspiration. Mean (SE).  
Oral furosemide given following 0h measures on Day 1, ivF given following 0h measures on Day 4. 
Day 4: ∆: maximal percentage change from 0h measures, ∗: time of maximal change from 0h measure. p value 
obtained from repeated measures one-factor within subject ANOVA. 
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7.4.4.2.2  Longitudinal response to diuretic manipulation during 7-day protocol  
                       (0h measures on Days 1, 2, 3, 4 and 7) 
 
The response of IVC indices to diuretic withdrawal followed by reinstitution of diuretic 
treatment is shown in Table 7.11 and in Figure 7.12 for LIVC indices, and in Table 7.12 for 
SIVC indices.  All LIVC and LIVCD indices showed statistically significant increase during 
diuretic withdrawal, and reduction following diuretic resumption. However, there was no 
statistically significant difference between the time points on post-hoc analysis for these 
biomarkers, except for LIVCi and LIVCDi.  LIVCCI indices did not change significantly.  
 
Table 7.11.  Response of long-axis inferior vena cava indices to 7-day diuretic 
manipulation. Mean (SD). 
Variable Baseline 
Day 1(0h) 
Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4(0h) 
LIVCe (cm) 
 
2.18 (0.52) 2.11 (0.55) 2.16 (0.53) 2.27 (0.50) 2.09 (0.49) 0.012 
LIVCi (cm) 
 
1.72 (0.49) 1.69 (0.49)
4
 1.78 (0.47) 1.85 (0.56)
2,7
 1.67 (0.44)
4
 0.006 
LIVCmi (cm) 
 
1.38 (0.43) 1.37 (0.46) 1.44 (0.45) 1.52 (0.49) 1.38 (0.43) 0.022 
LIVCDe (cm/m
2
) 
 
1.13 (0.25) 1.09 (0.26) 1.11 (0.24) 1.17 (0.25) 1.09 (0.25) 0.015 
LIVCDi (cm/m
2
) 
 
0.89 (0.23) 0.87 (0.23)
4
 0.91 (0.23) 0.95 (0.27)
2,7
 0.86 (0.22)
4
 0.014 
LIVCDmi (cm/m
2
) 
 
0.71 (0.21) 0.70 (0.22) 0.74 (0.23) 0.78 (0.24) 0.71 (0.22) 0.028 
LIVCCIi (%) 
 
20.9 (14.1) 19.9 (9.4) 17.7 (10.2) 19.0 (13.7) 20.3 (10.1) 0.683 
LIVCCImi (%) 
 
36.6 (14.4) 35.5 (11.2) 33.3 (12.8) 32.8 (14.9) 33.8 (13.1) 0.531 
L: long axis; IVC: inferior vena cava diameter; IVCD: IVC corrected for body surface area; IVCCI: IVC 
collapsibility index. 
p values obtained from repeated measures one-factor within subject ANOVA. 
Significant difference on Bonferroni post-hoc analysis between:  
1
: Day 1 and other day        
2
: Day 2 and other day        
3
: Day 3 and other day    
4
: Day 4 and other day        
7
: Day 7 and other day 
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Figure 7.12. Long-axis IVCe and IVCi response to 7-day diuretic manipulation protocol 
(0h measures on Days 1, 2, 3, 4 and 7). 
 
 
 
 
L: long axis; IVC: inferior vena cava diameter; e: expiration; i: inspiration; mi: maximal inspiration.   
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus of furosemide given after Day 4 0h measures. 
Red line joins mean values. 
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Similarly, SIVCe, SIVCmi, SIVCDe and SIVCDmi showed statistically signifcant increase 
from Day 1 to Day 4 and reduced following diuretic resumption (Table 7.12).  There was a 
similar but non-significant trend for SIVCi and SIVCDi.  Unlike for LIVCCI indices, both 
SIVCCI indices showed statistically significant changes during the 7-day protocol. SIVCCmi 
reduced gradually from baseline to Day 4 following diuretic withdrawal, and increased 
marginally from Day 4 to Day 7, however, post-hoc analysis did not show any significant 
difference between these measures. SIVCCmi reduced from baseline to Day 4, but continued 
to reduce following diuretic resumption. 
 
Table 7.12.  Response of short-axis inferior vena cava indices to 7-day diuretic 
manipulation protocol.  Mean (SD). 
Variable Baseline 
Day 1(0h) 
Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4(0h) 
SIVCe (cm) 
 
2.23 (0.46) 2.13 (0.43)
4
 2.20 (0.49)
4
 2.36 (0.45)
2,3,7
 2.17 (0.44)
4
 0.001 
SIVCi (cm) 
 
1.78 (0.44) 1.80 (0.46) 1.81 (0.46) 1.93 (0.46) 1.81 (0.42) 0.077 
SIVCmi (cm) 
 
1.51 (0.40) 1.46 (0.40)
1
 1.48 (0.47) 1.62 (0.44)
1
 1.46 (0.47) 0.027 
SIVCDe (cm/m
2
) 
 
1.15 (0.21) 1.10 (0.19)
4
 1.13 (0.23)
4
 1.21 (0.21)
2,3,7
 1.13 (0.24)
4
 0.002 
SIVCDi (cm/m
2
) 
 
0.92 (0.21) 0.92 (0.22) 0.93 (0.22) 0.99 (0.22) 0.94 (0.24) 0.114 
SIVCDmi (cm/m
2
) 
 
0.78 (0.19) 0.75 (0.19)
4
 0.76 (0.23) 0.83 (0.20)
2
 0.75 (0.24) 0.033 
SIVCCIi (%) 
 
20.2 (12.5) 16.4 (7.9) 22.9 (13.7)
7
 18.6 (10.3) 16.1 (11.8)
3
 0.032 
SIVCCImi(%) 
 
43.6 (21.4) 32.2 (9.5) 41.4 (19.7) 31.7 (11.1) 32.6 (15.0) 0.001 
S: short axis; IVC: inferior vena cava diameter; IVCD: IVC corrected for body surface area; IVCCI: IVC 
collapsibility index. 
p values obtained from repeated measures one-factor within subject ANOVA. 
Significant difference on Bonferroni post-hoc analysis between:  
1
: Day 1 and other day        
2
: Day 2 and other day        
3
: Day 3 and other day    
4
: Day 4 and other day        
7
: Day 7 and other day 
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7.4.4.2.3  Response to acute intravenous diuresis following presumed maximal  
                        volume expansion (0, 1, 2 and 4h measures on Day 4) 
 
The response of IVC indices to ivF on Day 4 is shown in Figure 7.11 as the Day 4 curves for 
LIVCe, L IVCi, LIVCmi, LIVCCImi and their corresponding short-axis indices.  All LIVC 
and SIVC diameters reduced significantly from baseline to the 4h measures, with their 
respective LIVCD and SIVCD indices following the same significant trend. However, 
maximal percentage change in biomarker levels from 0h was either smaller or marginally 
larger than the respective within-subject variance. None of the IVCCI indices changed 
significantly following ivF. 
 
7.4.5  Bioimpedance analysis 
7.4.5.1  Whole-body BIA 
7.4.5.1.1  Normal variance (0, 1, 2 and 4h measures on Day 1) 
 
The components of the variance of whole-body BIA measures are shown in Table 7.13. The 
variance of whole body BIA was generally very small. 
Table 7.13.  Within-day within-subject total variance (CVtws) and reference change 
values (RCV), intra-device variability (CVo) and between-subject variance (CVtbs) of 
whole-body bioimpedance measures. 
Biomarker Baseline 
 
CVtws (%) RCV (%) CVo (%) CVtbs (%) 
dECW (%) 24.3 (2.0) 0.9 2.5 0.2 8.4 
dICW (%) 31.8 (3.1) 0.9 2.5 0.4 9.3 
dTBW(%) 56.6 (5.5) 1.0 2.8 0.2 9.8 
dZ5kHz (Ω) 545 (90) 1.8 5.0 0.5 16.6 
dZ50 kHz (Ω) 482 (84)
 
1.8 5.0 0.6 17.4 
dZ100 kHz (Ω) 458 (81) 1.8 5.0 0.4 17.6 
dZ200kKHz (Ω) 435 (77) 1.9 5.3 0.3 17.6 
d: distal; ECW: extracellular water; ICW: intracellular water; TBW: total body water; Z: impedance; 5-200 kHz: 
current frequency. 
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The mean within-day within-subject variance for distal BIA indices is shown in Figure 7.13 
as the curves on Day 1. Despite very small increments between all 4 timed measures, there 
were significant trends towards a reduction in dTBW and dECW from baseline to the 4h 
measures (p<0.0001 respectively).  Similarly, despite small amplitudes of change between the 
4 timed measures, all impedance values showed significant trends towards increasing values 
over the 4h monitoring period (Z5kHz: p<0.0001; Z50kHz: p<0.0001; Z100kHz: p<0.0001; Z200kHz: 
p=0.001).  The dICW normal variance pattern showed a non-significant reducing trend over 
4h (p=0.182).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   199 
 
Figure 7.13.  1ormal variance of whole-body bioimpedance measures on chronic oral diuresis (Day 1) and 
response to acute intravenous diuresis following maximal volume expansion (Day 4). 
 
 
 
d: distal; Z: impedance; ECW: extracellular water; ICW: intracellular water; TBW: total body water; Z: 
impedance; 5-200 kHz: current frequency. Mean (SE).  
Oral furosemide given following 0h measures on Day 1; ivF given following 0h measures on Day 4. 
Day 4: ∆: maximal percentage change from 0h measure, ∗:time of maximal change from 0h measure. p value 
obtained from repeated measures one-factor within subject ANOVA. 
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7.4.5.1.2  Longitudinal response to diuretic manipulation during 7-day protocol  
                        (0h measures on Days 1, 2, 3, 4 and 7) 
 
The response of whole-body BIA measures to diuretic withdrawal followed by reinstitution of 
diuretic treatment is shown in Table 7.14 and for dZ5kHz and dECW in Figure 7.14.  Despite 
all estimates of body water composition showing statistically significant increase from 
baseline to Day 4 following diuretic withdrawal, and reducing by Day 7, these were by only 
small increments. All impedance values at all four current frequencies showed statistically 
significant reduction from baseline to Day 4 and increased following diuretic resumption by 
Day 7. 
 
Table 7.14.  Response of whole-body (distal) BIA measures to 7-day diuretic 
manipulation protocol. Mean (SD). 
Variable Baseline 
Day 1(0h) 
 Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4(0h) 
dECW (%) 
 
24.3 (2.1)
3,4
 24.1 (2.2)
3,4,7
 24.5 (2.3)
1,2,4
 24.8 (2.3)
1,2,3
 24.5 (2.3)
2
 <0.0001 
dICW (%) 
 
31.7 (3.1) 31.5 (3.0)
3,4,7
 31.8 (3.1)
2
 31.9 (2.9)
2
 31.9 (2.9)
2
 0.027 
dTBW (%) 
 
56.4 (5.6)
3,4
 56.0 (5.7)
3,4
 56.9 (5.8)
1,2,4
 57.6 (6.0)
1,2,3,7
 56.7 (5.6)
4 
<0.0001 
dZ5kHz (Ω) 
 
541 (89)
2,4
 553 (82)
1,3,4,7
 529 (77)
2,4
 515 (77)
1,2,3,7
 531 (79)
2,4
 <0.0001 
dZ50 kHz (Ω) 
 
473 (79)
2,4 
483 (76)
1,3,4,7 
463 (69)
2,4 
451 (68)
1,2,3 
461 (64)
2 
<0.0001 
dZ100 kHz (Ω) 
 
455 (80)
3,4
 462 (76)
3,4,7
 444 (71)
1,2,4
 434 (71)
1,2,3
 443 (71)
2
 <0.0001 
dZ200 kHz (Ω) 
 
432 (76)
4
 439 (73)
3,4,7
 422 (68)
2
 413 (68)
1,2
 421 (67)
2
 <0.0001 
d: distal; ECW: extracellular water; ICW: intracellular water; TBW: total body water; Z: impedance; 5-200 
kHz: current frequency. 
p values obtained from repeated measures one-factor within-subject ANOVA. 
Significant difference on Bonferroni post-hoc analysis between:  
1
: Day 1 and other day        
2
: Day 2 and other day        
3
: Day 3 and other day    
4
: Day 4 and other day        
7
: Day 7 and other day 
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Figure 7.14. Whole-body Z5kHz and ECW response to 7-day diuretic manipulation 
protocol (0h measures on Days 1, 2, 3, 4 and 7). 
 
d: distal; ECW: extracellular water; Z: impedance.  
Red line joins mean values. 
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus of furosemide given after Day 4 0h measures. 
 
 
7.4.5.1.3  Response to acute intravenous diuresis following presumed maximal  
                        volume expansion (0, 1, 2 and 4h measures on Day 4) 
 
The response curves of whole-body BIA measures to ivF on Day 4 are illustrated as the Day 4 
curves in Figure 7.1.  All impedance curves showed statistically significant increase from 0h 
to 4h, all estimates of body water composition showed statistically significant decrease after 
   202 
 
the administration of ivF. The maximal percentage changes in biomarker values changed 
above their respective within-subject variance except for dICW. 
 
7.4.5.2  Proximal BIA measures 
 
Proximal impedance values were smaller than corresponding distal impedance values, but 
larger than corresponding right lung impedance values as observed in Chapters Five and Six.  
Furthermore, estimates of body water percentage were also smaller when measured 
proximally compared to distally.   
 
7.4.5.2.1  Normal variance (0, 1, 2 and 4h measures on Day 1) 
The components of the variance of proximal BIA measures are shown in Table 7.15. 
Table 7.15.  Within-day within subject total variance (CVtws) and reference change 
values (RCV), intra-device variability (CVo) and between-subject variance (CVtbs) of 
proximal bioimpedance measures. 
Biomarker Baseline CVtws (%) RCV (%) CVo (%) CVtbs (%) 
pECW (%) 21.9 (2.6) 1.9 5.3 0.4 12.0 
pICW (%) 26.7 (3.7) 1.7 4.7 0.5 14.0 
pTBW (%) 48.6 (6.2) 1.5 4.2 0.2 12.8 
pZ5kHz (Ω) 122 (16) 3.5 9.7 0.7 13.2 
pZ50 kHz (Ω) 107 (15) 3.1 8.6 0.5 13.9 
pZ100 kHz (Ω) 101 (14) 3.3 9.1 0.5 14.1 
pZ200 kHz (Ω) 96 (14) 3.2 8.9 0.5 15.0 
p: proximal; ECW: extracellular water; ICW: intracellular water; TBW: total body water; Z: impedance; 5-200 
kHz: current frequency. 
 
The mean within-day within-subject variance for proximal BIA indices is shown in Figure 
7.15 as the curves on Day 1.There were significant reductions in estimated body water 
compartments from 0-4h, and significant increases for all impedance values at all four current 
frequencies (pECW: p<0.0001; pICW: p=0.006; pTBW: p<0.0001; Z5kHz: p<0.0001; Z50kHz: 
p<0.0001; Z100kHz: p<0.0001; Z200kHz: p<0.0001 respectively).     
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Figure 7.15.  1ormal variance of proximal BIA measures on chronic oral diuresis (Day 1) and response to 
acute intravenous diuresis following maximal volume expansion (Day 4).
 
 
 
p: proximal; ECW: extracellular water; ICW: intracellular water; TBW: total body water; Z: impedance; 5-200 
kHz: current frequency. Mean (SE).  
Oral furosemide given following 0h measures on Day 1; ivF given following 0h measures on Day 4. 
Day 4: ∆: maximal percentage change from 0h measure, ∗:time of maximal change from 0h measure. p value 
obtained from repeated measures one-factor within subject ANOVA. 
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7.4.5.2.2  Longitudinal response to diuretic manipulation during 7-day protocol  
                        (0h measures on Days 1, 2, 3, 4 and 7) 
 
The response of proximal BIA measures to diuretic withdrawal followed diuretic resumption 
is shown in Table 7.16 and for pZ5kHz and pECW in Figure 7.16.  Of the estimated body water 
compartments, only pECW showed a statistically significant increase from Day 1 to Day 4 
during diuretic withdrawal, with values remaining elevated from baseline on Day 7. All 
impedance values showed a statistically significant reduction from Day 1 to Day 4, but did 
not change significantly from Day 4 to Day 7 following diuretic resumption.  
 
Table 7.16.  Proximal (trunk) BIA responses to 7-day diuretic manipulation. Mean (SD) 
Variable Baseline 
Day 1(0h) 
 Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4(0h) 
pECW (%) 
 
22.1 (2.6)
7 22.0 (2.6)4,7 22.2 (2.6) 22.5 (2.8)2 22.5 (2.9)1,2 <0.0001 
pICW (%) 
 
26.8 (3.8) 27.0 (3.6) 27.0 (3.4) 26.9 (3.7) 27.0 (3.8) 0.445 
pTBW (%) 
 
48.8 (6.3) 49.0 (6.1) 49.3 (5.9) 49.3 (6.3) 49.6 (6.5) 0.071 
pZ5kHz (Ω) 
 
121 (15)
4 121 (12)3,4,7 117 (11)2 115 (12)1,2 117 (13)2 <0.0001 
pZ50 kHz (Ω) 
 
106 (14)
4 106 (11)3,4 103 (11)2 102 (11)1,2 103 (12) <0.0001 
pZ100 kHz (Ω) 
 
100 (14) 100 (11)4 98 (10) 97 (11)2 97 (12) 0.002 
pZ200 kHz (Ω) 
 
95 (14) 95 (10)3,4 92 (10)2 92 (11)2 92 (11) 0.009 
p: proximal; ECW: extracellular water; ICW: intracellular water; TBW: total body water; Z: impedance; 5-
200 kHz: current frequency. 
p values obtained from repeated measures one-factor within subject ANOVA 
Significant difference on Bonferroni post hoc analysis between:  
1
: Day 1 and other day        
2
: Day 2 and other day        
3
: Day 3 and other day    
4
: Day 4 and other day        
7
: Day 7 and other day 
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Figure 7.16.  pZ5kHz and pECW response to 7-day diuretic manipulation (0h measures on 
Days 1, 2, 3, 4 and 7) 
 
 
p: proximal; ECW: extracellular water; Z: impedance; 5 kHz: current frequency. 
Red line joins mean values. 
Baseline: 0h on Day 1; IV furosemide: 50 mg bolus of furosemide given after Day 4 0h measures. 
 
 
 
7.4.5.2.3  Response to acute intravenous diuresis following maximal volume  
                        expansion (0, 1, 2 and 4h measures on Day 4) 
 
The response curves of proximal BIA measures to ivF on Day 4 are illustrated as the Day 4 
curves in Figure 7.15. Time points of maximal biomarker change from 0h measures are 
highlighted, and maximal percentage change from 0h is shown for each biomarker. All 
impedance curves increased significantly from 0-4h, and all estimates of body water 
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compartments curves decreased significantly over that time. The maximal percentage change 
in biomarker levels was larger than the respective within-subject variance. 
 
7.4.5.3  Right-lung BIA  
7.4.5.3.1  Normal variance (0, 1, 2 and 4h measures on Day 1) 
The components of the variance of right-lung BIAmeasures are shown in Table 7.17. This 
was larger than for the corresponding distal and proximal impedance values, but nevertheless 
still small. 
 
Table 7.17.  Within-day within-subject total variance (CVtws) and reference change 
values (RCV), intra-device variability (CVo) and between-subject variance (CVtbs) of 
right-lung bioimpedance measures. 
Biomarker Baseline CVtws (%) RCV (%) CVo (%) CVtbs (%) 
apZ5kHz (Ω) 53 (9) 4.8 13.3 0.8 16.6 
apZ50kHz (Ω) 44 (8) 4.7 13.0 1.0 18.9 
apZ100kHz (Ω) 40 (8) 5.0 13.9 1.7 19.9 
apZ200kHz (Ω) 
 
37 (8) 5.1 14.1 1.1 21.2 
srZ5kHz (Ω) 55 (11) 6.6 18.3 2.6 19.7 
srZ50kHz (Ω) 47 (10) 6.8 18.8 2.1 21.7 
srZ100kHz (Ω) 44 (10) 6.8 18.8 2.4 23.4 
srZ200kHz (Ω) 41 (10) 7.2 19.9 2.9 24.0 
ap: anterior-posterior electrode position; sr: sternum-rib electrode position; Z: impedance; 5-200kHz: current 
frequency. 
 
 
The mean within-day within-subject variance of right-lung BIA measures derived from both 
electrode positions is shown in Figure 7.17 as the curves on Day 1. All impedance patterns 
from both right-lung electrode placements increased significantly from baseline to the 4h 
measures (all p<0.0001). 
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Figure 7.17.  1ormal variance of right lung BIA measures on chronic oral diuresis (Day 
1) and response to acute intravenous diuresis following maximal volume expansion (Day 
4). 
 
 
 
sr: sternum-rib; ap: anterior-posterior electrode positions; Z: impedance; 5-200 kHz: current frequency. Mean 
(SE). Oral furosemide given following 0h measures on Day 1; ivF given following 0h measures on Day 4. 
Day 4: ∆: maximal percentage change from 0h measure, ∗:time of  maximal change from 0h measure. p value 
obtained from repeated measures one-factor within subject ANOVA. 
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7.4.5.3.2  Longitudinal response to diuretic manipulation during 7-day protocol  
                       (0h measures Days 1, 2, 3, 4 and 7) 
 
The response of right-lung BIA measures to diuretic withdrawal followed by reinstitution of 
diuretic treatment is shown in Table 7.18. Only apZ5kHz changed statistically significantly, 
reducing from baseline to Day 4 before increasing again to baseline values following diuretic 
resumption (p=0.017). However, post-hoc analysis did not reveal significant differences 
between any time points.  
 
Table 7.18.  Right-lung BIA responses to 7-day diuretic manipulation.  Mean (SD). 
Variable Baseline 
Day 1(0h) 
 Diuretic withdrawal Diuretic 
resumption 
Day 7 
p 
Day 2 Day 3 Day 4(0h) 
apZ5kHz (Ω) 
 
53 (9) 54 (10) 53 (9) 50 (8) 54 (11) 0.017 
apZ50kHz (Ω) 
 
43 (8) 44 (10) 44 (9) 43 (12) 44 (10) 0.579 
apZ100kHz (Ω) 
 
40 (8) 41 (10) 40 (9) 39 (11) 41(10) 0.517 
apZ200kHz (Ω) 
 
37 (8) 38 (10) 37 (9) 37 (11) 38 (10) 0.558 
srZ5kHz (Ω) 
 
54 (11) 58 (12)2 56 (12) 54 (10)2 55 (11) 0.072 
srZ50kHz (Ω) 
 
47 (10) 48 (10) 48 (13) 46 (9) 47 (11) 0.497 
srZ100kHz (Ω) 
 
44 (11) 45 (10) 43 (8) 43 (9) 43 (10) 0.267 
srZ200kHz (Ω) 
 
41 (10) 42 (10) 42 (14) 41 (9) 40 (10) 0.809 
ap: anterior-posterior electrode placement; sr: sternum-rib electrode placement; Z: impedance; 5-200 kHz: 
current frequency. 
p values obtained from repeated measures one-factor within-subject ANOVA. 
Significant difference on Bonferroni post-hoc analysis between:  
1
: Day 1 and other day        
2
: Day 2 and other day        
3
: Day 3 and other day    
4
: Day 4 and other day        
7
: Day 7 and other day 
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7.4.5.3.3 Response to acute intravenous diuresis following maximal volume  
                        expansion (0, 1, 2 and 4h measures on Day 4) 
 
The response curves of right-lung impedance measures to ivF on Day 4 are illustrated as the 
Day 4 curves in Figure 7.17. Time points of maximal biomarker change from 0h measures are 
highlighted, and maximal percentage change from 0h is shown for each biomarker. All 
impedance curves showed statistically significant increase from 0-4h.The maximal percentage 
change in biomarker levels from the 0h measures all occurred above the respective within-
subject normal variance. 
 
7.4.6   Urine volumes and oral intake on Day 1 and Day 4 (0, 4 and 8h measures) 
 
Table 7.19 illustrates the urine volumes and oral intake during the 8h monitoring periods on 
Day 1 and Day 4. Patients were allowed comparable amounts of fluid as they would normally 
drink, and oral intake was no different on both days. There was a significantly larger total 
urine volume on Day 4 compared to Day 1, secondary to the significantly larger diuresis at the 
4h measures following ivF. 
 
Table 7.19. Urine output and oral intake during 8h monitoring on Day 1 and Day 4. 
Urine volume (mL) Day 1 Day 4 p value 
     4 h 878 (416) 1461 (577) <0.0001 
     8 h 215 (128) 242 (141) 0.395 
     Total 
 
1093 (465) 1703 (607) <0.0001 
Oral intake (mL) 653 (264) 742 (347) 0.145 
Comparison using t-test. 
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7.5   Discussion 
7.5.1   ormal variance (Day 1 8h monitoring) 
7.5.1.1  Blood biomarkers 
 
 Of the panel of blood biomarkers studied, normal variance in LVSD has only been 
established for ANP and BNP so far [Bruins et al., 2004; Wu et al., 2003; McDowell et al., 
2002; Araújo et al. 2006]. Consequently, this is the first study to establish the within-subject 
and between-subject normal variance of Hct, cTnI and IMA in stable LVSD patients. I 
observed the smallest within-subject variance for Hct, and the largest within-subject variance 
for cTnI. Furthermore, the within-subject variance of Hct and ANP was similar to that 
observed in my normal volunteers cohort (Chapter Six), the within-subject variance of IMA 
and cTnI was larger compared to that of normal volunteers [Wu et al., 2009; Govender et al., 
2008], and the within-subject variance of BNP was lower compared to normal volunteers. 
Overall, the between-subject variance for cardiovascular blood biomarkers appeared much 
larger in LVSD compared to normal volunteers. 
 
The within-subject total variance of ANP in my cohort of LVSD patients (10.2 %) was in 
contrast to that observed in the HF cohort in the study by McDowell et al. [2002] of 51 %, but 
similar to that observed in my cohort of normal volunteers (9.9 %).  As discussed in Chapter 
Six, this discrepancy may be due to the high variability of ANP levels in the morning and the 
much higher frequency of measurements made by McDowell et al. who measured ANP levels 
every 2 minutes over 90 minutes in the morning. The findings from my study are more 
clinically relevant as routine tests in patients will potentially take place at any time of the day.   
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The observed initial significant drop in Hct levels and increase in ANP levels from the 
baseline measure showed a similar but more blunted trend compared to that observed in the 
normal variance curves for the normal volunteers. The fact that Hct levels fall as ANP levels 
rise again suggests that blood volume is modulated by changes in ANP, resulting in the 
subsequent changes in Hct levels. The blunted trend may be secondary to reduced capacity for 
large increases in ANP secretion in view of the already increased levels in all patients in the 
LVSD cohort [Kjaer et al., 2005]. 
 
 For BNP, I demonstrated comparable within-day within-subject variance (16.9%) to the 
studies by Bruins et al. [2004] and O’Hanlon et al. [2007], where the within-subject variance 
obtained from 2-hourly and one-hourly measures respectively in LVSD ranged between 12 to 
15%. The reduced within-subject variance observed for BNP compared to that observed in 
normal volunteers (44 %) has previously been reported by Wu et al., 2003 and may be 
secondary to the reduced capacity of myocytes to further release BNP from an already 
elevated baseline. 
 
Only one study so far has established the normal variance of IMA in healthy individuals 
[Govender et al., 2008].  IMA levels were measured weekly over a 5-week period.   Between-
week within-subject variance was 3% and between-subject variance was 7%. Using a high-
sensitivity assay, Wu et al. [2009] reported on the normal variance of cTnI in normal 
volunteers where blood was taken hourly over a 4h period and on alternate weeks over an 8-
week period.  Within-day within-subject variance was 9.7% and between-subject variance 
was 57%.  Between-week within-subject variance was 14% and between-subject variance was 
63%.  The increased within-subject variance observed in my LVSD cohort for both these 
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biomarkers may be due to the ongoing process of myocardial remodelling or other 
pathophysiological processes involved in LVSD.  
 
The increased between-subject variance observed in this cohort of LVSD patients for all 
blood biomarkers compared to normal volunteers could be explained by the presence of 
differing degrees of haemodilution or haemoconcentrition secondary to diuretic therapy, 
differing baseline volume status and neurohormomal activation, or concurrent illness.
 
 
7.5.1.2  Biomarkers of renal tubular function 
 
The use of renal tubular markers at predicting acute kidney injury is still at a pre-clinical 
stage.  As is often the case, the normal variance of biomarkers and how this impacts on their 
routine clinical application, tends to be studied after clinical utility has been established for 
the biomarker, such that normal variance for the renal tubular markers studied in this thesis is 
as yet unknown. I observed for the first time, very high within-subject variance (33-89%) and 
between-subject variance (37-235%) for all urinary renal tubular markers in stable LVSD 
patients on optimal medical treatment, perhaps reflecting their sensitivity to chronic oral 
furosemide. While elevated uNGAL levels have previously been documented in LVSD 
[Damman et al., 2007], the median uNGAL at baseline in my cohort was within normal limits 
with only 3 patients having elevated baseline levels.  uNGAL for both studies were collected 
and analysed in a similar way, the analyses being performed in the same location by the same 
team in Groningen, such that significant analytical variability is unlikely. Despite similar 
LVEF and use of RAAS blockade, Damman’s population of LVSD patients were younger [59 
(11) years], had more severe HF symptoms (93% had NYHA class III/IV) and only 70% were 
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on diuretics. This suggests that uNGAL levels may only be elevated in patients with more 
severe HF who are possibly undertreated.  The fact that both uKIM-1 and uNAG levels were 
elevated at baseline in the majority of my patients (these values being observed for the first 
time in a cohort of stable LVSD patients) suggests that levels of these latter biomarkers, 
contrary to uNGAL, may be more likely to be elevated in lesser severities of HF.  
 
7.5.1.3  Echocardiographic measures 
 
The within-subject and between-subject variance of the panel of echocardiographic variables 
studied in this thesis has not been established to date, although Schirmer et al. [2000] 
determined population reference values corrected for gender and age for MVE, MVA, 
MVE/A, MVDT.  The variance of echocardiograpic variables was moderate and comparable 
to that of some blood biomarkers, with the intra-observer variability being an important 
contributor to total variance.  The variance of IVC indices was least when measured in 
expiration and most when measured in maximal inspiration, likely due to easier measurement 
of the vessel at its maximal diameter. This suggests that IVC measured in expiration should 
be used preferentially to the other IVC indices. This is further supported by the observation 
that the bias in the measurement of IVC diameters was smallest for IVCe (-0.05 cm). 
 
7.5.1.4  Bioimpedance measures 
 
BIA measures had the smallest variance of the panel of biomarkers. This variance was 
smallest for whole-body measures and highest for right-lung measures, consistent with the 
findings from the normal volunteers study in Chapter Six. and with previous studies [Steiner 
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et al., 2002; Ng et al., 1993; Verhoeve et al., 1998; Jewkes et al., 1991]. Thus, in clinical 
practice, it would be preferable to measure whole-body BIA in preference to BIA across 
smaller body segments. 
 
7.5.2   Longitudinal response to diuretic manipulation (0h measures on Days 1, 2,  
  3, 4 and 7) 
 
7.5.2.1  Visual analogue score and body weight 
 
Visual analogue scores are an accurate means of measuring patients’ perceived general health 
and feeling of well being in a number of chronic conditions [Sneed et al., 2001; Cowley et al., 
1986].  The use of a non-graduated visual analogue score constituted a simple means of 
determining whether despite an asymptomatic increase in volume status as evidenced by no 
change reported on direct questionning regarding dyspnoea, ankle oedema, tiredness, etc., 
there might be a subconscious deterioration in my volunteers’ general feeling of well being.  
Interestingly, visual analogue scores reduced non-significantly from Day 1 to Day 6, and 
increased from Day 6 to Day 7, perhaps reflecting the patients’ anxiety during the diuretic 
manipulation protocol due to the potential risks of decompensation and the psychological and 
emotional stress of attending the study centre for timed measures.  Patients may have felt 
relieved on the last day of the protocol when they were reassured that they had remained 
stable during the protocol. Nevertheless, the non-significant change observed implies that the 
changes in volume status induced during the protocol were indeed subclinical. 
 
The non-significant changes in body weight during this study are not surprising. Although 
body weight has been shown to increase up to 7-11 days prior to the onset of decompensation 
[Chaudhry et al., 2007], and the absence of an increase in body weight (2Kg or 2% increase in 
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body weight over 48-72 h) has high specificity for excluding clinical deterioration, weight 
gain has poor sensitivity at predicting clinical deterioration.  This is because weight gain can 
also occur as a result of increases in non-fluid body mass, but also because fluid retention may 
occur without a significant increase in body weight due to the simultaneous loss of lean mass 
secondary to cardiac cachexia. Furthermore, decompenstation can result from volume 
redistribution rather than volume overload. It is also possible that the magnitude of volume 
changes in my LVSD patients was too small to be reflected in significant changes in body 
weight. The mean weight increased by a maximum of 1.6 (0.49) Kg which was achieved on 
Day 4.  This is lower than the increase in weight observed in Braunschweig’s study [2002], 
which ranged from 2.5-4.0 Kg, which was associated with increased intracardiac pressures.  
 
7.5.2.2   Blood biomarkers 
 
Of the blood biomarkers studied, only BNP levels seemed to track presumed volume changes 
with some accuracy in response to diuretic manipulation over the 7-day protocol, with levels 
increasing significantly to peak at presumed maximal volume expansion on Day 4, and 
reducing again to baseline value on Day 7. However, the percentage increase in BNP levels 
from Day 1 to Day 4 was 41 %, which is above its within-subject normal variance (17 %), but 
lower than its within-subject RCV (47 %). The lack of significant change from within-subject 
variance and RCV may also explain why Lewin et al. [2005] failed to show the utility of 
serial BNP monitoring for predicting clinical deterioration in a group of stable LVSD patients 
on an outpatient basis. They measured BNP at recruitment into their study, and on 
decompensation, and  used the difference between these values to determine the optimal cut-
off value for their receiver operating curve, only achieving a sensitivity and specificity of 47%  
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and 77% respectively for a BNP increase of >100 pg/mL. Baseline BNP levels were much 
higher in their cohort of patients that decompensated clinically [781 (898) pg/mL], such that 
an increment of 100 pg/mL does not exceed the within-subject normal variance of BNP. Thus, 
depite previous studies suggesting that BNP may reflect medium to long-term haemodynamic 
changes [Disomma et al., 2008; Paterna et al., 2005; Metra et al., 2007], my findings suggest 
that the relatively small amplitude of change in BNP levels may not be sensitive enough to 
track the subclinical volume changes induced over the 7-day protocol, particularly when 
considered in the context of LVSD patients with higher baseline BNP levels.  
  
ANP levels, like BNP levels, increased following diuretic withdrawal, however, they 
continued to increase following diuretic resumption. Similar trends were observed in the Hct 
and IMA response curves, whereby the Hct levels continued to reduce, and the IMA levels 
continued to rise following diuretic resumption potentially suggesting that plasma volume 
continued to increase following resumption of diuretic treatment [Yamasaki et al., 1998; Lobo 
et al., 2010]. While this may a priori seem unlikely due to the significant diuresis observed on 
Day 4 after the bolus dose of ivF, and the subsequent resumption of oral diuretic, an increase 
in intravascular volume may have resulted from redistribution of volume from the interstitial 
space, with a net overall reduction in ECW. The release of ANP in response to atrial and 
ventricular stretch is quicker than the release of BNP in response to ventricular stretch in 
LVSD following different volume loading protocols [Gabrielsen et al., 2000; Larsen et al., 
2006]. However, the secretion of ANP and BNP in response to volume depletion may be 
inherently different, with the ANP response being slower in this instance; this has not been 
previously studied.  
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While the increase in IMA following diuretic withdrawal supports my hypothesis that some 
degree of ischaemic stress is induced by volume expansion/furosemide withdrawal, possibly 
secondary to the remodelling process, the reason for the continuing increase following 
diuretic resumption is unclear. It might suggest ongoing subclinical cardiac ischaemia as part 
of ongoing LV remodelling despite resumption of diuretics, but could also be linked to the 
same volume modulating mechanisms involved in the ANP and Hct response. IMA levels do 
correlate with echocardiographic estimates of LV filling pressure (E/Ea) in stable end stage 
renal failure [Sharma et al., 2005], 
 
and correlate inversely to LVEF in LVSD [Franceschi et 
al., 2009],
 
however, they have not been linked to invasive haemodynamic measures.  The 
nature of the response of IMA thus needs to be clarified in further studies. 
 
cTnI as expected 
did not change significantly with presumed volume changes, reflecting understandably its 
poor sensitivity to small volume changes. 
 
7.5.2.3  Renal tubular biomarkers 
 
The effects of diuretic manipulation on markers of renal tubular function were studied as they 
are more sensitive than conventional measures of renal function such as sCreatinine; their 
levels increase within hours of acute kidney injury [Vaidya et al., 2008]. Withdrawal of 
diuretics resulted in a significant increase in uCreatinine, and reinitiation of diuretic resulted 
in return of uCreatinine to baseline values. The percentage increase from baseline on Day 4 
was 106 %, which is above the within-subject total variance of uCreatine (58 %), but less that 
its within-subject RCV (160 %). Thus, despite this very large increment in uCreatinine levels, 
uCreatinine may be limited as a potential marker of volume change, in the same respect as 
BNP. The statistically significant increase of uKIM-1 and uNAG corrected for urine 
   218 
 
concentration during diuretic withdrawal followed by return to baseline values of the 
biomarkers after re-initiation of oral diuretics was relatively smaller compared to the changes 
seen in uCreatinine, with the least change observed for uNAG. Furthermore, the maximal 
percentage changes in both these biomarkers during diuretic manipulation occurred over their 
respective within-subject variance, but much lower than their respective within-subject RCV. 
This will limit their potential clinical application for volume status monitoring. 
 
However, the observed response of these renal biomarkers to diuretic manipulation was of 
considerable interest from a pathophysiological point of view. The response of uKIM-1 and 
uNAG, which are mostly markers of hypoxic renal tubular injury, suggest that contrary to the 
hypothesis that furosemide may contribute to renal impairment in LVSD as a result of 
dehydration, it may in fact, be beneficial to renal tubular function. This would potentially 
explain why the addition of hydorcholorothiazide to angiotensin-receptor blocker treatment 
resulted in more pronounced reduction in both u KIM-1 and uNAG concentrations in normal 
volunteers in a study by Waanders et al. [2009].  
 
A number of potential mechanisms may explain these observed changes in renal tubular 
markers following diuretic manipulation. In LVSD, reduced renal blood flow is the main 
determinant of renal function [Damman et al., 2007], however, venous congestion also plays a 
role in worsening renal function, especially in the presence of already reduced renal perfusion 
[Mullens et al., 2009; Damman et al., 2009]. Diuretics may thus have a protective renal effect 
by their effects on volume modulation, whether by reducing venous congestion and/or 
improving renal blood flow. Unfortunately, I did not have surrogate measures of renal blood 
flow in my panel of non-invasive biomarkers to shed more light on the potential mechanisms 
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of these changes. While an inverse correlation has been observed between right atrial pressure 
and renal blood flow in LVSD [Kos et al., 1998], the effect of blood volume on renal blood 
flow in LVSD has not been documented.  
 
Furthermore, the linkage of diuretics to deleterious renal effects and worsening of outcome 
[Dries et al., 2000; Domanski et al., 2006]
 
and the association of increasing doses of diuretics 
to worsening renal function [Eshaghian et al., 2006], may merely represent the fact that higher 
risk patients with worse renal function require higher doses of loop diuretics to treat abnormal 
volume status rather than representing adverse treatment effect of loop diuretics through 
dehydration and neurohormonal activation . The diuretic response to furosemide  depends on 
its urinary concentration (mainly by tubular secretion), the time of delivery to its site of action 
in the ascending loop of Henle (dependent on cardiac output and renal blood flow) and the 
dynamics of the response at the loop of Henle (determined by RAAS activation) [Ho et al., 
2010]. Thus, in LVSD patients with reduced renal function,  a combination of reduced 
proximal tubular secretion due to underlying renal dysfunction, reduced furosemide delivery 
due to reduced renal blood flow and increased  neurohormonal activation my all contribute to 
the need for higher doses of furosemide to achieve adequate diuresis. 
 
However, the apparent beneficial renal effects of diuretic withdrawal may occur 
independently/in conjuction with other mechanisms not involving volume modulation, such 
that the observed changes in uCreatinine, uKIM-1 and uNAG may have been secondary to the 
direct renal effects of furosemide therapy.Oxygen tensions in the medulla are comparatively 
low, with only 10% of renal blood flow going to the inner medulla. The high metabolic 
demands of the loop of Henle and relatively low Hct levels in the medulla mean that the 
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medulla is more prone to ischaemia with reduced renal blood flow such as in LVSD [Evans et 
al., 2008].  Furosemide may thus improve medullary oxygen tensions by reducing the Na-K-
Cl2 activity and by increasing prostaglandins [Gerber et al., 1980].  
 
The lack of response of sCreatinine to diuretic manipulation over 7 days is not surprising as 
its changes in response to renal injury lag behind changes in markers of renal tubular function 
by at least 12h (Mishra et al., 2005).  The reasons for the lack of response of sNGAL and 
uNGAL however, are unclear. NGAL levels are known to be elevated in a number of 
pathophysiological conditions other than simply tubular dysfunction [Schmidt-Ott et al., 
2007]. Furthermore, while both uKIM-1 and uNAG are markers that represent proximal 
tubular injury, uNGAL levels are more dependent of production of NGAL in the distal tubule 
following renal injury, with only a small contribution to urinary levels from sNGAL filtered 
through the glomerulus [Schmidt-Ott et al., 2007]. Thus, changes in diuretic treatment may 
primarily affect proximal tubular function as opposed to the distal tubule.  
 
7.5.2.4  Echocardiographic variables 
7.5.2.4.1  Mitral Doppler indices 
 
Despite significant statistical changes in MVE, vMVE and MVE/A in response to diuretic 
manipulation, the amplitude of the changes their measures were very small, with the maximal 
percentage changes observed being lower than their respective within-subject variance, let 
alone their respective RCV. Thus, unlike their response in the study in normal volunteers, 
where MVE and vMVE levels changed above their respective within-subject variance in 
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response to IV Saline, they do not appear to be sensitive markers of the smaller changes in 
volume status in the stable LVSD cohort. 
 
I also observed no significant change in E/Ea indices over the 7-day protocol. As previously 
discussed, E/Ea indices have varying correlations to mean PCWP in a wide variety of cardiac 
conditions [Mansencal et al., 2004; Mansencal et al., 2007; Nagueh et al., 1997]; good 
correlation with spot haemodynamic measures clearly not translating into good performance 
of these biomarkers in tracking volume changes.  Furthermore, E/Ea indices are less reliable 
at predicting LV filling pressure in the presence of basal regional motion wall abnormalities, 
especially at the septum [Lim et al., 2009]. Two-thirds of my cohort of LVSD patients had 
ischaemic cardiomyopathy, thus with a large likelihood of having significant regional wall 
abnormalities. In addition, Mullens et al. [2009] showed no correlation between E/Ea indices 
and PCWP in a group of advanced decompensated LVSD patients with similar mean LVEF 
[28 (8) %] to that in my cohort of LVSD patients. Importantly however, some of the patients 
in their study had biventricular pacemakers and/or significant mitral regurgitation which may 
have confounded their findings.  
 
7.5.2.4.2  Inferior vena cava indices 
 
Despite statistically significant changes in some LIVC and SIVC indices with increase in 
values following diuretic withdrawal and decrease in values following diuretic resumption, 
post-hoc analysis showed little difference between individual time points, and the amplitude 
of the changes in measures was very small. All maximal percentage changes occurred below 
the within-subject total variance for each respective biomarker.This may be explained by the 
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fact that a large proportion (>50 %) of the patients had IVC diameters >2cm at baseline, thus 
limiting the amount of dilatation in response to volume expansion.  In agreement with the 
study by Brennan et al. [2007], indexing the indices for body surface area did not improve 
their sensitivity. Furthermore, the changes in the IVCCI indices were inconsistent with 
biologically significant change, for example, SIVCCI indices reduced consistently during 
diuretic manipulation.  
 
7.5.2.5  Bioimpedance analysis 
 
Similarly to the echocardiographic variables, none of the BIA measures appeared to have 
potential clinical application for the monitoring of volume status in the setting of this study. 
Despite all body water compartments increasing following diuretic withdrawal and reducing 
following diuretic resumption, statistically significant changes were only seen with whole-
body TBW, ECW and ICW, and trunk ECW. The amplitude of these changes however, 
similar to that of all impedance values, was very small despite the maximal percentage change 
occurring over and above the within-subject total variance as well as the within-subject RCV 
for all these measures.  
 
7.5.3   Response to acute intravenous diuresis following presumed maximal  
                        volume expansion (Day 4 8h monitoring) 
 
Patients were studied on Day 4 after their 0h measures in addition over 8h mainly to ensure 
there were no complications following a bolus dose of ivF. Biomarker responses were 
documented over this time period in response to acute intravenous diuresis. This response 
could not be directly compared to the normal variance pattern of the biomarkers on Day 1 for 
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reasons outlined earlier in this Chapter. A significant diuresis occurred as a result of ivF 
administration, as evidenced by a significantly larger urine volume at 4h compared to Day 1 
[(1461 (577)mL versus 878 (416)mL, p<0.0001], suggesting significant volume depletion in 
response to ivF.  
 
All the biomarkers studied were inadequate for mapping this level of change in volume status. 
Overall, their levels did not change significantly from the 0h measures, and their maximal 
percentage change from 0h was inferior to their within-day within-subject variance 
determined on Day 1. The mitral Doppler indices, IVC indices, and urine biomarkers of 
tubular function showed statistically significant change from the 0h measures, however, their 
maximal percentage change were in most cases, inferior to both their within-day within-
subject variance and RCV. The BIA measures showed statistically significant change 
following ivF and their maximal percentage change was superior to their corresponding 
within-subject variance, and in some cases, their RCV as well. However, the relative changes 
were too small to suggest that these biomarkers would be suitable for monitoring of acute 
volume changes in this cohort. 
 
7.6   Limitations  
 
There are a number of limitations to this section of my study.  Patients were not standardised 
in terms of their salt and water intake during the study protocol, such that their baseline 
hydration states may have varied considerably. While the significant changes in uCreatinine 
and non-significant trends of body weight change over the diuretic manipulation protocol 
suggest subclinical increase in volume status during diuretic withdrawal and reduction in 
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volume status during diuretic reinitiation, it is difficult to gauge the amplitude of this volume 
change, and thus to determine whether the observed lack of sensitivity of the biomarkers was 
genuine or whether the volume stimuli were too small.  However, the volume stimuli used in 
this study are very realistic of a routine clinical setting; diuretic manipulation and/or non-
adherence is a real clinical phenomenon.The lack of gold standard measures of volume status 
thus limits the ability of this study to make any definite conclusions regarding the sensitivity 
of the biomarkers studied at tracking volume changes. The use of blood volume analysis, 
haemodynamic measures, as well as isotopic determination of renal blood, would have also 
enabled the determination of the exact changes occurring in specific volume compartments, 
and would have clarified, for example, the ANP, Hct and IMA responses, as well as the 
reason for the changes in renal tubular markers.Unfortunately, the use of central lines or 
pulmonary artery catheters was not feasible, nor was the use of radioactive material to 
perform blood volume analysis within the setting of the study. 
 
In the absence of gold standard measures of volume status, surrogate measures could have 
been used. However, the equation used for estimation of blood volume in the normal 
volunteers study was only validated in normal volunteers, and cannot be applied to LVSD 
patients undergoing dynamic fluid shifts and who were on concomitant vasoactive 
medication.  Blood pressure and heart rate were also not measured. Furthermore, the 
longitudinal response of biomarkers to diuretic manipulation over the 7-day protocol could 
have been compared directly to the within-subject normal variance of respective biomarkers 
on their usual medication over a similar period in a similar way to the normal volunteers 
study. This would enable further insight into the sensitivities of each bioamarker, with the 
most sensitive deviating the most from their normal variance. However, establishing this 
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normal variance pattern over 7 days would involve doubling the study time, which was not 
practically feasible in the frailer LVSD cohort.  
 
The significant changes seen in uKIM-1 and uNAG corrected for urinary concentration in 
response to diuretic manipulation may in addition have been due to changes in uCreatinine. 
Normalising the renal biomarker levels to uCreatinine should in theory correct for differences 
in urinary flow rate as a result of diuretic manipulation, on the assumption that uCreatinine is 
constant. However, the rate of creatinine excretion by the kidneys may also have differed in 
response to diuretic manipulation as a result of changes in GFR. This possible effect on 
uCreatinine concentration is likely to have been small.  However, timed urine collections to 
allow the calculation of both uCreatinine concentration and renal biomarker levels over 24 
hours may have been more appropriate [Waikar SS et al., 2010]. Unfortunately, this was not 
feasible within the study setting. 
 
A large number of statistically significant changes in biomarker levels was observed, some of 
which may have resulted from the large number of statistical comparisons made rather than 
due to physiologically significant changes in response to the volume manipulation protocols 
used. This has been recognised, such that despite this observation, I concluded that none of 
the biomarkers studied appeared to have potential clinical utility for monitoring volume 
changes in this study setting.  However, the aim of this study was to identify the most 
potentially useful markers of volume change, such that it was important to study a large 
number of markers in order to optimise the interventions applied in this population of LVSD 
patients.  
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 7.7   Summary 
 
In this study, I demonstrated, in some cases for the first time, the normal variance of blood 
and urine biomarkers and physical biomeasures in stable LVSD patients on optimised medical 
therapy. The largest variance was observed for the urine renal tubular markers and smallest 
variance for BIA measures.  None of the biomarkers studied appeared to have potential 
clinical utility for the monitoring of the subtle changes in volume status induced in this cohort 
of patients, whether over the medium term or acutely in response to ivF. Their utility in this 
context seems to be limited in some instances by large within-subject variance, or by very 
small incremental changes in response to the volume changes induced. I also demonstrated, 
for the first time, an increase in some renal tubular markers as a result of diuretic withdrawal, 
suggesting potential renal benefit of diuretic treatment. 
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Chapter Eight 
 
Summary, Suggestions for Future Studies and 
Conclusion 
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8.1    Summary 
 
The main aim of this thesis was to establish the feasibility and potential clinical utility of 
repeated measures assessment of non-invasive biomarkers in tracking change in volume 
status. This was particularly in the context of patients with LVSD, where abnormal volume 
homeostasis prevails, and abnormal volume status, whether present overtly or subclinically, is 
linked to symptoms and poor prognosis. The overall clinical goal driving this programme of 
work is the need to prevent acute decompensation, and for different LVSD therapies to be 
optimised on an individual basis, tailored to the baseline volume  status of each individual, 
thus achieving an equilibrium between optimal symptom control and volume status with 
minimal detrimental neurohormonal activation and detrimental effects on the kidneys. 
 
Extensive review of the literature identified potential non-invasive means of volume 
assessment. A panel of these non-invasive biomarkers was selected on the basis of their 
availability and use in current clinical practice, their ease of applicability and reproducibility 
by a variety of health care professionals and patients alike, as opposed to biomarkers which 
were still at an experimental stage. I also explored interventions which would result in volume 
changes in a number of conditions, and applied these to different volunteer groups in order to 
test the comparative performance of the panel of blood biomarkers and physical biomeasures 
to volume changes. Literature review also revealed that, despite the wide clinical and 
investigational application of some of these biomarkers to guide diagnosis, prognosis, and in 
some cases to guide treatment in LVSD, there was little or no documentation of their normal 
variance. In cases where the normal variance was established, measured values of biomarkers 
were not always interpreted in the context of this variance, and in some studies, variance 
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determined in one group of volunteers (e.g., normal volunteers) was applied to interpret 
measured biomarker values in a different group of volunteers (e.g., stable cardiac patients). 
 
I observed smallest variance for BIA measures, moderate variance for echocardiographic 
variables, and largest variance for urinary renal tubular markers. Variance for blood 
biomarkers was small (Hct and IMA), moderate (ANP and BNP) or large (cTnI). I 
demonstrated that measurement variance in the form of intra-observer variability, was the 
main contributor to the total variance of echocardiographic measures. This measurement 
variance could be reduced by devising a systematic way to perform the measurements and 
with practice and increased familiarity with the set pattern of performing the measurements. 
This has implications for the training of staff employed to perform physical biomeasures, in 
particular echocardiographic measures, for monitoring purposes.  I demonstrated reduced 
within-subject variance for some biomarkers in LVSD patients compared to normal 
volunteers (BNP), and increased within-subject variance in LVSD compared to normal 
volunteers for others (IMA, cTnI, echocardiographic and BIA variables). Overall, between-
subject variance was larger in LVSD compared to normal volunteers for all biomarkers. These 
observations have implications for the interpretation of these biomarkers, whose use in 
clinical practice is already widely established. Thus, clinicians need to be aware of these 
issues when using biomarker levels to diagnose disease in unselected groups of patients or in 
monitoring disease progression or response to treatment in select groups of patients.  
 
Establishing the within-subject variance of biomarkers was crucial for the interpretation of the 
sensitivity of biomarker responses to volume manipulations within this programme of work. 
However, the clinical application of this concept is not well-tested. Clearly, a random 
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measurement of a biomarker in a clinically stable patient which falls outside population 
reference values but within the within-subject normal variance for that individual should be 
reassuring. However, it is unclear whether every biomarker measure that falls outside this 
within-subject variance indicates clinical instability, and how much deviation from the within-
subject variance would be clinically significant. The clinical applicability of RCV appears 
limited in that respect, these being merely laboratory-generated percentages suggesting 
statistically significant differences between serial measures in an attempt to aid clinical 
decision-making. It is however, unclear whether they actually predict 
decompensation/worsening of disease in practice.  
 
Furthermore, I observed that within-subject or between-subject variance tends to increase the 
longer the time frame over which it is measured. In addition, the within-subject variance 
increases the more times it is measured over a specific period of time.  Assuming clinical 
practice evolved to incorporate the widespread use of within-subject normal variance for the 
interpretation of biomarker levels within an individual patient, it is unclear how this within-
subject normal variance would be calculated in practice. How many measures of the 
biomarker would be needed and over how long a period of time they should be collected is 
not known, in addition to how often the biomarker level would need to be repeated to enable 
satisfactory monitoring of disease status. These factors will undoubtedly be limited by the 
resources available. The impact on the patient of increased frequency of measurents also 
needs to be carefully assessed. 
 
The key to applying repeated measures of biomarkers to predict clinical decompensation 
could lie in the persistent or sustained deviation of biomarker measures from their within-
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subject normal variance on repeated measurements. Studies do show that persistently elevated 
body weight, invasively-measured haemodynamic variables, or fluid index measured from 
implantable devices in clinically stable patients precede decompensation. It is as yet unclear 
whether intensification of treatment at the point of this asymptomatic sustained deviation 
from normal variance results in better outcomes.  
 
The panel of biomarkers studied in the three experiments showed, in general, little sensitivity 
at tracking the volume changes induced by the interventions used, except for whole-body BIA 
and trunk impedance in the normal volunteers in response to IV Saline. While this may be 
partly due to a failure of the protocols to induce large enough overall amplitudes of change in 
volume status, especially in the heterogeneous group of patients with decompensated heart 
failure, and to some extent in the patients with stable LVSD, the findings are more likely to 
relate to poor performance of the biomarkers as markers of volume change. In fact, the 
settings applied in these latter two experiments are very realistic of routine clinical situations, 
and the emphasis of the thesis was to identify biomarkers which would be sensitive enough to 
track even small amplitudes of volume change in order to detect sublclinical deterioration. 
Thus, the sensitivity of biomarkers that changed significantly would have been in theory, 
strenghthened. 
 
I undertook to study a large number of potential candidate biomarkers for the accurate 
mapping of volume change in a variety of settings in order to optimise the chances of 
identifying a suitably sensitive marker. The large number of statistical comparisons performed 
is thus likely to inevitably give rise to a number of statistically significant results at random. 
This may explain why, despite a large number of statistically significant changes in some 
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biomarkers, only few response patterns were consistent with potential clinical significance, 
and thus utility.  
 
To decide whether those biomarkers whose levels showed statistically significant trends of 
response in the various settings would display clinically useful characteristics, I first of all 
examined the post-hoc analysis, which did not reveal any significant differences between the 
different time points or interventions in some instances, e.g., IVC indices, thus unlikely to 
suggest biologically significant biomarker response. Secondly, I examined the magnitude of 
the biomarker changes in response to volume change in the context of their respective within-
subject total variance and within-subject RCV. Changes in biomarker levels that occurred 
below the respective within-subject variance clearly demonstrated lack of sensitivity for 
tracking volume changes, e.g., MVE in the LVSD cohort. Some changes in biomarker levels 
occurred above the within-subject variance but below the within-subject RCV, again 
potentially suggesting limited clinical applicability. In theory, changes in biomarker levels 
over and above both the within-subject variance and the within-subject RCV should imply 
potential clinical utility for tracking volume changes, e.g., BIA measures in the patients with 
stable LVSD. However, the amplitude of the changes in BIA measures was generally very 
small (around or less than 5%) such that the changes were either inconsistent with 
physiological significance (e.g., right lung BIA in the LVSD cohort) or, even if consistent 
with physiological significance (e.g., whole-body Z5kHz in the LVSD cohort), the small 
degree of change would limit their applicability as markers of volume status.  
 
The limitations of blood biomarkers as non-invasive markers of volume change include their 
lack of sensitivity, the large within-subject variance for some biomarkers, the discomfort of 
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venepuncture, and the latency of the availability of their results which is entirely dependent on 
local laboratory processes.   
 
For urine biomarkers, it is still unclear whether the changes observed are secondary to the 
small volume changes induced in the study in stable LVSD patients or whether these are due 
to volume-independent effects of diuretic manipulation. In any case, their extremely large 
variance will limit their application as markers of volume change. Furthermore, their results 
are not immediately available as is the case for blood biomarkers. However, the fact that 
uKIM-1 and uNAG increased following diuretic withdrawal and reduced following diuretic 
resumption in the LVSD patients suggests potential beneficial renal effects of furomide in 
LVSD, possibly involving the proximal tubule. 
 
The use of echocardiographic measures for monitoring volume status is attractive as these 
measures are freely available as part of a routine study, and the use of hand held 
echoarcardiography could be easily disseminated to be used by a number of health care 
personel for the targeted measurement of some of the easily and consistently imaged 
variables. However, the potential for echocardiogaphic variables as markers of volume change 
is severely hampered by operator experience (as I demonstrated by in Chapter Five), their 
relatively large intra- and inter-observer variability and patients’echogeneicity.  MVE indices 
were the potentially most promising echocardiographic markers of volume change due to the 
sensitivity shown during volume loading with IV Saline in the normal volunteers even 
following the Valsalva manoeuvre. However, these significant changes in MVE indices were 
induced following the relatively larger volume change in response to IV Saline in normal 
volunteers, which if induced in stable LVSD patients for example, might have resulted in 
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acute decompensation, thus defeating the purpose of using these markers to prevent 
decompensation. 
 
BIA was the least invasive, time consuming and operator-dependent of all biomarkers studied, 
with the least variance of its measurements and with results being immediately available.   
However, the amplitude of change in their levels was too small to imply clinical utility in 
mapping volume change, except in the setting of the large volume changes induced by IV 
Saline in the normal volunteers study, which as previously discussed, if induced in LVSD 
patients, may already have resulted in decompensation.  The main issue with bioimpedance, 
however, seems to lie in its lack of specificity for volume change; significant changes in 
bioimpedance can occur due to other physiological or pathological processes, or simply for no 
apparent reason. Catanzariti et al. [2009]  showed that of 362 OptiVol alerts registered over a 
12-month period in a cohort of stable HF patients, only 175 resulted in a clinical event, of 
which only 145 were due to worsening of HF (40 % of alerts), the remaining were due to for 
example, sepsis, respiratory pathologies, or arrhythmias. Moreover, 120 (33 %) alerts were 
unexplained. Thus while most whole body and trunk BIA measures changed statistically 
significantly in response to volume manipulation in all three study settings, these changes 
may not have specifically indicated volume change. 
 
 8.2   Suggestions for future studies 
 
Study limitations have been discussed following each stage of investigation. In view of these 
limitations, future studies are needed to clarify and further investigate the hypotheses tested 
while addressing the limitations encountered during this programme of work.  
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The main limitation highlighted in all three sectional studies was the lack of gold standard 
measures of different volume compartments against which to compare biomarker responses to 
different volume manipulation protocols. Future studies should ideally employ radioisotope 
analysis for the determination of not only different body water compartments, but also to 
determine isotopic renal blood flow in an attempt to elucidate the mechanisms for increased 
markers of tubular function secondary to diuretic withdrawal. Furthermore, invasive 
haemodynamic measures should be considered to not only provide accurate measures of LV 
filling pressure, cardiac output and systemic vascular resistance but also renal venous 
pressure.   
 
The control of volume homeostasis in LVSD involves a number of pathophysiological 
mechanisms as discussed in Chapter One.  Some of these mechanisms occur upstream and 
thus modulate volume change, such as the processes involved in neurohormonal activation. 
These biomarkers would in theory, predict change in volume, rather than simply track 
subclinical or clinical change in volume status. It is thus forseeable that biomarkers depicting 
each of these different processes, whether upstream or downstream, can be used to map 
volume status longitudinally in individual patients. A multi-marker strategy of non-invasive 
repeated measures assessment of these biomarkers could become clinically applicable, 
offering a graded measure of impending decompensation and potentially mapping body water 
compartments, invasive haemodynamic measures or measures of baseline neurohormonal 
activation and renal function/injury. Considered together with clinical assessment, they would 
allow an integrated approach to the individual patient such that therapy can be tailored to each 
individual patient, whether in the subclinical or symptomatic phase of abnormal volume 
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status. Furthermore, it is forseeable that biomarker measurement technology will evolve to 
enable finger-prick testing of blood biomarkers, or rapid measurement of markers of renal 
function by spot urine testing, thus enabling even quicker and less intrusive testing, as well as 
telemonitoring of repeated measures as is already the case with invasive impedance measures 
from implantable cardiac devices. 
 
Given the general lack of sensitivity of the biomarkers studied in this thesis for mapping 
changes in volume status, these being chosen primarily due to their availalility in current 
clinical practice, the clinical applicability of other potential biomarkers must be investigated, 
which are possibly still at an investigational stage. Future studies will also need to 
demonstrate how much deviation from normal variance would imply a change in clinical 
status, and whether intensification of treatment based purely on changes in biomarker levels 
has a significant impact on outcome. Furthermore, the practical and financial implications of 
monitoring biomarkers on a large scale in the context of an increasing HF population need to 
be established.  Once suitably sensitive non-invasive biomarkers of volume change have been 
identified and validated against gold standards, algorithms for a multi-marker strategy need to 
be developed and tested for beneficial effects on morbidity and mortality.  
 
8.3   Conclusion 
 
In conclusion, the repeated measures assessment of the biomarkers studied in this thesis 
appeared, in general, limited in terms of its clinical applicability for tracking subclinical 
volume changes, and would thus have limited potential for application in the monitoring of 
volume status in LVSD. This is despite established good correlations of their spot 
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measurements with isolated measures of volume status, thus illustrating that good sensitivity 
of a biomarker for monitoring purposes is discerned primarily by its capacity for rapid and 
clinically appreciable changes in response to clinical changes, and not necessarily by good 
correlation with static measures of change in clinical status. Thus, this thesis has highlighted 
some important principles underlying the clinical application of repeated measures assessment 
for monitoring of clinical status , in particular volume status, with an important strength of the 
study involving performing repeated measures assessment of biomarkers within individuals to 
various volume stimuli such that each volunteer acted as his/her own control.  
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